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Abstract 
 
In mammals, ten isoforms of Nav channels (Nav1.1-1.9 and Nax) are known that 
exhibit specific spatial and temporal expression patterns. Human genetics and 
transgenic mouse studies have revealed a pivotal role for voltage-gated sodium 
channel Nav1.7 in both acute and chronic pain. Therefore Nav1.7 is a promising 
analgesic drug target as individuals with loss of function mutations are normal 
except for a complete inability to perceive pain and having anosmia. As Nav 
family members share high sequence homology, potential Nav1.7 blockers need 
to be highly selective. 
 
The aim of this thesis was to gain a greater understanding of Nav1.7. Firstly, I 
examined the regulation of the SCN9A gene, which encodes Nav1.7, through 
cloning and analysis of a natural antisense transcript (NAT). The 
complementary NAT overlaps tail-to-tail with the SCN9A/Scn9a sense transcript 
in both human and mouse genomes. Overexpression of the NAT in vitro 
specifically decreases the level of mRNA, protein and peak current of Nav1.7. 
Therefore the NAT may play an important role in regulating human pain 
thresholds and is a potential candidate gene for individuals with chronic pain 
disorders that map to the SCN9A locus. Secondly, I investigated the protein-
interaction network of Nav1.7 through analysis of a newly developed Nav1.7 
TAP tagged mouse. Here, I aimed to identify subtype specific interaction 
partners of Nav1.7 and found that Nav1.7 is associated with β3 and β4 subunits 
(Navβ) as well as functional molecules that play a crucial role in protein 
synthesis, intracellular trafficking and pain processing. Finally, I studied a newly 
developed mouse model of inherited Primary Erythromelalgia (PE, hNav1.7 
L858F), a human pain disorder caused by a mutation in SCN9A. This hNav1.7 
L858F TAP tag mouse line recapitulated the human PE phenotype and will 
potentially be useful in preclinical screening of candidate Nav1.7 blockers.  
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1  Introduction  
 
Chronic pain is a major clinical problem. A Europe wide survey on the 
prevalence, severity, treatment and impact of pain found that 19 per cent of the 
participants suffered from chronic pain for more than 6 months, with one third 
describing their pain as so severe that it negatively impacted their life (Breivik, 
Collett et al. 2006). When asked about their pain treatment, 40 per cent of 
chronic pain sufferers reported that their pain medications were inadequate. 
This survey clearly depicts the magnitude of people affected but also highlights 
that analgesic drugs currently available are seemingly insufficient for the 
treatment of chronic pain. In order to develop new approaches to treat chronic 
pain, it is important to understand the key genes and mechanisms involved in 
pain processing.  
The focus of this thesis is Nav1.7, a voltage-gated sodium channel that is 
primarily found in peripheral sensory neurons and which has been highlighted 
as a promising new analgesic drug target through analysis of pain-free humans 
and transgenic mice (Nassar, Stirling et al. 2004, Cox, Reimann et al. 2006, 
Gingras, Smith et al. 2014). Blocking the function of this channel within 
damage-sensing neurons or by interfering with the transcription/translation of 
the SCN9A gene, which encodes Nav1.7, may lead to the development of a new 
class of analgesic drugs (King and Vetter 2014). 
Pain and Nociception 
The international association for the study of pain (IASP) defines pain as “An 
unpleasant sensory and emotional experience associated with actual or 
potential tissue damage, or described in terms of such damage.” 
(http://www.iasp-pain.org). Pain in itself is essential for survival but in contrast to 
acute pain (which enables a fast response to a noxious stimulus) or 
inflammatory pain (which promotes the healing process), chronic pain fails to 
fulfill any useful physiological role. A further important distinction is made 
between pain and nociception. Pain is a perception, like vision or smell that is 
achieved by higher cortical processing. The sensation of pain not only leads to 
physical withdrawal and avoidance but also evokes an emotional response and 
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dramatic injury might change our perception of future pain experiences (Dar, 
Ariely et al. 1995). In contrast, nociception can be defined as the neural 
processes involved in detecting noxious stimuli and can occur in an 
unconscious individual. Hence, nociception can exist without pain. 
Classification of Nociceptors  
In 1906, Sherrington first suggested the existence of primary afferent neurons 
or nociceptors, which only respond to noxious stimuli but do not activate in the 
presence of innocuous stimuli such as light touch (Burgess and Perl 1967). Our 
current understanding confirms that nociceptors are a subset of sensory 
neurons that innervate the skin and deep tissue and convey noxious sensory 
information from the periphery to the central nervous system. Structurally, 
nociceptors are pseudo unipolar neurons with a small (<30 μm) to medium (30-
40 μm) diameter somata that are located in dorsal root and trigeminal ganglia 
(Bessou and Perl 1969), and with a peripheral and central terminal. The 
peripheral terminals of primary afferents are typically free nerve endings, while 
the central branch projects its axon to second order neurons in the spinal cord 
(Figure 1-1). However, not all neurons in the dorsal root ganglia are nociceptors 
(e.g. proprioceptive neurons). An important goal of pain research is to further 
understand the subpopulations of nociceptive neurons and the types of noxious 
stimuli they detect. 
 
One approach to categorize DRG neurons is based on anatomical features, 
such as diameter and myelination. For example, Aα- and Aβ-fibres are fast 
conducting (70-120m/s, and 40-70m/s, respectively) large (>40 μm) to medium 
size (30-40 μm) myelinated afferents, which have been historically associated 
with activation by innocuous stimuli (Julius and Basbaum 2001, Black, Frezel et 
al. 2012).  
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Figure 1-1: Pain signalling pathways 
Unmyelinated C-fibres (orange) and thinly myelinated Aδ-fibres (green) innervate the skin 
(epidermis, light purple) with their free nerve endings that contain specialized channels and 
receptors (e.g. ASICs, G-protein-coupled receptors (GPCRs), and transient receptor potential 
(TRP) channels. In the presence of noxious stimuli, ion channels at the axon tip of primary 
afferents open and thereby create a generator potential that leads to further opening of voltage-
gated sodium channels (VGSCs). VGSCs amplify the initial depolarization and enable action 
potentials to be generated. The generated action potential is transmitted from damage-sensing 
neurons in the periphery through the spinothalamic tract into the somatosensory cortex (not 
shown here) where finally the sensation of pain is created (Raouf, Quick et al. 2010). Taken 
from King and Vetter (2014). 
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Thinly myelinated Aδ-fibres or unmyelinated C-fibres differ in their conduction 
velocity (2-30 m/s and 1m/s respectively) (Figure 1-1). Functionally Aδ-fibres 
mediate first pain, which is well localized and fast. Aδ-fibers can be further 
divided into two classes according to their response to high threshold 
mechanical stimuli and responsiveness to noxious heat and tissue damage 
(Julius and Basbaum 2001). 
C-fibres are unmyelinated small diameter primary afferents but in contrast to Aδ 
fibers, C-fibres mediate second or slow pain (Julius and Basbaum 2001). 
Functionally most C-fibres are polymodal (>70%) nociceptors that respond to 
mechanical, thermal and chemical stimuli (CMH) or are mechanoinsensitive (C-
MIA) (Meyer, Davis et al. 1991, Cain, Khasabov et al. 2001). There is also a 
specific subset of C-fibres, known as silent or sleeping nociceptors. These 
‘silent’ nociceptors are normally unresponsive to noxious stimuli but can 
become activated when sensitized by tissue injury (Schmidt, Schmelz et al. 
1995).  
Besides the broad classification of C-fibres by mechanosensitivity, C-fibre 
nociceptors are also biochemically distinguishable. Peptidergic and non-
peptidergic nociceptors are two subpopulations of C-fibres that differ in 
expression of cell surface molecules and presence of neuropeptides. In 
peptidergic nociceptors, substance P and/or calcitonin gene-related peptide 
(CGRP) are present in the cytoplasm and trkA is expressed on the surface. 
Non-peptidergic damage sensing neurons are isolectin B4-positive (IB4+) 
(Bennett, Michael et al. 1998) and express RET (receptor for the glia cell-line-
derived family of neurotropic factors) and P2X3 receptors on their surface 
(Snider and McMahon 1998). A further refinement can be made via the 
expression of Mas-related G-protein coupled receptors (Mrgprs), a subfamily of 
G-protein coupled receptors (Dong, Han et al. 2001). Other markers include 
voltage-gated sodium channels (Nav1.7 and Nav1.8) and TRP channels (TRPA 
and TRPV1) (Tominaga, Caterina et al. 1998, Kobayashi, Fukuoka et al. 2005), 
VGlut, Tyrosine hydroxylase (TH) and delta opioid receptor (DOR) (Le Pichon 
and Chesler 2014) (Figure 1-2). The listed anatomical and functional attributes 
of nociceptors are useful but have limitations or overlap in defining certain 
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subpopulations of nociceptors. Therefore, no single criterion is a reliable 
indicator and often does not take into account the target of innervation (Le 
Pichon and Chesler 2014). Recent publications describe the differentiation of 
nociceptors based on their transcriptional profile. Thakur and Crow et al. (2014) 
identified nociceptor-enriched genes, most of which appear to be PNS specific 
(Thakur, Crow et al. 2014). A groundbreaking paper by Usoskin et al. (2015) 
examines the gene expression profile of DRG neurons and accordingly 
classified DRG neurons into 11 subtypes (Usoskin, Furlan et al. 2015). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 	  
 
 
 
Figure 1-2: Venn diagram illustrating the distribution of markers across different classes 
of C-fibres (not to scale).  
IB4 (isolectin B4-positive); TRPV1 (Transient receptor potential channel V1); TRPA1 (Transient 
receptor potential channel A1); TRPM8 (Transient receptor potential channel M8); CGRP 
(calcitonin gene-related peptide); DOR (delta opioid receptor); TH (Tyrosine hydroxylase); 
MrgprB4/D/A3 (Mas-related G-protein coupled receptor B4/D/A3); VGlut3 (vesicular glutamate 
transporter type 3). Taken from Le Pichon and Chesler (2014). 
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1.1  Molecular mechanisms of Nociception: Transduction  	  
Sensory transduction is the process of converting information from the 
periphery into action potentials. In the presence of noxious stimuli, ion channels 
(e.g. TRP channels or acid-sensing ion channels) at the axon tip of primary 
afferents open and allow the influx of cations, thereby creating a generator 
potential that leads to further opening of voltage-gated sodium channels 
(VGSC) (Figure 1-3). VGSCs amplify the initial depolarization and enable action 
potentials to be generated. The generated action potential is transmitted from 
damage-sensing neurons in the periphery through the spinothalamic tract into 
the somatosensory cortex where finally the sensation of pain is created (Raouf, 
Quick et al. 2010). This section focuses on known key transduction channels 
expressed within DRG neurons and their role in transducing thermal, chemical 
and inflammatory pain. 
Transient receptor potential channel (TRP)  
Transient receptor potential (TRP) channels are highly conserved throughout 
the animal kingdom and expressed in sensory and non-sensory cells (Cheng, 
Sun et al. 2010). TRP channels act as polymodal cellular sensors that activate 
through a broad range of internal and external stimuli such as noxious and 
thermal heat, cold, chemicals, mechanical stimulation and osmolarity. In 
vertebrates, the TRP channel family is divided into two groups and seven 
subfamilies, based upon structure and sequence homologies (Montell 2005, 
Cheng, Sun et al. 2010). Structurally, TRP channels are integral membrane 
proteins with six transmembrane domains (S1-S6) and form a non-selective 
permeable cation pore (Ramsey, Delling et al. 2006). Mutations in TRP 
channels have been linked to human cardiovascular diseases, inflammation, 
sensory dysfunction and familial episodic pain syndrome (Nilius 2007). In 
particular, transient receptor potential vanilloid receptor 1 (TRPV1), member of 
the vanilloid subfamily of TRP channels, transient receptor potential melastatin 
8 (TRPM8), member of the melastatin subfamily of TRP channels and transient 
receptor potential ankyrin 1 (TRPA1), member of the ankyrin TRP subfamily 
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have gained attention as possible new analgesic drug targets due to their role in 
nociception (Brederson, Kym et al. 2013). 
 
Figure 1-3: Schematic of ion channel distribution on nociceptors.  
Taken from Raouf, Quick et al. (2010) 
 
Transient receptor potential vanilloid receptor 1 (TRPV1) 
TRPV1 is a thermo-sensitive TRP channel that marks a subpopulation of C-fibre 
nociceptors and is activated by noxious-heat (>43C) and tissue acidosis caused 
by inflammation (Caterina, Schumacher et al. 1997, Tominaga, Caterina et al. 
1998, Kobayashi, Fukuoka et al. 2005, Leffler, Monter et al. 2006). Animal 
studies confirm that Trpv1 is an important target for various inflammatory 
agents. After traumatic injury, “the inflammatory soup” is released that render 
Trpv1 hypersensitive by lowering the channel’s activation threshold (Huang, 
Zhang et al. 2006). Trpv1-/- mice exhibit a decreased response to acute thermal 
stimuli and develop milder thermal hyperalgesia due to inflammation (Caterina, 
Leffler et al. 2000, Kasama, Kawakubo et al. 2007).  
Transient receptor potential ankyrin 1 (TRPA1) 
TRPA1 is the only member of the ankyrin subfamily of TRP channels that is 
also found in humans, and is required for thermo-sensation and nociception. 
TRPA1 is mainly expressed in a subpopulation of primary sensory neurons 
(Story, Peier et al. 2003, Nagata, Duggan et al. 2005) but also in non-neuronal 
cell types (Nozawa, Kawabata-Shoda et al. 2009). Besides TRPA1’s essential 
role in mediating acute inflammatory pain (Chen, Joshi et al. 2011, Moilanen, 
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Laavola et al. 2012), it is also activated by environmental irritants (Bautista, 
Jordt et al. 2006, Andrade, Meotti et al. 2012) and has been postulated to play a 
role in injury-evoked cold hypersensitivity (del Camino, Murphy et al. 2010) and 
hearing (Nagata, Duggan et al. 2005). Recently, a gain-of-function mutation in 
TRPA1 has also been implicated in inherited familial episodic pain syndrome 
type I (Kremeyer, Lopera et al. 2010). 
Transient receptor potential melastatin 8 (TRPM8) 
Inflammation, viral induced nerve injury and tissue damage can produce cold 
evoked hypersensitivity, which is primarily mediated by TRPM8 (Dhaka, Murray 
et al. 2007). Whereas TRPV1 is only activated by noxious stimuli, (Huang, 
Zhang et al. 2006), TRPM8 is also activated by innocuous cold temperatures 
(Bautista, Siemens et al. 2007). Genetic and pharmacological ablation provides 
the strongest evidence for this channel’s non-redundant role in cold sensation. 
TRPM8-/- mice exhibit almost a complete loss of acute cold sensation 
(Knowlton, Bifolck-Fisher et al. 2010) and show attenuated injury-evoked 
hypersensitivity after inflammation and neuropathic nerve injury. However, 
knockout mice still remain responsive to noxious heat and mechanical stimuli 
(Proudfoot, Garry et al. 2006, Colburn, Lubin et al. 2007). 
Acid-sensing ion channels (ASICs) 
ASICs are voltage-independent, proton-gated ion channels (Waldmann, 
Champigny et al. 1997) that form homo- or heterotrimeric transmembrane 
complexes (Jasti, Furukawa et al. 2007, Gonzales, Kawate et al. 2009). ASICs 
are primarily expressed in the cell body, peripheral terminals of nociceptors 
(Price, McIlwrath et al. 2001) and central neurons (Alvarez de la Rosa, Krueger 
et al. 2003). At the peripheral terminals, ASICs are activated through changes in 
pH caused by inflammation and endo/exogenous irritants (Reeh and Steen 
1996, Price, McIlwrath et al. 2001, Deval, Noel et al. 2008). In rodents, at least 
seven isoforms are known and implicated peripherally in nociception and 
possibly mechano-sensation (Gonzales, Kawate et al. 2009) Centrally, ASICs 
are believed to play a role in synaptic plasticity, learning, memory and pain 
processing (Zha, Wemmie et al. 2006, Cho and Askwith 2008). Furthermore, 
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several studies report a link between ASIC3 and anxiety and ASIC3 and insulin 
resistance (Huang, Yang et al. 2008, Wu, Lin et al. 2010).  
1.2  Molecular mechanisms of Nociception: Transmission  	  
Transduction sensors like TRP channels convey sensory information into an 
initial electrical signal, a generator potential. This leads to changes in the 
membrane potential and triggers the opening of voltage-gated sodium channels 
(VGSCs). VGSCs control cellular excitability and play a key role in action 
potential generation and propagation. However, dysregulated activity of voltage-
gated sodium channels has been implicated in spontaneous and inherited 
human pain disorders. In the following section, the structure, function and 
distribution of voltage-gated sodium channels in the PNS and CNS will be 
discussed, with a special focus on Nav1.7. 
Voltage-gated sodium channel family  
Sodium channels are members of the ion channel superfamily that also includes 
potassium and calcium channels. In contrast to sodium channels, potassium 
and calcium channels have lower amino acid sequence conservation among 
family members. In the mammalian VGSC superfamily, ten different members 
have been cloned (Nav1.1-1.9 and Nax), all of which have greater than 50 per 
cent conserved sequence homology in the transmembrane and extracellular 
domains (Catterall 2000, Yu and Catterall 2004, Catterall, Goldin et al. 2005). 
Voltage-gated sodium channels can be distinguished by their sensitivity to TTX, 
a tetrodotoxin from puffer fish that blocks the ion selective pore (Klugbauer, 
Lacinova et al. 1995). In both humans and mice, Nav1.1, Nav1.2, Nav1.3 and 
Nav1.7 are the most closely related and are encoded by a set of four genes 
clustered on chromosome 2 (George, Knittle et al. 1992). These channels 
exhibit high tetrodotoxin sensitivity (TTXs) and are blocked by the presence of 
nanomolar concentrations of TTX. Nav1.4 and Nav1.6 are also TTXs and share 
a greater than 80 per cent sequence homology with the gene cluster on 
chromosome 2. However, their locus of transcription in humans and mice is on 
chromosome 17 and 12 respectively (Catterall, Goldin et al. 2005). The voltage-
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gated sodium channels, Nav1.5, Nav1.8 and Nav1.9 share a greater than 64 per 
cent conservation with the four on chromosome 2q while in humans and mice 
their locus of transcription is on chromosome 3. In comparison, this group of 
channels is insensitive to TTX up to micromole concentrations. Mutagenesis 
studies show that responsiveness to TTX is determined by a single amino acid 
sequence at position 384 in domain I (Sivilotti, Okuse et al. 1997). In particular, 
a change from tyrosine or phenylalanine to serine at position 384 can transform 
a channel from TTX sensitive (TTXs) to almost TTX resistant (TTXr) (Herzog, 
Cummins et al. 2003). Given the high conservation and the clustering of genes 
in chromosomal loci, it was suggested that the family of voltage-gated sodium 
channels has arisen from gene duplication and chromosomal rearrangements 
relatively recently in evolution (Catterall, Goldin et al. 2005). 
Structure and function of voltage-gated sodium channels  
Voltage-gated sodium channels are essential for action potential generation and 
propagation and change conformation with changing membrane potential. 
Membrane depolarization induces the opening of the channel and influx of 
sodium, which is followed by inactivation, through intracellular binding of the 
cytoplasmic loop to the pore, which terminates the sodium flow. While the 
membrane potential is repolarizing to return to the resting membrane potential (-
60mV) the channel is in a closed state: repriming (recovery from inactivation) 
(Klugbauer, Lacinova et al. 1995). 
 
Structurally voltage-gated sodium channels are large multi-domain proteins 
composed of a 220-260 kDa large alpha subunit protein with associated beta 
subunits (Klugbauer, Lacinova et al. 1995). The alpha subunit of voltage-gated 
sodium channels is organized into four domains (DI-DIV), each of which 
consists of six transmembrane segments (S1-S6) that form the voltage sensors 
and the ion selective pore. The voltage sensors are found in the S4 alpha helix 
in each of the four alpha subunit domains (I-IV) (Figure 1-4). Residues in S4 are 
either lysine or arginine that are arranged in an interval of every third amino 
acid. The ion selective pore is formed by a re-entrant loop between helices S5 
and S6 and is embedded into the transmembrane region of the channel to form 
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a narrow, ion selective filter at the extracellular end of the pore (Noda, Shimizu 
et al. 1984, Guy and Seetharamulu 1986). Due to membrane depolarization, the 
voltage-gated sensors that are surrounding the central part of the ion selective 
pore undergo rearrangements that lead to opening of the pore. When the pore 
is open the ion selective filter will allow positively charged Na+ ions to enter 
through the pore.  However, it is still unclear how ion selectivity and voltage-
dependent pore gating is achieved in mammalian VGSCs. Our current 
understanding of channel structure is based on comparative sequence analysis 
(Noda, Shimizu et al. 1984), predictions of two-dimensional folding patterns 
(Guy and Seetharamulu 1986) and functional assays, as crystallization of a 
mammalian VGSC has not been successful yet (Figure 1-4,Top). Valuable 
insights have been gained from crystallization of NavAb, a bacterial voltage-
gated sodium channel that shares around 20 percent sequence homology with 
mammalian Nav channels (Charalambous and Wallace 2011). NavAb, originally 
derived from Acrobacter butzleri, is a homotetrameric VGSC with each of the 
homomers consisting of 6 transmembrane segments (Figure 1-4,Bottom). Its 
crystal structure revealed that the NavAb consists of two interconnected parts: 
the pore module and the voltage sensor domains. The pore is composed of four 
modules 1) an outer funnel-like vestibule 2) a selectivity filter 3) a central cavity 
and 4) an intracellular activation gate. These parts are enclosed and interact 
with four peripheral voltage sensor domains (VSD). Changes in membrane 
potential induce structural changes in the VSD that lead to the structural 
rearrangement of the pore module and subsequently its opening. The selectivity 
filter in the pore module is short and water filled with four glutamate residues at 
its narrowest part that generate an electronegative high-field strength side 
where Na+ is captured and partial dehydrated via interaction with the acidic side 
chains. In this way, Na+ is conducted though the pore (Payandeh, Scheuer et al. 
2011)(Figure1-4, Bottom). 
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Figure 1-4: The subunit organization of the voltage-gated Nav channel.  
Top | Alpha subunits of voltage-gated sodium channels (VGSCs) are integral membrane 
proteins organized in four homologous domains (DI-DIV). Each domain consists of 6 
transmembrane segments (S1-S6) that form voltage sensors and ion selective pores. The 
voltage sensor is found in the S4 alpha helix in each of the four alpha subunit domains (I-IV) 
residues in S4. The ion selective pore is formed by a re-entrant loop between helices S5 and S6 
and is embedded into the transmembrane region of the channel to form a narrow, ion selective 
filter at the extracellular end of the pore (Noda, Shimizu et al. 1984, Guy and Seetharamulu 
1986). Bottom | Crystallization of NavAb. Top and side view of the NavAb channel from the 
bacterium Acrobacter butzleri. Taken from Namadurai, Yereddi et al. (2015). 
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The high resolution crystal structure of NavAb in a closed conformation but with 
an activated voltage sensor domain (Payandeh, Scheuer et al. 2011) and in two 
potentially inactivated states (Payandeh, Gamal El-Din et al. 2012) has shed 
light on a possible mechanism of voltage-dependent pore gating and ion 
selectivity in mammalian VGSCs. However, it is important to note that 
mammalian VGSCs are likely to be structured differently as they are multi-
domain proteins. Only a high-resolution crystal structure of a mammalian VGSC 
will bring clarity on how precisely pore gating is achieved (Dib-Hajj, Yang et al. 
2013). 
Beta subunits  
Alpha subunits are associated with beta subunits and can function to modulate 
their gating properties. Four β-subunit genes (SCN1B-SCN4B) (Isom, De Jongh 
et al. 1992, Isom, Scheuer et al. 1995, Kazen-Gillespie, Ragsdale et al. 2000, 
Morgan, Stevens et al. 2000, Qin, D'Andrea et al. 2003, Yu, Westenbroek et al. 
2003, Cheng, Sun et al. 2010) have been identified in the human genome, 
which encode for β1, β2, β3, β4 subunit. These subunits have a molecular 
weight of around 30-40 kDa. In addition, β1-subunit is alternatively spliced into 
β1a and β1b (Kazen-Gillespie, Ragsdale et al. 2000). Aside from β1b, which is 
soluble, all β-subunits share a common structure: an extracellular N-terminal 
immunoglobulin loop (Ig), a transmembrane domain and a small intracellular C-
terminal domain. Nav alpha subunits and β-subunits are linked together through 
the extracellular Ig domain with disulfide bonds in β2 and β4 and non-covalently 
with β1 and β3 (Hartshorne, Messner et al. 1982, Messner and Catterall 1985, 
Chen, Calhoun et al. 2012). Although all β-subunits were thought to be single 
transmembrane proteins, this seems to hold true for most but not all subunits 
i.e. β1b is soluble (Kazen-Gillespie, Ragsdale et al. 2000) and a high-resolution 
crystal structure has revealed that β3 assembles into a trimer (Namadurai, 
Balasuriya et al. 2014). Trimeric formation of β3 increases the number of 
possible binding sites to Nav channels and might be important in connecting the 
Nav alpha subunits to each other and to other functional components. Higher 
order clusters of Nav channels may also influence the electrophysiological 
properties of the channel individually as well as the whole cluster (Namadurai, 
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Balasuriya et al. 2014). A comparison of primary structures indicates that β3 
and β1 are closely related, with most of the amino acids critical for trimerization 
found at identical positions with the exception of Pro-6 that is changed to Asp-6 
in β1. Although β1 trimers may also form, they will most likely differ from β3 
trimers as the change from proline to aspartic acid will interfere with trimer 
formation due to electrostatic repulsion (Namadurai, Balasuriya et al. 2014). β4 
and β2 also share high sequence homology. In contrast to β3, crystallization 
showed that β4 does not form oligomers (Gilchrist, Das et al. 2013). Association 
of a Nav α-subunit with a specific β-subunit can directly modulate the sodium 
channel gating properties (Isom, Ragsdale et al. 1995, Zimmer and Benndorf 
2002, Meadows and Isom 2005). 
Animal studies confirm that electrophysiological properties of sodium channels 
are changed in β-subunit null mice. For instance, Scn1b null mice have severe 
neurological deficiencies and exhibit hyperexcitable DRG neurons (Lopez-
Santiago, Brackenbury et al. 2011). In contrast, DRG neurons in Scn2b 
knockout mice exhibit a fifty per cent decrease in activation and inactivation of 
TTX-S sodium currents due to decreased Nav1.7 expression in the plasma 
membrane (Lopez-Santiago, Pertin et al. 2006). Although Scn2b null mice are 
more susceptible to seizures, they exhibit no severe neurological deficits (Chen, 
Bharucha et al. 2002, Chen, Westenbroek et al. 2004, Patino, Brackenbury et 
al. 2011). Scn3b mice suffer from arrhythmia, likely due to Scn3b being 
normally expressed in the heart (Hakim, Gurung et al. 2008, Hu, Barajas-
Martinez et al. 2009, Hakim, Brice et al. 2010). A recent publication by 
Laedermann et al. (2013) suggests that the co-expression of Nav1.7 with β1- or 
β3-subunits in HEK293 cells not only changes gating properties of the channel 
in the cell membrane but also modulates the Nav1.7 glycosylation state and in 
this way regulates its trafficking and stabilization in the plasma membrane 
(Laedermann, Syam et al. 2013). 	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Distribution of voltage-gated sodium channels (VGSCs) 
 
VGSCs are structurally and functionally related to each other but cellular and 
subcellular location varies among family members. Nav1.1, Nav1.2, Nav1.3 and 
Nav1.6 are predominantly located in the CNS, whereas Nav1.7, Nav1.8 and 
Nav1.9 are primarily found in the peripheral nervous system, Nav1.4 mainly in 
the skeletal muscles and Nav1.5 in heart (King and Vetter 2014). The following 
section gives examples of the diverse location and function of voltage-gated 
sodium channel family members. 
Nav1.1 (SCN1A) 
Nav1.1 is found in the soma and dendrites of neuronal cells, the spinal cord 
(Westenbroek, Merrick et al. 1989) and in cardiac myocytes where it plays a 
significant role in excitation-contraction coupling (Maier, Westenbroek et al. 
2003). Missense and nonsense mutations in SCN1A have been linked to 
generalized-epilepsy with febrile seizures plus type 2 or GEFS+2 (Escayg, Heils 
et al. 2001), familial hemiplegic migraine (Dichgans, Freilinger et al. 2005) and 
various other forms of epilepsy (Nabbout, Gennaro et al. 2003, Meisler and 
Kearney 2005). 
Nav1.3 (SCN3A) 
In DRG, Nav1.3 is predominantly expressed during embryonic and prenatal 
stages and is transcriptionally silent during adulthood (Beckh, Noda et al. 1989, 
Shah, Stevens et al. 2001). In rats, peripheral nerve and CNS injuries re-
induces and upregulates the expression of Nav1.3 mRNA and protein in spinal 
cord and DRG neurons (Waxman, Kocsis et al. 1994, Dib-Hajj, Tyrrell et al. 
1998), which possibly contributes to neuronal hyperexcitability in neuropathic 
pain states. However, the role of Nav1.3 in neuropathic pain is still unclear and a 
species-specific effect could be present. Global and DRG specific Nav1.3-/- mice 
do not exhibit alleviated pain behaviour after nerve injury (Lindia, Kohler et al. 
2005, Nassar, Baker et al. 2006). In contrast, neuropathic rats show decreased 
pain-related behavior after intrathecal AS-ODN treatment and virus-mediated 
siRNA knock down of Nav1.3 (Hains, Saab et al. 2006, Samad, Tan et al. 2013). 
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Nav1.8 (SCN10A)  
Nav1.8 is exclusively found in peripheral sensory neurons (Akopian, Sivilotti et 
al. 1996) with 85 per cent of Nav1.8-positive cells identified as nociceptors 
(Djouhri, Fang et al. 2003). In contrast to Nav1.7, Nav1.8 activates at a higher 
threshold and exhibits slow-inactivating characteristics. Therefore, it is the most 
significant contributor in the depolarization phase of action potentials in DRG 
neurons. Animal studies report a specialized role for Nav1.8 in mediating 
noxious cold pain. While very low temperatures affect responsiveness of TTXs 
channels, Nav1.8 still remains responsive (Zimmermann, Leffler et al. 2007). 
Knockout studies on Nav1.8 emphasize its crucial role in cold but also 
inflammatory and mechanical pain. However, development of neuropathic pain 
and the response to acute heat stimuli are seemingly unaffected by the ablation 
of Nav1.8 (Nassar, Levato et al. 2005, Abrahamsen, Zhao et al. 2008). A recent 
study by Faber et al. (2012) concludes that certain gain-of-function mutations in 
Nav1.8 (SCN10A) underlie painful peripheral neuropathy (Faber, Lauria et al. 
2012). Furthermore, in rats with bone cancer the expression of Nav1.8 is linked 
to the development of pain in this model (Qiu, Jiang et al. 2012). 
Nav1.9 (SCN11A) 
Nav1.9 is mostly found in small diameter nociceptive DRG neurons (Dib-Hajj, 
Tyrrell et al. 1998, Fang, Djouhri et al. 2002) and expresses a permanent TTX 
resistant current that is around the resting membrane potential (Cummins, Dib-
Hajj et al. 1999, Priest, Murphy et al. 2005). Therefore Nav1.9 mainly 
contributes to the setting of DRG excitability by modulation of the resting 
potential (Baker, Chandra et al. 2003, Ostman, Nassar et al. 2008). Nav1.9 
knockout mice exhibit attenuated inflammatory pain responses whereas acute 
and neuropathic pain thresholds are unchanged (Priest, Murphy et al. 2005, 
Amaya, Wang et al. 2006). A recent study by Leipold et al. (2013) showed that 
a recurrent gain-of-function missense mutation in Nav1.9 can lead to congenital 
inability to experience pain (Leipold, Liebmann et al. 2013). 
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1.3   Distribution of Nav1.7 and SCN9A/Scn9a 
SCN9A/Scn9a 
 
Nav1.7 plays an important role in initiation and propagation of action potentials 
(Cummins, Howe et al. 1998) and acts as a threshold channel. Spontaneous 
and inherited mutations in SCN9A (Nav1.7) are associated with the human pain 
disorders Primary erythromelalgia (PE) (Yang, Wang et al. 2004, Drenth, te 
Morsche et al. 2005), Paroxysmal extreme pain disorder (PEPD) (Fertleman, 
Baker et al. 2006, Dib-Hajj, Estacion et al. 2008) and Channelopathy-associated 
insensitivity to pain (CAIP) (Cox, Reimann et al. 2006).  
Cellular distribution of Nav1.7 
 
Nav1.7 is mainly expressed in small and medium diameter nociceptive DRG 
neurons, sympathetic ganglia (Sangameswaran, Fish et al. 1997, Toledo-Aral, 
Moss et al. 1997) and olfactory sensory neurons (Weiss, Pyrski et al. 2011). 
Nociception and olfaction are both linked to Nav1.7 function: CIP patients are 
anosmic and individuals carrying specific SNPs in SCN9A (R1150W allelic 
frequency of 14%, and P610T allelic frequency of 4%) that are associated with 
altered pain perception (Samuels, te Morsche et al. 2008, Reimann, Cox et al. 
2010) also have altered olfactory thresholds. These findings highlight that 
Nav1.7 blockers will likely block nociception and olfaction (Heimann, Lotsch et 
al. 2013).  
Additionally, Nav1.7 is expressed in adrenal chromaffin cells (Toledo-Aral, Moss 
et al. 1997), visceral sensory neurons, nodose ganglion neurons (Muroi, Ru et 
al. 2011), smooth myocytes (Holm, Rich et al. 2002, Jo, Nagata et al. 2004), 
myenteric neurons (Sage, Salin et al. 2007) and non-excitable cells such as 
immune cells (Kis-Toth, Hajdu et al. 2011), human erythroid progenitor cells 
(Hoffman, Dodson et al. 2004) and β-cells in the pancreatic islets where Nav1.7 
might trigger glucose-stimulated insulin secretion (Ernst, Aguilar-Bryan et al. 
2009, Zhang, Chibalina et al. 2014). Furthermore, human cells derived from 
prostate cancer (Diss, Stewart et al. 2005) and breast cancer patients (Fraser, 
Diss et al. 2005) show increased expression of Nav1.7.  
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Subcellular location of Nav1.7  
Immuno-staining of DRG neurons shows that Nav1.7 is highly expressed in 
unmyelinated small diameter C-fibre neurons. Co-immunostaining of Nav1.7 
with the C-fibre marker peripherin (Einheber, Zanazzi et al. 1997) shows that 
around sixty-three per cent of peripherin-positive neurons exhibit Nav1.7 
expression whereas only a small minority of peripherin-negative cells is 
immunolabelled for Nav1.7. Co-immunostaining of Neurofilament 200 (N200), an 
A-fiber marker (Goldstein, House et al. 1991) and Nav1.7 exhibits a fifteen per 
cent overlap in expression of Nav1.7 in medium diameter neurons. However, 
large diameter DRG neurons only rarely exhibit Nav1.7 expression (Figure 1-
5,Top).  
C-fibres can be divided into peptidergic and non-peptidergic nociceptors that 
differ in expression of cell surface molecules and presence of neuropeptides 
(Bennett, Michael et al. 1998, Snider and McMahon 1998). Black, Frezel et al. 
(2012) report that a similar percentage of peptidergic (CGRP) and non-
peptidergic (IB4) neurons express Nav1.7 (Figure 1-5,Top) (Black, Frezel et al. 
2012)(Figure 1-5,Top). A recent paper by Usoskin, Furlan et al. (2015) identified 
11 subtypes of DRG neurons based on comprehensive RNA-seq. Controversly, 
they showed that Scn9a is highly expressed in small unmyelinated low 
threshold mechano C-fibre neurons, unmyelinated peptidergic and non-
peptidergic neurons as well as myelinated neurons with the exception of only 
one subtype of large propioceptor neurons (‘NF5’) (Usoskin, Furlan et al. 2015). 
 
Co-immunostaining of Nav1.7, peripherin (unmyelinated fibres) and caspr 
(paranodal regions of myelinated fibers) in the sciatic nerve shows that Nav1.7 
is also strongly expressed along the peripheral branch of approximately 27 per 
cent of unmyelinated C-fibres. Additionally, in a subset of small diameter 
myelinated Aδ-fibers, Nav1.7 is expressed in the nodes of Ranvier. Nav1.7 is 
usually not expressed in the nodal or paranodal segment of nodes of Ranvier 
(Figure 1-5,Bottom). This expression pattern correlates with the expression of 
Nav1.6 and might underlie a regulatory function in pain signaling (Black, Frezel 
et al. 2012).	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Figure 1-5: Expression of Nav1.7 in DRG neurons and sciatic nerve.  
Top | Expression of Nav1.7 in DRG neurons (A)	   Expression of Nav1.7 in DRG neurons, 
immunostaining against peripherin (green), neurofilament 200 (NF, blue) and Nav1.7 (red). 
Peripherin co-localization with Nav1.7 (yellow). A few small peripherin-negative neurons display 
robust Nav1.7 immunolabeling (arrows) and NF co-localization with Nav1.7 (magenta). (B) 
IB4+(green) CGRP (blue) and Nav1.7 (red). IB4+ co-localization with Nav1.7 (yellow) and CGRP 
co-localization with Nav1.7 (magenta). Few DRG neurons display co-localization of IB4, CGRP 
and Nav1.7 (arrow). Bottom | Expression of Nav1.7 in sciatic nerve (A) Immunostaining 
against peripherin (green), Nav1.7 (red) and co-localization with Nav1.7 (yellow) (B) Nodal 
regions in sciatic, paranodal marker caspr (green) and Nav1.7 (red). Taken from Black, Frezel 
et al. (2012). 
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The central branch of nociceptors projects its axon to second order neurons in 
the superficial lamina of the spinal cord dorsal horn. Co-immunostaining of 
Nav1.7 with peripherin and Neurofilament 200 in the dorsal and ventral roots 
reveals that Nav1.7 is present along unmyelinated and myelinated fibres in the 
dorsal but not the ventral roots. Similar to sciatic nerve, a small subset of small 
diameter myelinated A-fibres express Nav1.7 in the nodal region of the dorsal 
but not the ventral root (Black, Frezel et al. 2012). Peripherally, peptidergic and 
non-peptidergic C-fibers terminate in different layers in the epidermis. In skin, 
intraepidermal nerve fibres (IENF) are the peripheral terminals of C-fibre and A-
fibres (Zylka, Rice et al. 2005). Co-immunostaining of Nav1.7 with Protein Gene 
Product 9.5 (PGP9.5), an IENF marker, shows that Nav1.7 is robustly 
expressed in IENFs, from the point of branching to the axon tip (Figure 1-
6,Top). 
Centrally, peptidergic fibres (CGRP) terminate in lamina I and IIo and non-
peptidergic (IB4+) fibers terminate in lamina IIi of the spinal cord dorsal horn 
(Snider and McMahon 1998). Co-immunostaining of Nav1.7 with CGRP and 
IB4+ as well as synaptophysin, a pre-synaptic marker, demonstrated that Nav1.7 
is robustly expressed within pre-synaptic terminals in lamina I, Iio and IIi (Figure 
1-6,Bottom). However, Nav1.7 is not expressed in post-synaptic neurons (Black, 
Frezel et al. 2012). 
	   35	  
 
Figure 1-6: Expression of Nav1.7 in glabrous skin and spinal cord dorsal horn.  
Top | Expression of Nav1.7 in glabrous skin PGP9.5 (green) intraepidermal fibres (IENF) 
branch from nerve bundles (arrowheads) at dermis/epidermis boundary (dotted line) and ascend 
in the epidermis. PGP9.5-positive IENFs exhibit Nav1.7 (red) immunolabeling. Bottom | Nav1.7 
expression in spinal cord dorsal horn. (A) Immunostaining against IB4 (green), CGRP (blue) 
and Nav1.7 (red). Robust Nav1.7 immunolabelling is present within lamina I and II. Nav1.7 co-
localization with IB4+ (yellow) and with CGRP (magenta). (B) Increased magnification of IB4, 
CGRP and Nav1.7 labeling in superficial lamina of dorsal horn. Taken from Black, Frezel et al. 
(2012). 
 
 
 
 
 
 
 
	   36	  
Alternative splicing of SCN9A in human DRG 
Sanger sequencing of SCN9A PCR products amplified from human DRG cDNA 
showed that SCN9A (Nav1.7) is alternatively spliced in exon 5 and exon 11 
(Raymond, Castle et al. 2004).  Further qPCR analysis of SCN9A splice variant 
distribution in human DRG also showed that splicing of exon 5 and exon 11 is 
uncoupled (Figure 1-7). Exon 5 encodes for the extracellular linker and voltage 
sensor in DI and exists as two similar mutually exclusive exons that are denoted 
as exon 5N and 5A. The second site, exon 11, encodes for an intracellular 
linker between DI and II and is spliced into 11S (short) and exon 11L (long) 
(Figure 1-7). The exon 5N-containing transcript is reported to be a 
developmental and DRG restricted variant only, whereas the alternatively 
spliced exon 5A transcript is found in the adult PNS and CNS (Raymond, Castle 
et al. 2004). Also, 11S shows increased expression in neonatal DRG neurons 
whereas the longer isoform 11L is predominantly found in adult tissues. The 
11S-containing Scn9A transcripts are enriched in rats after neuropathic surgery 
(Raymond, Castle et al. 2004). Functionally, alternative splicing changes the 
channel’s ability to interact with the beta1-subunit and thereby modulates its 
voltage dependent activation and steady state inactivation (Farmer, Cox et al. 
2012). 
 
 
 
 
 	  
 
Figure 1-7: Alternative splicing patterns of SCN9A are not coupled.  
Top | Sanger sequencing of SCN9A PCR products amplified from human DRG cDNA showed 
that SCN9A is alternatively sliced in exon 5 and exon 11. Exon 5 has a neonatal (N) and adult 
(A) and exon 11 has an extended coding exon 11 (EXT or 11L), shorter coding exon 11 (RS or 
11S) variant. Bottom | SCN9A isoform specific qPCR analysis from human DRG cDNA showed 
that splicing of exon 5 and exon 11 is not linked. Taken from Raymond, Castle et al. (2004). 
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1.4 Post-translational modification of Nav1.7  
Akin to other proteins, voltage-gated sodium channels undergo post-
translational modification and intracellular trafficking, yet our understanding of 
possible mechanisms and protein-protein interaction partners that mediate 
these processes is very limited, in particular in regards to specific voltage-gated 
sodium channel subtypes such as Nav1.7. This section discusses post-
translational modification and protein-interactions of VGSCs that have been 
identified through Yeast-2-hybrid, Co-immunoprecipitation, pull-down assays 
and phosphorylation studies. 
Post-translational glycosylation  
 
A protein’s journey starts with its synthesis in the rough endoplasmic reticulum 
(RER) followed by transportation into the ER lumen where it is folded. Proteins 
are then moved toward the smooth ER, where the newly synthesized protein is 
packed into vesicles that bud off to the Golgi apparatus. In the ER and Golgi 
apparatus proteins undergo extensive glycosylation, which can make up 30 per 
cent of a protein’s molecular weight (MW) (Schmidt and Catterall 1987). As the 
mature protein arrives at the trans-end (the site of the release) of the Golgi 
apparatus, it is packed into vesicles and sent off to its final destination i.e. the 
plasma membrane in the case of VGSCs (Alberts, Bray et al. 1995, Alberts 
2010, Moremen, Tiemeyer et al. 2012).  
Protein glycosylation is functionally important in a variety of biological 
processes, from protein folding, cell signaling, cell-cell adhesion to regulation of 
development and immunity (Moremen, Tiemeyer et al. 2012). Voltage-gated 
sodium channels are subject to glycosylation that directly impacts their gating 
properties and trafficking (Waechter, Schmidt et al. 1983, Schmidt and Catterall 
1987, Bennett, Urcan et al. 1997, Zhang, Hartmann et al. 1999, Tyrrell, 
Renganathan et al. 2001, Cronin, O'Reilly et al. 2005). As for Nav1.7, active 
alpha subunits are present on the cell surface. However, the majority of Nav1.7 
might be localized intracellularly, either going through the secretory pathway or 
stored in intracellular pools (Schmidt, Rossie et al. 1985). In the ER/Golgi where 
glycosylation takes place, alpha subunits and β1/β3 assemble, which enhances 
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trafficking of the Nav alpha subunit to the plasma membrane (Fahmi, Patel et al. 
2001, Zimmer, Biskup et al. 2002). In the case of Nav1.8, this is achieved by 
binding of β3, which mask an ER retention signal and leads to increased 
transport of the channel to the plasma membrane (Zhang, Li et al. 2008). The 
impact of glycosylation on Nav1.7 electrophysiological properties is well 
documented and so is the direct influence on alpha subunit gating properties 
and expression by β-subunits (O'Malley and Isom 2015). Leaderman et al. 
(2013) addressed the question of whether these two regulator mechanisms are 
linked, hence if β-subunits directly influence alpha subunit glycosylation. Under 
experimental conditions, when Nav1.7 is expressed on its own, the channel is 
present in two mutually exclusive glycosylated forms 1) a core-glycosylation 
with a MW of 250 kDA and 2) a full-glycosylation state with a MW of 280 kDA. 
However, Nav1.7 glycosylation state shifts (i.e. from core-glycosylation to fully-
glycosylation) and current density increases when co-transfected with β1- or 
β3-subunit while the activation and inactivation kinetics are only modestly 
altered. This argues for an increased number of Nav1.7 molecules in the plasma 
membrane (Laedermann, Syam et al. 2013). The proposed model is that β1- 
and β3-subunits assemble with the alpha subunits in the ER/Golgi and mediate 
from there a specifically glycosylated form of cell surface expressed Nav1.7. Co-
expression of β1/Nav1.7 enhances the plasma membrane expression of a fully 
glycosylated Nav1.7 but strikingly also of a third alternatively glycosylated form. 
β3 mediates the membrane expression of the core-glycosylated form (Figure 1-
8). In contrast co-expression of Nav1.7 and β2 or β4 does not shift the 
glycosylation pattern towards a particular form, neither is the current density 
changed (Figure 1-8). These findings correlate with the kinetics model proposed 
by Schmidt and Catterall et al. (1987) and findings from Ho et al. (2012). Here, 
interaction of β2 or β4 with the alpha subunit occurs just before anchoring in the 
membrane, thus after the Golgi apparatus where the glycans are added 
(Schmidt and Catterall 1987, Ho, Zhao et al. 2012, Laedermann, Syam et al. 
2013). The physiological relevance of different glycosylation states is still 
elusive, however it may be important in membrane stabilization and relevant in 
pathological pain conditions that are linked to altered Nav1.7 excitability.  
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Figure 1-8: Proposed model of the different intracellular pathways of α-subunits 
depending on the presence of different β-subunits. 
The proposed model is that β1- and β3-subunits assemble with the alpha subunits in the 
ER/Golgi and mediate from there a specifically glycosylated form of cell surface expressed 
Nav1.7. In contrast, co-expression of Nav1.7 and β2 or β4 does not shift the glycosylation state 
of Nav1.7. Here interaction of β2 or β4 with the alpha subunit occurs just before anchoring in the 
membrane, thus after the Golgi apparatus where the glycans are added. Taken from 
Laedermann, Syam et al. (2013). 
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Post-translational phosphorylation  
MAPK – ERK1/2  
Phosphorylation is a reversible post-translational mechanism that mediates a 
broad range of functions from membrane transport to gene transcription. During 
development and in pathological pain states, neurotrophic factors are released 
that activate mitogen-activated protein kinases (MAPKs), which in turn recruit 
transcription factors and turn on gene expression (Averill, Delcroix et al. 2001, 
Woodall, Richards et al. 2008). Extracellular signal-regulated protein kinase 1/2 
(ERK1/2) a member of the MAPK family, is found in DRG neurons where 
pERK1/2, the kinase’s active, phosphorylated form is implicated in injury-
induced hyperalgesia. Hyperalgesia is a common symptom of acute and chronic 
pain and is caused by altered neuronal excitability (Ji, Baba et al. 1999, Ji, 
Samad et al. 2002, Obata, Yamanaka et al. 2004). Stamboulian et al. (2010) 
reported a link of hyperalgesia with altered Nav1.7 activity on the level of 
ERK1/2. During hyperalgesia, neurotrophic factors are released that activate 
ERK1/2, which in turn phosphorylates Nav1.7 in the intracellular loop (L1) 
between domains I and II. This leads to structural changes and altered gating 
properties of the channel, which subsequently influence the excitability of DRG 
neurons. In comparison to glycosylation, phosphorylation does not change 
Nav1.7 current density but its ion conductance (Stamboulian, Choi et al. 2010). 
Furthermore phosphorylation also regulates SCN9A mRNA stability. 
Constitutive phosphorylation of ERK1/2 leads to increased degradation of 
SCN9A (Nav1.7) mRNA and in this way alters the amount of functional Nav1.7 
protein in the plasma membrane (Yanagita, Kobayashi et al. 2003).  
Protein Kinase A  
Protein kinase A (PKA) and C (PKC) are important cellular modulators of ion 
channel activity under normal and pathological conditions. Activation and 
regulation of PKA are dependent on activation via cAMP and interaction with 
AKAP15 (Cantrell, Tibbs et al. 1999, Cantrell, Tibbs et al. 2002).  
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Figure 1-9: Sodium channel alpha subunit-AKAP15-PKA complex and PKC.  
Sodium channel alpha subunit (yellow, Nav1.2); AKAP15 binding site (dark red;LZ, bracket and 
segment); PKA (light red); four phosphorylation sites for PKA within loop I/II (arrows); PKC 
(orange) PKC phosphorylation site serine-1506, and the inactivation gate sequence within loop 
III/IV (arrow). Taken from Dai, Hall et al. (2009). 
 
Additionally, the PKA isoform RIIβ, which is primarily expressed in peripheral 
nociceptive DRG neurons, is activated through inflammatory agents (Isensee, 
Diskar et al. 2014). Multiple VGSCs are reported to have PKA phosphorylation 
sites in their DI-II loop while the AKAP15 binding site is present in all channel 
subtypes (Dai, Hall et al. 2009). AKAP15 is a small cAMP-dependent protein 
kinase-anchoring protein that binds to a cytoplasmic motif (LZ-binding site) in 
loop I/II (L1) of Nav channels (Figure 1-9) (Cantrell, Tibbs et al. 2002, Few, 
Scheuer et al. 2007). Although the regulatory and phosphorylation sites are 
highly conserved, PKA mediated effects on Nav alpha subunits may be subtype-
specific. In Nav1.2, PKA phosphorylates the alpha subunit at four conserved 
residues in the DI-II linker domain (Smith and Goldin 1996, Smith and Goldin 
2000)(Figure1-9). This in turn reduces the channel’s opening probability in 
response to depolarization (Rossie and Catterall 1987, Li, West et al. 1992, 
Murphy, Rossie et al. 1993, Cantrell, Tibbs et al. 2002). In Nav1.5, PKA 
phosphorylation sites coincide with a retention signal and phosphorylation of 
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these sites increasing the trafficking of the channel to the plasma membrane 
(Zhou, Shin et al. 2002). 
As for Nav1.7, a study in Xenopus oocytes reports that PKA activation causes a 
reduction of Nav1.7 sodium peak current while the gating kinetics and voltage 
sensitivity of Nav1.7 were not affected (Vijayaragavan, Boutjdir et al. 2004). 
However, PKA regulation of Nav1.7 could be dependent on the expression 
system and on the channel isoform. For instance exon 11 that encodes for the 
cytoplasmic loop in DI-DII is spliced into long (11L) or short (11S) splice 
variants, which affect the loop I-II length that contains an important regulatory 
site for AKAP15/PKA. While Scn9a splice variant 11L has no impact on Nav1.7 
kinetics, expression of the exon 11S isoforms and the presence of the PKA 
activator cAMP lowers the Nav1.7 activation threshold (Chatelier, Dahllund et al. 
2008) and could be an explanation for the observed hyperexcitablity of DRG 
neurons during pathological pain states. This is consistent with observations 
from Raymond et al. (2004) that surgery induced neuropathic pain leads to 
upregulation of cAMP and 11S-containing Scn9a transcripts (Raymond, Castle 
et al. 2004). 
Protein Kinase C 
PKC, similar to PKA, phosphorylates alpha subunit Nav1.2 at specific residues 
in two sites in L1, DI-DII domain of VGSCs and at an additional site in the DIII-
DV region, the inactivation loop (Figure 1-9). Both regions are highly conserved 
among all voltage-gated sodium channels and may be also required for the 
regulation of Nav1.7 (Numann, Catterall et al. 1991, Cantrell, Tibbs et al. 2002). 
Various studies suggest that PKC isoforms modulate specific alpha subunits in 
an isoform and tissue-dependent manner. For instance activation of PKCα 
isoform in adrenal chromaffin cells, promotes Nav1.7 internalization while PKCε 
activation negatively influences the stability of SCN9A mRNA (Wada, Yanagita 
et al. 2004). Vijayaragavan et al. (2004) also reports that two isoforms of PKC 
(ε and βII) are responsible for reduction of Nav1.7 and Nav1.8 current 
amplitudes in Xenopus oocytes (Vasilets, Schmalzing et al. 1990, 
Vijayaragavan, Boutjdir et al. 2004). 
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PKC isoforms are also involved in modulation of inflammatory and neuropathic 
pain responses (Malmberg, Chen et al. 1997, Aley, Messing et al. 2000, Igwe 
and Chronwall 2001). Inhibition of PKC in DRG neurons of diabetic rats 
attenuates hyperalgesia (Ahlgren and Levine 1994, Kim, Sasaki et al. 2003). 
Moreover inhibition of specific PKC isoforms in mice diminishes thermal 
hyperalgesia and opioid-mediated anti-nociceptive behavior (Ohsawa and 
Kamei 1997, Ohsawa and Kamei 1999). This is consistent with findings in 
rodents where increased PKC activity correlates with enhanced MAPK p38 
activity and upregulation of Nav1.7 (Hong, Morrow et al. 2004, Jin and Gereau 
2006, Chattopadhyay, Mata et al. 2008). PKC activation reportedly induces 
upregulation of Nav1.7 in DRG neurons via activation of p38. Additionally a 
synergetic effect of PKC activation on PKA was reported. Here, PKC binding to 
the DI-DII loop of Nav1.2 through AKAP-15/18 mediates PKA activation and 
targeting to its phosphorylation sites on Nav1.2 (Cantrell, Tibbs et al. 2002). 
 
Calmodulin (CaM) and Ca2+-dependent CaM-kinase II (CaM-KII) 
Calmodulin (CaM) is a Ca2+-sensing protein that is ubiquitously expressed. 
Increase in cytoplasmic Ca2+ activates CaM and induces intracellular signaling 
cascades. CaM binds and modulates voltage-gated sodium channels (Figure 1-
10). Nav1.4 in the skeletal muscle associates with CaM via a C-terminal motif, 
also known as an IQ motif (Mori, Konno et al. 2000, Deschenes, Neyroud et al. 
2002). Although the IQ motif appears to be highly conserved among voltage-
gated sodium channels, CaM regulation may be subtype-specific and for some 
ion channels, CaM binding is calcium-independent (Deschenes, Neyroud et al. 
2002, Herzog, Liu et al. 2003, Adams, Ben-Johny et al. 2014). Nav1.2, Nav1.4, 
and Nav1.6 are prime targets of CaM while Nav1.1 and Nav1.3 show lower 
affinity to CaM in the presence or absence of calcium. Herzog et al. (2003) 
reported that CaM regulates the current density of both Nav1.4 and Nav1.6. 
However, binding of calcium/CaM to Nav1.4 is critical and mutations in the IQ 
motif reduce the number of Nav1.4 channels in the plasma membrane but only 
mildly impact its gating properties (Biswas, Deschenes et al. 2008).  
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Figure 1-10: Nav channel as a macromolecular signalling complex.  
AnkG, ankyrin-G; Nedd4, neural precursor cell expressed developmentally downregulated 
protein 4; C, catalytic; R, regulatory; P, phosphorylation; Cav3, caveolin-3; PDZ, postsynaptic 
density protein/Drosophila disk large tumor suppressor/zonula occludens-1; SNTA1, α1-
syntrophin. PKA, Protein kinase A; PKC protein kinase C; CaM, Calmodulin; CaM-KII, 
Ca2+/CaM-dependent kinases II; Taken from Herren, Bers et al. (2013). 
 
 
In comparison, IQ motif mutations in Nav1.6 impact the channel’s gating 
properties (Herzog, Liu et al. 2003). Also mutations of this motif in Nav1.5 have 
little effect on CaM binding but reduce calcium affinity in another regulatory 
domain. It was suggested that Nav1.5 is indirectly regulated by CaM through 
activation of CaM-KII (Deschenes, Neyroud et al. 2002, Shah, Wingo et al. 
2006). Calmodulin activates a group of Ca2+/CaM-dependent kinases (CaM-K) 
that phosphorylate membrane proteins including ion channels. CaM-kinase II is 
a multifunctional Ser/Thr kinase that mediates a broad range of cellular 
functions i.e. membrane excitability, ion channel biophysical properties and 
synaptic plasticity (Frankland, O'Brien et al. 2001). It targets specific isoforms to 
the AIS (Axon initial segment) by βIV-spectrin–targeted calcium/calmodulin-
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dependent kinase II (CaM-KII) interaction (Uemoto, Suzuki et al. 2007). This 
complex is an important regulatory unit for voltage-gated sodium clustering in 
the membrane (Hund, Koval et al. 2010) (Figure 1-10). In cardiac myocytes, 
Nav1.5 is directly phosphorylated via a βIV-spectrin–targeted 
calcium/calmodulin-dependent kinase II complex in loop I (DI-II, L1) (Wagner, 
Dybkova et al. 2006, Ashpole, Herren et al. 2012). This in turn regulates the 
membrane excitability in the mouse heart. During heart failure, CaM-KII 
expression is significantly increased and CaM-KII overexpression in myocytes 
recapitulates the human Brugada and long QT syndrome phenotype. Both 
diseases are linked to dysregulated expression of Nav1.5 that lead to cardiac 
arrhythmia (Veldkamp, Viswanathan et al. 2000, Wagner, Dybkova et al. 2006, 
Herren, Bers et al. 2013). As for Nav1.7, increased intracellular Ca2+ in adrenal 
chromaffin cells decreases the level of surface expressed protein. This effect 
might be mediated by the interaction of a PKC isoform with calneurin and 
calpains (Wada, Yanagita et al. 2004). 
Post-translational SUMOtylation   	  
Collapsin response mediator protein 2 (CRMP2), a protein linked to axonal 
growth, axonal and dendritic fate (Inagaki, Chihara et al. 2001) and trafficking of 
voltage-gated ion channels (Brittain, Piekarz et al. 2009, Chi, Schmutzler et al. 
2009), undergoes reversible SUMOtylation (small ubiquitin-like modifier, 11 kDA 
SUMO proteins are added) at 1 to 3 lysine residues (Wilkinson and Henley 
2010, Ju, Li et al. 2013). Mutations in CRMP2 SUMOtylation sites decrease the 
level of surface expressed Nav1.7. The effect is specific to Nav1.7, which by 
itself, unlike other VGSCs, does not have a SUMOtylation motif. However, 
CRMP2 does not directly interact with Nav1.7 but rather CRMP2 SUMOtylation 
recruits isoform-specific binding proteins that promote the trafficking of the 
channel to the plasma membrane. Hence, CRMP2 SUMOtylation provides a 
novel mechanism for the modulation of Nav1.7 trafficking (Dustrude, Wilson et 
al. 2013).  
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Post-translational ubiquitylation 
 
Newly synthesized proteins undergo various quality controls in the ER to 
prevent partially or incorrectly folded proteins from leaving the endoplasmic 
reticulum (Alberts, Bray et al. 1995). Voltage-gated sodium channels Nav1.5 
and Nav1.8 are held back through arginine-based intracellular retention motives 
of the type RXR that are found in the DI-DII loop. Nav1.8 is released, for 
instance, when β3 associates with the channel and thereby masks the C-
terminal RXR signal in the DI-DII loop, which leads to increased membrane 
expression of the channel (Zhang, Li et al. 2008). Although not highly 
conserved, RXR motifs are also present and functionally important in other 
voltage-gated sodium channels (Figure 1-12) (Allouis, Le Bouffant et al. 2006, 
Zhang, Li et al. 2008). However, the majority of Nav1.7 might be stored in 
intracellular pools. This may permit the cell to quickly change the number of 
surface expressed channels (Schmidt, Rossie et al. 1985). 
 
Another quality and regulatory mechanism is ubiquitylation. Ubiquitylation is a 
reversible post-translational modification that regulates the internalization and 
degradation of proteins through covalent, C-terminal attachment of ubiquitin. 
Ubiquitylation was first discovered as a mechanism to mark cytosolic proteins 
for proteomic degradation (Abriel and Staub 2005) and can be reversed by 
deubiquitylating enzymes (DUBs)(Amerik and Hochstrasser 2004) (Figure 1-11, 
right). Cell surface proteins, such as voltage-gated sodium channels, are tagged 
for internalization or degradation by the lysosome or proteasome to control the 
number of channels present in the plasma membrane (van Bemmelen, Rougier 
et al. 2004, Xu, Duong et al. 2009). The ubiquitylation pattern determines the 
fate of a protein and can be mono-, multi-, or polyubiquitylated. The latter is 
often a marker for degradation by cytoplasmic, nuclear or endoplasmic 
proteasomes (Xu, Duong et al. 2009). Ubiquitylation requires three consecutive 
enzymatic steps 1) E1 (ubiquitin activation enzyme) activates ubiquitin, 2) 
activated ubiquitin is transferred to E2, an ubiquitin carrier enzyme that allows 
the interaction with 3) E3 (ubiquitin protein ligase) that in the final step 
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covalently ubiquitylates lysine residues in the target protein (Huang, Kinnucan 
et al. 1999) (Figure 1-11). 
There are two main classes of E3 ligases, Ring finger E3 (Joazeiro and 
Weissman 2000) and HECT E3 ligases with more than 1000 isoforms in 
humans to ensure the specificity of the ubiquitylation (Varshavsky 2012). HECT 
E3 ligases, which include Nedd4 and Nedd4-like proteins (Rotin, Staub et al. 
2000), contain a catalytic HECT domain (Huibregtse, Scheffner et al. 1995), a 
C2 domain (Nalefski and Falke 1996) and various WW domains (Staub, Dho et 
al. 1996). These domains are responsible for ubiquitylation, target localization, 
phospholipid binding and protein-protein interaction (Plant, Lafont et al. 2000, 
Rotin and Kumar 2009). WW domains of E3 ligases recognize highly conserved 
proline-rich sequences, also known as PPxY motifs, in the C-terminal region of 
the substrate (Macias, Hyvonen et al. 1996) (Figure 1-11). 
Most voltage-gated sodium channels contain a PPxY motif except for Nav1.4, 
Nav1.9 and Nax  (Decosterd and Woolf 2000, Fotia, Ekberg et al. 2004, Rougier, 
van Bemmelen et al. 2005). In vitro and in vivo studies of voltage-gated sodium 
channel PPxY motifs and Nedd4/Nedd4-like proteins have shed light on the 
importance of these proteins in the regulation of Nav trafficking. 
 
Nedd4-2 expression is decreased after surgery-induced neuropathic pain (SNI) 
(Decosterd and Woolf 2000,Cachemaille, Laedermann et al. 2012), which 
coincides with an increased expression of Nav1.7 and Nav1.8 in damage-
sensing neurons after SNI. The strongest evidence comes from nociceptor 
specific Nedd4-2-/- mice that exhibit changes in pain thresholds and 
dysregulated trafficking of Nav1.7 and Nav1.8 (Cachemaille, Laedermann et al. 
2012, Laedermann, Cachemaille et al. 2013). In vitro, neuronal isoforms like 
Nav1.5 and Nav1.7 are polyubiquitylated suggesting that they are degraded by 
the proteasome (Rougier, van Bemmelen et al. 2005, Xu, Duong et al. 2009). 
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Figure 1-11: Schematic representation of the roles of Nav channel ubiquitylation and its 
regulatory pathways.  
Ub, ubiquitin; E1, Ubiquitin-activating enzyme; E2, Ubiquitin-conjugating enzyme; E3, Ubiquitin 
ligase; C, cysteine residue; L, lysine residue; RING, really interesting new gene ubiquitin ligases 
family; HECT, Homologous to E6-AP carboxyl-terminus ubiquitin ligases family; C2, calcium-
dependent lipid binding domain; dubs, deubiquitylating enzymes; P, phosphate group; MPKA, 
protein kinase A; IKK, IκB [inhibitor of nuclear factor κB (NF-κB) kinase; IKKβ, IκB kinase β-
subunit; Taken from Laedermann, Decosterd et al. (2014). 
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However, Nav1.7 expression in Nedd4-2-/- shows no change in total channel 
number but increased amount of Nav1.7 in the plasma membrane, suggesting 
that channel ubiquitylation mediates internalization and recycling of channels 
rather than degradation (Cachemaille, Laedermann et al. 2012, Laedermann, 
Cachemaille et al. 2013, Laedermann, Decosterd et al. 2014). Similar 
observations were made for Nav1.5 in vivo (Fotia, Ekberg et al. 2004, van 
Bemmelen, Rougier et al. 2004). In contrast, Nav1.8 is internalized and 
degraded as the amount of total protein changes in Nedd4-2-/- mice compared to 
wild-type (Cachemaille, Laedermann et al. 2012). Alteration in Nedd4-2 
expression in primary sensory neurons leading to changes in voltage-gated 
sodium channel trafficking might be the underlying cause for hyperexcitablity of 
sensory neurons in pathological states (Laedermann, Cachemaille et al. 2013). 
Lipid rafts and post-translational palmitylation  
 
Lipid rafts are highly dynamic micro-membrane domains, rich in 
glycosphingolipids, cholesterol, gangliosides and other functional components 
including cytoskeletal regulators. Voltage-gated sodium channel Nav1.5 is 
clustered in caveols, a type of lipid raft that is rich in the cholesterol-binding 
protein caveolin (Yarbrough, Lu et al. 2002, Head, Hu et al. 2011) (Figure 1-10). 
Various reports suggest a regulatory role of lipid rafts in the dynamic 
rearrangement of the cytoskeleton and modulation of signaling molecules 
(Echarri, Muriel et al. 2007, Gowrishankar, Ghosh et al. 2012). Pristera et al. 
(2012) reports that Nav1.8 is clustered in lipid rafts along the sciatic nerve and 
DRG neurons. Chemically-induced dissociation of the channel from the rafts 
negatively impacts neuronal excitability (Pristera, Baker et al. 2012). 
Palmitylation of cysteine residues is a reversible lipid modification on newly 
synthesized protein in the ER/Golgi (Schmidt and Catterall 1987) that plays a 
role in cellular signaling, protein trafficking and functionality of membrane 
proteins (Iwanaga, Tsutsumi et al. 2009) by targeting proteins to lipid rafts in the 
plasma membrane. Dysregulation of this process is suspected to underlie 
various neurodegenerative diseases and psychiatric disorders (Huang, Kang et 
al. 2010). Nav channel palmitylation provides an important step in channel 
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biosynthesis but also influences Nav gating properties and toxin sensitivity. 
C1182A in the intracellular loop of Nav1.2 is an important palmitylation site. 
Mutation in this site and another independent mutation to cysteine (G1079C) 
also within the loop region of DII-DIII render Nav1.2 more sensitive to the 
PaurTx3 toxin and influence the channel’s gating properties. As the mutations 
are in the intracellular loop and in no direct contact with the toxin, it is believed 
that they influence palmitylation. Normally palmitylation helps to traffic 
membrane proteins to specific lipid micro domains and changes in the 
palmitylation state may lead to altered trafficking (Bosmans, Milescu et al. 
2011). 
1.5 Voltage-gated sodium channel protein-protein interactions  
Ankyrin 
The scaffolding protein ankyrin is important in clustering and localization of 
membrane and cytosolic proteins to specific domains. Three isoforms of the 
protein are known (Ankyrin-R, -B, -G) which mediate voltage-gated sodium 
channel clustering and supra-molecular complex formation at the axon initial 
segment, somata and node of Ranvier (Hedstrom and Rasband 2006). This is 
likely achieved through an N-terminally membrane-binding domain in ankyrin 
that recognizes a highly conserved 9 residue long segment in the DII-III loop of 
VGSCs (Figure 1-10 and Figure 1-12) (Lemaillet, Walker et al. 2003). The 
domain is essential for channel expression in the plasma membrane. Brugada 
Syndrome, a cardiac arrhythmic disorder, is caused by a mutation in this 
binding site in Nav1.5 and leads to loss of channel function by preventing its 
clustering in the cardiomyocyte plasma membrane (Mohler, Rivolta et al. 2004). 
This is further supported by siRNA-induced knockdown of ankyrin-G that 
causes loss of function in Nav1.5 in cardiomyocytes (Lowe, Palygin et al. 2008). 
The exact molecular mechanism through which ankyrin achieves trafficking and 
clusters voltage-gated sodium channels still remains elusive. However a 
possible mechanism might involve the interaction with the cytoskeletal protein 
spectrin. Here spectrin and ankyrin might act as a scaffold for newly 
synthesized VGSCs and facilitate trafficking after the ER/Golgi (Jenkins and 
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Bennett 2001, Garrido, Fernandes et al. 2003, Shao, Okuse et al. 2009). 
Makara et al. (2014) showed that ankyrin-G functionally guides Nav1.5 and 
calcium/calmodulin-dependent kinase-II to their destined site via interaction with 
βIV-spectrin (Makara, Curran et al. 2014).	  
P11 or annexin A2 light chain 	  
P11 or annexin A2 light chain is a Ca2+-insensitive protein that forms 
heterotetrameric complexes with the calcium-sensitive membrane-binding 
protein annexin 2 that targets the complex to specific sites i.e. to the plasma 
membrane.  p11 also interacts with Ca2+-independent partners including ASIC 
(Donier, Rugiero et al. 2005), Serotonin 1B receptor (Svenningsson, Chergui et 
al. 2006) and the voltage-gated sodium channel Nav1.8 (Okuse, Malik-Hall et al. 
2002). Okuse et al. (2002) reports that p11 binds to the cytosolic N-terminus of 
Nav1.8 and when co-overexpressed in vitro leads to an increased functional 
expression and activity of the channel in the plasma membrane (Okuse, Malik-
Hall et al. 2002). Further evidence for the role of p11 in protein trafficking comes 
from the finding that a tissue-specific knockout of p11 in small nociceptive 
neurons leads to decreased levels of functional Nav1.8. 
Furthermore, Nav1.8 null mice and p11 null mice have a similar acute pain 
response. Surprisingly, the absence of p11 in nociceptive neurons does not 
change inflammatory pain thresholds but ameliorates neuropathic pain behavior 
(Okuse, Malik-Hall et al. 2002, Foulkes, Nassar et al. 2006). Also, annexin 2 
levels in p11 knockout mice are unchanged suggesting that p11 appears to be 
important but not essential for the intracellular trafficking of Nav1.8 to the 
plasma membrane (Foulkes, Nassar et al. 2006). 
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Figure 1-12: Schematic overview of Nav protein interactions. 
 AKAP15 (cAMP-dependent protein kinase-anchoring protein); PKC (Protein Kinase C); PKA 
(Protein Kinase A); RXR motif (ER retention signal); p11 (Annexin A2 light chain); Papin 
(Plakophilin-related armadillo-repeat protein-interacting protein); Nedd4 (neural precursor cell 
expressed developmentally down-regulated protein 4); Moesin (Ezrin/radixin/moesin (ERM) 
cytoskeletal linker proteins). Taken from Shao, Baker et al. (2009). 
 
Papin  
 
Plakophilin-related armadillo-repeat protein-interacting protein or papin, was 
first discovered in rat brain and prostate cancer cells and later in small and large 
diameter sensory neurons (Deguchi, Iizuka et al. 2000, Chaib, Rubin et al. 
2001, Shao, Baker et al. 2009). Structurally, papin has four N- and two C-
terminally located PDZ domains that interact with a highly conserved binding 
motif in the DII-III loop of VGSCs (Shao, Baker et al. 2009) (Figure1-12). The 
PDZ binding motif is found in most VGSCs with the exception of Nav1.4. Papin 
has been shown to directly interact with Nav1.8 and Nav1.7 via this DII-DIII 
binding domain (Malik-Hall, Poon et al. 2003). 
However unlike p11, papin is not required for the translocation of Nav1.8 but 
rather acts as scaffolding protein that stabilizes the channel in the membrane. 
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siRNA-mediated knockdown of papin in vitro reduces Nav1.8 current density 
possibly due to decreased numbers of channels in the plasma membrane. In 
comparison to Nav1.8-/-, papin-/- mice show no change in pain thresholds but 
exhibit increased levels of p11 mRNA through a yet unknown mechanism 
(Shao, Baker et al. 2009, Shao, Okuse et al. 2009). Papin is believed to act as 
an intermediate between plasma membrane localized VGSCs and the E-
cadherin-catenin system that plays a crucial role in cell motility. For instance, 
Chaib et al., (2001) reported that in non-cancerous prostate cells papin 
expression is only found in the basal cell layer. However during early stages of 
prostate cancer its expression extents to other areas and correlates with the 
upregulated expression of known papin binding proteins such as Nav1.7 (Diss, 
Stewart et al. 2005) and δ-catenin (Lu, Dobbs et al. 2005) that have also been 
be implicated in human prostate cancer (Shan, Dong et al. 2014). 
Syntrophin/Dystrophin Complex  
 
The adapter protein syntrophin consists of two-pleckstrin homology domains, a 
PDZ domain and a unique, highly conserved syntrophin domain that enables 
simultaneous association with a variety of proteins. All known isoforms of 
syntrophin (alpha, beta and gamma) directly interact with members of the 
dystrophin family through binding to the pleckstrin and the unique syntrophin 
domain. The PDZ domain is important in binding signaling proteins and 
interacts with the C-terminal residues in Nav1.4 and Nav1.5 (Schultz, Hoffmuller 
et al. 1998). VGSC Nav1.5 is in complex with syntrophin and dystrophin: tissue 
specific knockout of dystrophin in cardiomyocytes decreases the level of 
functional Nav1.5 while mRNA levels are unchanged (Gavillet, Rougier et al. 
2006). Functionally the syntrophin/dystrophin complex is important in capturing 
and anchoring signaling proteins and voltage-gated sodium channels in the 
plasma membrane and prohibiting internalization by stabilizing Nav1.5 in the 
plasma membrane (Schultz, Hoffmuller et al. 1998) (Figure 1-12). 
ERM proteins  
 
Ezrin/radixin/moesin (ERM) are cytoskeletal linker proteins that share a high 
level of homology. Functionally, ERM proteins have been implicated in cellular 
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adhesion, changes of motility, polarity and membrane protein trafficking. These 
processes are achieved through interaction and modulation of the actin 
cytoskeleton underneath the plasma membrane. Indeed ERM proteins and Rho 
GTPase provide the dynamic link between plasma membrane proteins and the 
actin cytoskeleton (McClatchey 2014). Nav1.8 pull-down assays provide 
evidence for direct interaction between a highly conserved C-terminal region in 
Nav1.8 and moesin (Malik-Hall, Poon et al. 2003). Although no functional 
mechanism has been established yet, it is possible that ERM proteins are 
important in clustering voltage-gated sodium channels in specialized membrane 
segments (i.e. nodes of Ranvier) (Shao, Baker et al. 2009, Shao, Okuse et al. 
2009). Furthermore actin and moesin interaction and subsequent reorganization 
of the cytoskeleton may influence Nav1.8 gating properties through actin (de) 
polymerization (Shumilina, Negulyaev et al. 2003). In D. Melanogaster eye, 
ERM protein Dmoesin is essential in light-induced reorganization of the actin 
cytoskeleton and translocation of a light sensitive TRP channel, the main 
contributor to light induced currents in eye (Hardie and Minke 1992). In 
illuminated conditions, Dmoesin is not bound to the TRP channel and is 
trafficked to the cytosol. Ablation of Dmoesin decreases the viability of retinal 
cells suggesting that the dynamic association of Dmoesin and TRP are 
important in regulation and maintenance of the Drosophila eye (Chorna-Ornan, 
Tzarfaty et al. 2005). A hallmark of cancer is increased motility and 
invasiveness of cells supported by rapid changes of the cytoskeleton. 
Dysregulation of ERM and Rho GTPase protein activity is implicated in various 
invasive forms of cancer including breast cancer (Fritz, Brachetti et al. 2002, 
Halon, Donizy et al. 2013). Nav1.7 expression can also impact cytoskeletal-
mediated cellular activity and lead to increased invasiveness in cancer. For 
instance Nav1.7 is upregulated in human prostate, breast and non-small cell 
lung cancer (Fraser, Diss et al. 2005, Brackenbury, Chioni et al. 2007, Roger, 
Rollin et al. 2007). Uysal-Onganer and Djamgoz (2007) found that upregulation 
of epidermal growth factor (EGF) in the human prostate cancer cell line PCa 
PC-3M stimulates the expression of Nav1.7, which in turn enhances migration, 
endocytosis and invasiveness of these cells. Additional evidence for an 
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important role of Nav1.7 in these cancer cells comes from the finding that 
metastatic invasion in these cells can be blocked by TTX. (Uysal-Onganer and 
Djamgoz 2007). A recent paper by Campbell, Main et al. (2013) showed that 
epidermal growth factor (EGF) induces Nav1.7 expression in cultured non-small 
cell lung cancer (NSCLC) which is crucial for proliferation, migration and 
invasiveness of these cancer cells. However, human non-invasive NSCLC cells, 
which lack expression of Nav1.7, can be transformed into invasive cells by 
expression of the channel (Campbell, Main et al. 2013). 
1.6  Natural antisense transcript 
 
Natural antisense transcripts have long been described as ‘junk DNA’ or 
transcriptional noise (Alberts, Bray et al. 1995). However, in recent years, long 
non-coding RNAs (LncRNA) including natural antisense transcripts have 
emerged as a new class of RNA-based regulation (Wang, Yang et al. 2011, 
Rinn and Chang 2012, Yang and Deng 2014). A clear advantage for RNA 
mediated transcriptional regulation is RNA’s quick production and degradation, 
its local storage, conformational flexibility, distribution, and its ability to interact 
with both nucleic acids and proteins (Lapidot and Pilpel 2006). Natural 
antisense transcripts (NATs) are endogenous, protein or non-protein coding 
transcripts that work through a broad range of mechanisms from interfering with 
transcription (Prescott and Proudfoot 2002), translation (Centonze, Rossi et al. 
2007), or masking binding sites on DNA, RNA and proteins (Lapidot and Pilpel 
2006). NATs can act on their targets in cis through perfect sequence 
complementary or in trans through imperfect sequence complementary (Li, Qin 
et al. 2006, Faghihi and Wahlestedt 2009) (Figure 1-13). The most 
comprehensive studies predict that in humans 35% and in mice 72% of the 
transcriptome is transcribed bidirectionally (Grinchuk, Jenjaroenpun et al. 2010, 
Katayama, Tomaru et al. 2005), most of which give rise to partially or fully 
overlapping non-coding RNAs (Yelin, Dahary et al. 2003). Given NAT 
abundance throughout the genome, then this implies an evolutionary benefit of 
such a genomic arrangement (Werner and Berdal 2005, Ling, Ban et al. 2013). 	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Figure 1-13: Regulatory mechanisms of natural antisense transcripts.  
Possible regulatory mechanisms by which NATs can influence expression levels of 
corresponding sense transcripts. Left: Mechanism of antisense action: (A) Transcriptional 
interference (B) Alternative splicing (C) RNA editing and RNAi (D) Chromatin remodeling. Right: 
Relationship between sense and antisense mRNA levels. Taken from Lapidot and Pilpel 
(2006). 	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However, evolutionary conservation of NATs may not be primarily at the 
sequence level, as non-protein coding NATs genes have quite a low sequence 
conservation (Beiter, Reich et al. 2009), but common characteristics of NATs 
suggest that conservation occurs on a structural level either through splicing 
patterns or secondary or tertiary structures (Khaitovich, Kelso et al. 2006, 
Werner, Carlile et al. 2009). Furthermore natural antisense transcripts are 
unequally distributed on the autosomes and X chromosomes with 
underrepresentation of exonic overlapping NATs on the X chromosome 
(Kiyosawa, Yamanaka et al. 2003). 
Natural antisense transcripts as therapeutic targets   
 
Prominent examples of NATs regulating their corresponding sense transcripts 
include BACE-1 antisense that regulates beta secretase levels in Alzheimer’s 
disease through RNA masking (Faghihi, Modarresi et al. 2008), HTT antisense 
at the Huntington gene locus which regulates HTT expression levels through 
RNA interference (Chung, Rudnicki et al. 2011) and Wrap53 NAT of p53 that 
stabilizes p53 mRNA upon damage and leads to an increase in both mRNA and 
protein levels of p53 (Mahmoudi, Henriksson et al. 2009). The CDKN1A 
antisense transcript regulates the expression of cell cycle regulator and tumor 
suppressor gene CDKN1A (p21) through chromatin remodeling. The expression 
of the CDKN1A antisense RNA recruits histone-modifying enzymes and 
mediates trimethylation at the sense promoter region, which induces 
heterochromatin formation and subsequently suppresses transcription of the 
sense gene (Morris, Santoso et al. 2008). Another example of a NAT that 
regulates its corresponding sense transcript is HIF1-α antisense transcript. The 
HIF1-α sense gene encodes for a transcription factor that is linked to tumour 
growth and progression. Binding of the HIF1-α antisense transcript to HIF1-α 
decreases the sense mRNA stability dramatically by exposing an Alu rich 
element in HIF1-α, which induces its decay (Uchida, Rossignol et al. 2004). 
Evidence for the regulatory role of antisense transcripts and its involvement in 
pain comes from Zhao et al. (2013). Kcna2 encoding for a voltage-dependent 
potassium channel and predominately found in DRG neurons has a conserved 
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natural antisense transcript. Nerve injury induces the binding of transcription 
factor myeloid zinc finger protein 1 to the Kcna2 antisense promoter and 
upregulates expression of the transcript in DRG. Although the exact mechanism 
by which the Kcna2 antisense transcript acts on the Kcna2 is still elusive, the 
authors found that increased expression of the Kcna2 antisense downregulates 
Kcna2 and leads to a reduction of total voltage-gated potassium current. This in 
turn increases the excitability in DRG neurons and leads to neuropathic pain 
symptoms (Zhao, Tang et al. 2013). Interestingly, SCN9A (Nav1.7) has a 
corresponding natural antisense transcript encoded on the opposite strand that 
overlaps tail-to-tail (3’ end overlap of the sense and NAT) with the sense 
transcript in both human and mouse and has a putative role in Nav1.7 regulation 
(Koenig, Werdehausen et al. 2015).  
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1.7   Nav1.7 in inherited human pain syndromes 
Channelopathy-associated inability to experience pain (CIP)  
 
CIP is a rare autosomal recessive disorder with only a handful of reported 
cases. Individuals suffering from CIP do not exhibit cognitive or inherited 
physical impairments and have normal responses to light touch, warm and cold 
stimuli, and proprioception but their sense of pain and smell is completely 
abolished (Cox, Reimann et al. 2006, Weiss, Pyrski et al. 2011). CIP is caused 
by nonsense mutations in SCN9A that leads to a loss of function in Nav1.7. 
Genome-wide linkage analysis of three consanguineous Pakistani families led 
to the identification of nonsense amino acid changes in exon 10 (S459X), 13 
(I767X) and exon 15 (W897X) to be responsible for the pain-free phenotype 
(Cox, Reimann et al. 2006). While loss of function mutations in Nav1.7 in 
humans are associated with a congenital inability to experience pain in 
otherwise healthy individuals, global Nav1.7 knockout mice die shortly after 
birth. One explanation for the perinatal lethality in Nav1.7 knockout mice draws 
on the finding that no milk content was found in their stomach suggesting they 
were not able to find their mother’s mammary gland and die due to malnutrition 
(Nassar, Stirling et al. 2004). 
Primary erythromelalgia (PE)  
 
Primary erythromelalgia is a rare inherited autosomal dominant neuropathy 
characterized by an early onset phenotype with painful reddened feet and 
hands due to moderate physical exercise, long periods of standing and 
exposure to warm temperatures. In the later stages of inherited PE, the 
individual experiences reoccurring episodes of persistent pain, redness and 
elevated temperatures of the lower extremities which can extend to the upper 
legs, feet, and also often the hands (Finley, Lindsey et al. 1992, van Genderen, 
Michiels et al. 1993). SCN9A mutations were first reported to cause PE 
following genome-wide linkage analysis in a three-generation Chinese family 
(Yang, Wang et al. 2004). To date, all known PE mutations are gain-of-function 
(Figure 1-14) that lead to increased Nav1.7 activity by lowering the channel’s 
activation threshold and also slowing deactivation (Cummins, Dib-Hajj et al. 
	   60	  
2004). Additionally, some reported mutations including I136V, L858F, A863P 
and F1449V boost Nav1.7’s recovery from inactivation (Dib-Hajj, Rush et al. 
2005, Harty, Dib-Hajj et al. 2006, Cheng, Dib-Hajj et al. 2008). This in turn 
increases the frequency of action potential firing and prolongs the opening of 
the channel, which subsequently renders DRG neurons hyperexcitable. 
Furthermore, a correlation with clinical severity, age of PE onset and mutation 
has been reported with the greater the hyperpolarization shift due to the 
mutation, the earlier the PE age of onset (Han, Rush et al. 2006, Cregg, Cox et 
al. 2014). 
Paroxysmal extreme pain disorder (PEPD) 
 
PEPD is a rare inherited autosomal dominant disease characterized by sudden 
onset of reoccurring pain in the rectal, submandibular and ocular regions. 
Generally, affected individuals experience their first painful episodes during 
infancy (Hayden and Grossman 1959, Fertleman, Baker et al. 2006, Fertleman, 
Ferrie et al. 2007). Painful episodes are triggered by drinking hot or cold liquids, 
eating spicy, acidic or hot food and also by strong wind and sunlight. During the 
course of PEPD, the intensity of episodes steadily increases and are often 
accompanied by non-epileptic seizures and cardiac symptoms (Fertleman, 
Ferrie et al. 2007). Similar to PE, genome-wide linkage analysis identified gain-
of-function mutations in SCN9A/Nav1.7 as the underlying cause for PEPD 
(Figure 1-14). Nav1.7 gain-of-function mutations render DRG neurons 
hyperexcitable by increasing the frequency of action potential firing (Fertleman, 
Baker et al. 2006). In contrast to PE, SCN9A mutations in PEPD do not lower 
the Nav1.7 voltage-dependent activation threshold but shift the voltage-
dependent steady-state fast inactivation towards more depolarizing potentials 
and, depending on the mutation, cause incomplete inactivation of Nav1.7 which 
leads to a persistent current (Fertleman, Baker et al. 2006, Dib-Hajj, Estacion et 
al. 2008). Although both inherited pain disorders have been linked to gain-of-
function mutations in SCN9A, it is still not clear why affected areas and clinical 
symptoms vary significantly between PE and PEPD    
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Figure 1-14: Structure of Nav1.7 and mutations in inherited pain syndromes.  
Alpha subunits of voltage-gated sodium channels (VGSC) are integral membrane proteins that 
are organized in four homologous domains (DI-DIV). Each domain consists of 6 transmembrane 
segments (S1-S6) that form voltage sensors and ion selective pores. (Guy and Seetharamulu, 
1986; Noda et al 1984). SCN9A mutations that are linked to primary erythromelalgia (red 
symbols), PEPD (grey symbols), small fibre neuropathy (yellow symbols). (Bottom, left) Nav1.7 
crystal structure based on recently determined crystal structure of a bacterial sodium channel 
(right). Taken from Dib-Hajj, Yang et al. (2013). 
 	  	  
	   62	  
1.8   Nav1.7 in chronic pain disorders 
Neuropathic pain 
 
The international association for the study of pain (IASP) defines neuropathic 
pain as ‘‘pain caused by a lesion or disease of the somatosensory system’’ 
(Jensen, Baron et al. 2011). In contrast to nociceptive pain, neuropathic pain is 
spontaneous, provoked and long-lasting and not per se a physiological reaction 
to potential or actual tissue damage (Serra, Bostock et al. 2012). Neuropathic 
pain is classified as central (caused by brain damage i.e. stroke, Multiple 
sclerosis, spinal cord injury) or peripheral (referring to damage to PNS nerve 
pathway) or a combination of both. Some of the most common causes are post-
traumatic, post surgery induced nerve injury, post herpetic neuralgia and 
diabetes with prevalence steadily increasing (Wild, Roglic et al. 2004). 
Nav1.7 and neuropathic pain 
 
Neuropathic pain is one of the most common but yet least understood forms of 
pain mostly due to its multi-mechanistic nature. Symptoms may include 
spontaneous burning pain, allodynia and dysesthesias (Attal, Fermanian et al. 
2008). Electrophysiological recording on DRGs shows that these neurons 
exhibit ectopic TTXs discharge after insult, concluding that TTXs voltage-gated 
sodium channels might underlie neuropathic pain (Matzner and Devor 1994, 
Omana-Zapata, Khabbaz et al. 1997). Damage-sensing DRG neurons express 
different subsets of VGSCs thus expression and electrophysiological properties 
are subject to change due to inflammation and nerve injury. In particular, the 
role of Nav1.7 in various animal models of neuropathic and inflammatory pain 
has been closely examined. Global ablation of Nav1.7 is postnatal lethal in mice 
but deletion of Nav1.7 in Nav1.8 positive neurons abolishes inflammatory 
symptoms and sensitivity to high-threshold noxious mechanical stimuli (Nassar, 
Stirling et al. 2004). However, SNL induced neuropathic pain develops normally 
in Nav1.7Nav1.8 and Nav1.7-/- Nav1.8-/- double knockout mice (Nassar, Stirling et 
al. 2004, Nassar, Levato et al. 2005). Interestingly, in humans some 
neuropathies can be successfully treated with sympathetic blockers suggesting 
an involvement of the sympathetic nervous system in the development of 
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neuropathic pain (Yoo, Nahm et al. 2011, de Oliveira Rocha, Teixeira et al. 
2014). Nav1.7 is expressed in peripheral sensory neurons and sympathetic 
neurons (Toledo-Aral, Moss et al. 1997). Minett et al., (2012) compared three 
different tissue specific Nav1.7-/- mouse lines and reported that some forms of 
neuropathic pain are mediated by Nav1.7 in sensory neurons while others 
require the Nav1.7 expression in both sensory and sympathetic neurons. 
Ablation of Nav1.7 in all sensory neurons attenuates mechanical, inflammatory 
pain and spinal withdrawal reflexes to heat but not surgically induced 
neuropathic pain. Deletion of SCN9A in sensory and sympathetic neurons 
abolishes surgically-induced neuropathic pain and recapitulates the human 
loss-of-function phenotype. In contrast, other neuropathies as bone cancer-
induced pain and oxaliplatin-induced pain operate under a Nav1.7-independent 
mechanism (Minett, Falk et al. 2014). It has been suggested that oxaliplatin-
induced pain is mediated by Nav1.6 (Sittl, Lampert et al. 2012, Deuis, 
Zimmermann et al. 2013). However in the course of bone cancer induced pain 
in rats, Nav1.8 and Nav1.9 are upregulated (Qiu, Jiang et al. 2012). In recent 
studies, antisense knockdown of Nav1.8 in this model reversed pain-related 
behaviour suggesting development and maintenance of bone cancer pain relies 
on Nav1.8 (Miao, Gao et al. 2010, Liu, Yang et al. 2014). The role of other 
VGSCs, such as Nav1.3, in neuropathic pain is still not clear: a species-specific 
effect and mechanistic differences could be the reason for the contradicting 
results obtained from mouse and rat and in different models of neuropathic 
pain. Global and DRG specific Nav1.3-/- mice did not exhibit alleviated pain 
behaviour after nerve injury (SNL) (Lindia, Kohler et al. 2005, Nassar, Baker et 
al. 2006). CCI induced but not SNT in Nav1.3-/- reduced mechanical and cold 
allodynia (Minett, Falk et al. 2014). In contrast, intrathecal AS-ODN treatment 
and virus-mediated shRNA knockdown of Nav1.3 in rats attenuates mechanical 
allodynia in neuropathic pain (Hains, Saab et al. 2004, Samad, Tan et al. 2013). 
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Inflammatory pain   
Acute inflammatory pain is a crucial physiological response to infection and 
tissue damage that promotes healing. Peripheral damage recruits immune cells 
to the site of injury and induces the release of inflammatory mediators ATP, H+, 
NGF, pro-inflammatory cytokines and others, which are collectively referred to 
as “the inflammatory soup”. This in turn stimulates and modulates peripheral 
primary sensory neurons and renders them hyperexcitable. Peripheral 
sensitization of nociceptors is a hallmark of inflammation and increases 
neurotransmitter (Glutamate) and neuromodulator (Substance P, CGRP, BDNF) 
release from their peripheral and central terminals. Neurogenic inflammation is 
a result of peripheral release of neuromodulator agents as it induces the 
production and release of inflammatory agents from cells in the vicinity and the 
vascular tissue and the release from neurotransmitters and neuromodulators at 
central terminals into the spinal cord (Julius and Basbaum 2001, Tan, Piekarz et 
al. 2014). 
Nav1.7 in inflammatory pain   
During acute inflammation, a cocktail of inflammatory mediators are released 
leading to increased sensitivity in and around the injured site (Julius and 
Basbaum 2001). The general consensus is that chronic pain states arise from 
altered neuronal activity due to peripheral and central sensitization of 
nociceptive neurons. Nav1.7 has been shown to mediate inflammatory pain 
states. In inflammatory pain rat and mouse models, the TTXs sodium current is 
increased and Nav1.7 is upregulated (Toledo-Aral, Moss et al. 1997, Black, Liu 
et al. 2004, Gould, England et al. 2004, Strickland, Martindale et al. 2008). 
Sensory neuron specific knockdown of Nav1.7 and Nav1.7/Nav1.8 attenuates 
pain related behaviour in inflammatory pain models (Nassar, Stirling et al. 2004, 
Nassar, Levato et al. 2005). Components of the ‘inflammatory soup’ directly 
interact with Nav1.7 and modulate the magnitude of Nav1.7 sodium currents and 
shift the threshold of activation to more hyperpolarized potentials (Black, Liu et 
al. 2004). This increases the rates of activation and inactivation dramatically 
and in a second instance leads to increased sensitization of the nociceptors and 
the inflamed tissue (Julius and Basbaum et al. 2001). 
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1. 9 Aim of thesis 	  
The principal aim of this thesis was to investigate the post-transcriptional 
regulation of SCN9A and to identify novel protein-protein interactions that 
influence trafficking and regulation of voltage-gated sodium channel Nav1.7.  
 
In chapter 2, I cloned a previously unreported SCN9A natural antisense 
transcript (NAT) that overlaps tail-to-tail with Scn9a/SCN9A in human and 
mouse DRG.  The aim of this project was to evaluate the regulatory role of this 
NAT on Scn9a/Nav1.7 expression. I demonstrated that the NAT is a non-protein 
coding RNA (lnRNA) that is alternatively spliced in DRG neurons and when 
overexpressed in vitro, specifically reduces mRNA, protein and sodium peak 
current of Nav1.7 by around 30 percent. Given these results, it is possible that 
the NAT plays an important role in regulating pain thresholds in vivo and is 
therefore a potential new analgesic drug target. 
 
In chapter 3, I examined the protein – protein interactome of Nav1.7 through an 
in-depth analysis of a newly developed epitope-tagged Nav1.7  (Nav1.7TAP) 
mouse. The goal was to get a comprehensive picture of all direct and indirect 
interaction partners of Nav1.7. The TAP-tag method described in this chapter 
allowed me to isolate Nav1.7 under native conditions, and coupled with mass 
spectrometry, it revealed a list of protein interaction partners. These proteins 
might be the key to understanding the basic nature of Nav1.7 trafficking and 
regulation. 
 
In the final chapter, I investigated a new mouse model of Primary 
Erythromelalgia (PE) that recapitulates the human phenotype. In humans, 
Primary Erythromelalgia is caused by autosomal dominant mutations in Nav1.7 
and is characterized by recurring episodes of excruciating pain that are induced 
by moderate heat and exercise. The aim of this project was to establish and 
characterize the first transgenic mouse model of PE that carries the human 
Nav1.7L858F PE mutation. Therefore, I examined the transgene integration of 
the human gene in mouse and assessed the behavioral phenotype. I found that 
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this mouse model mimics the to human PE phenotype whereby warm 
temperatures or an irritant trigger painful episodes. In the future this mouse 
model will not only enable us to further study this disease but potentially also 
help in the screening of new analgesic drugs. 
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2  Scn9a / SCN9A natural antisense transcripts 
2.1 Summary 
 
The voltage-gated sodium channel Nav1.7, encoded by SCN9A, is critical for 
human pain perception yet the transcriptional and post-transcriptional 
mechanisms that regulate this gene are still incompletely understood. In this 
chapter I examine a novel natural antisense transcript (NAT) for SCN9A, which 
is conserved in humans and mice. The NAT has a corresponding tissue 
expression pattern to the sense gene and is alternatively spliced within dorsal 
root ganglia. The human and mouse NATs exist in cis with the sense gene in a 
tail-to-tail orientation and both share sequences that are complementary to the 
terminal exon of SCN9A/Scn9a. Overexpression analyses of the human NAT in 
human embryonic kidney (HEK293A) and human neuroblastoma (SH-SY5Y) 
cell lines show that it can function to downregulate Nav1.7 mRNA, protein levels 
and currents by at least thirty per cent. Therefore the NAT may play an 
important role in regulating human pain thresholds and is a potential candidate 
gene for individuals with chronic pain disorders that map to the SCN9A locus, 
such as Inherited Primary Erythromelalgia, Paroxysmal Extreme Pain Disorder 
and Painful Small Fibre Neuropathy, but who do not contain mutations in the 
sense gene. My results strongly suggest the SCN9A NAT as a prime candidate 
for new chronic pain therapies based upon augmentation of existing antisense 
RNAs in the treatment of chronic pain conditions in man. 
2.2 Introduction  
Natural antisense transcripts	  
In recent years, it has become apparent that there are probably more genes in 
the human genome that encode regulatory RNAs than those that encode 
proteins (Morris and Mattick 2014). One major class of regulatory RNAs is the 
long non-coding RNAs (lncRNAs), of which natural antisense transcripts (NATs) 
are an important subset. NATs can be defined as processed transcripts that are 
complementary to the corresponding processed sense transcript in exonic 
regions (Werner and Sayer 2009). NATs can exist in cis or trans and are 
relatively common, with approximately 70% of all genomic loci showing 
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evidence of transcription from both sense and antisense strands (Katayama, 
Tomaru et al. 2005). Prominent examples of NATs include Tsix (the NAT for 
Xist), Wrap53 (the NAT for p53) and BACE1-AS (the NAT for beta-secretase-1) 
(Lee, Davidow et al. 1999, Faghihi, Modarresi et al. 2008, Mahmoudi, 
Henriksson et al. 2009). In the pain field, a NAT was recently reported for the 
voltage-dependent potassium channel Kcna2 (Zhao, Tang et al. 2013). This 
NAT is expressed in rat dorsal root ganglia (DRG) neurons and is upregulated 
in response to peripheral nerve injury. The increase in NAT levels 
downregulates Kcn2a, reducing total voltage-gated potassium currents, 
increasing excitability in DRG neurons and producing neuropathic pain 
symptoms.  
 
In this chapter, I show that the SCN9A gene also has a corresponding natural 
antisense transcript that is encoded on the opposite strand and overlaps tail-to-
tail with the sense transcript. The SCN9A NAT is present in both human and 
mouse genomes and has a putative role in Nav1.7 regulation.  
 
2.3  Results  
Genomic arrangement of SCN9A/Scn9a natural antisense transcripts 
 
In silico analysis of the human SCN9A gene footprint using the UCSC genome 
browser identified several expressed sequence tags (ESTs) (BC051759, 
BC029452, BM905527, BE566126, BG215777, AA383040) that were partially 
complementary to exonic regions of the sense gene. Alignment of the longest 
human EST, BC051759, to the genomic sequence indicated a cDNA comprised 
of 12 exons four of which were complementary and overlapped exons from 
SCN9A and with five exons containing Short Interspersed Nuclear Elements 
(SINEs) and/or Long Interspersed Nuclear Elements (LINEs) repeat sequences. 
Exons were flanked with the canonical AG-GT splice acceptor and donor sites 
and the final exon contained an AAUAAA polyadenylation signal. In Genbank 
the assembly of ESTs has subsequently been annotated as LOC101929680 
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(NR_110260), an uncharacterized long non-coding RNA of 2305 bp that spans 
220 kb on chromosome 2 (Figure 2-1,B).  
 
Analysis of the mouse genome also led to the identification of several ESTs 
that were antisense to Scn9a. For the mouse antisense gene, I identified the 
following antisense ESTs: AK039017 (hypothalamus cDNA), AK045660 
(corpora quadrigemina cDNA), AK020721 (hypothalamus cDNA), AK138511 
(spinal cord) and AK138532 (spinal cord). EST AK138532 indicated a cDNA 
comprised of four exons, one of which splices into a LINE repeat and two of 
which overlap Scn9a sense gene exons (NR_033495; Figure 2-1,A). Similar to 
the human SCN9A NAT, exons were flanked with canonical AG-GT splice 
acceptor and donor sites and the final exon contained an AAUAAA 
polyadenylation signal. Both the human and mouse NATs contain sequences 
that overlap the final sense SCN9A/Scn9a exon, potentially indicating a 
conserved regulatory function of these NATs in man and mouse. Using mouse 
dorsal root ganglia cDNA as template I amplified the identical sequence to 
NR_033495 (KM096552, Figure 2-1,A) as well as a splice variant (KM096553), 
which uses an alternative splice donor site in exon 3. 
 
The human and mouse SCN9A/Scn9a sense genes are organized in a tail-to-
tail arrangement on chromosome 2. A tail-to-tail arrangement of NAT and 
sense gene is given when both genes overlap at their 3’ ends while the 
transcription start sites (TSS) are not within the overlapping region. By way of 
comparison, in a head-to-head arrangement, NAT and sense gene overlap at 
the 5’ ends which includes the TSS (Lapidot and Pilpel 2006). The genomic 
footprints of both the human and mouse NATs overlap with their corresponding 
sense SCN9A genes. Additionally in human, SCN1A and NAT are arranged in 
a head-to-head orientation with the transcription start sites at the 5’ ends of 
both NAT and SCN1A overlapping (Figure 2-1,B). In mouse the TSS of the 
Scn9a NAT and SCN1A are in close proximity but not overlaping (Figure 2-
1,A). 	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Cloning of the mouse and human antisense transcripts: splice variants 
detected 
The mouse Scn9a natural antisense transcript was amplified from freshly 
prepared mouse DRG cDNA with primers flanking the 3´and 5´ of the longest 
EST, AK138532 (see Methods 6.1.1). Primers were designed using the mouse 
genomic sequence (UCSC genome browser) and online primer design tool 
Primer3. Amplification of the potential full-length transcript gave two different 
sized fragments. The longer isoform has a 993 bp overlap with the Scn9a 
sense gene over exons 2 to 4 (Figure 2-1,A). The shorter isoform misses parts 
of the penultimate exon 3 due to an internal exonic splice donor site. 
Consequently, the overlap with the sense gene is around 797 bp long hence, 
200 bp shorter in comparison to the longer isoform. 
 
Using human dorsal root ganglia cDNA as template I amplified two alternative 
splice variants, which were submitted to Genbank. Compared to NR_110260, 
the first splice variant (KM096550) excludes exon 2 and uses an alternative 
splice acceptor site within exon 7. The second splice variant (KM096551) 
excludes both exon 2 and exon 8 (Figure 2-1,B). 
 
In silico translation of the cloned human and mouse NAT sequences in three 
frames shows that the longest potential open reading frames are 67 (Figure 2-2) 
in human and 114 amino acids in mouse (Figure 2-3). The lack of a long open 
reading frame and the poor codon conservation is consistent with the definition 
of a long non-coding RNA (Morris and Mattick 2014). 
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A	     
Figure 2-1: Genomic organization of the mouse (A) and human (B) SCN9A/Scn9a natural 
antisense transcripts (NATs).  
The sense genes are shown at the top of each panel with the NAT splice variants shown below. 
Scn9a/SCN9A and NATs are arranged in a tail-to-tail orientation in human and mouse (3’ ends 
overlapping), while human SCN1A and NATs are arranged in a head-to-head orientation (5’ 
ends overlapping). In mouse the transcriptional start sites of the NAT and Scn1a are in close 
proximity but not overlaping. Transcriptional start sites (TSS) and direction of transcription are 
denoted by green exons and arrows respectively; overlapping regions between sense and NAT 
sequences are shown by purple exons; LINE and SINE repeat sequences are shown as orange 
exons; and the primer pairs used to amplify the respective NAT sequences are also highlighted.	  
Scn9a                Scn1a
       
NR_033495
 KM096552
 KM096553
TSS
LINE/SINEComplementary
SCN9A                   SCN1A
NR_110260
KM096550
KM096551
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A"
B"
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Translation	  of	  KM096550	  (human	  NAT	  splice	  variant	  1):	  
Frame	  1:	  
PRDTQHPQLHTLMPLCIYARNTITKELDIIRQ-IKRY-QLRLSDGPCLGFGIFA-NRDSS 
HQRQRSQGDCGL-EALPGNRNSGKVGHSKDGVDEHDQEEQEADVKQRRKGHHQSKEQRAD 
PLCSFD-T-DSANPGKTDHSEQGNRDLWR-NIALNWH-F-PSSCRPITNLSISLQCLELD 
LAHRQRVINCAAL-GA-PV-SLERNSPPHQHAEHNQEGVEEVVHVPPWERTVIIDLADTF 
FVALTKELHADHSKNEDDDGQH-AFRLKRKQILHTLNLC-NHKGEHLWILPSNKNILLKK 
NLNSYNITDFNL-L--RRSN-KI-LLGDFWSNHGRKTMKSDILGFECCFYPFLT-IHGHS 
LSSVPNLAEPQSTHNLASVFSMLATKWLNVGGETLTTK-MVIF-FRSCCPGWSAMARSRL 
TATSASRVQAILLPQPPE-LELQAPTTMPG-FFVFL 
Frame	  2:	  
RETPSIHNFTL-CHCVFMQEIP-LRNLTSSDSKSRGTDN-D-VMVPA-DLESLHEIGTLA 
TSDKEVRETAVSRKHFQETGIQAKLDIPKMA-MNMTRKSRRPMLNNAGRDIIKAKSSVRI 
PFAPLTRRRIRPILARRITRNRVTEISGGETLL-TGIDSSPALVDQLPTCPSPSSAWNWT 
WHTGKGLSTVLHSEELDRFNL-KGIHHPTSTRNTIRKEWKKSFMCHRGSVQSSLILQTHS 
L-LLPKSCMPTTAKMKTMMANTKPLD-KENKYYIP-ICAETTKESIFGSFQVIKIFC-RR 
I-TVITSQTLICDCDKGGQIKKSDYWETFGVIMEERL-NQIFLDLNVASIPS-LKSMGIH 
YHQCLTWQNHSLHIIWHLSFPCWLPNG-MLVEKLSQPSEWLYFNFALVAQAGVQWHDLGS 
PQPLPPEFKRFSCLSLLSSWNYRRPPPCPANFLYF 
Frame	  3:	  
ERHPASTTSHSDAIVYLCKKYHN-GT-HHQTVNQEVLTTETE-WSLPRIWNLCMK-GL-P 
PATKKSGRLRSLGSTSRKQEFRQSWTFQRWRR-T-PGRAGGRC-TTQEGTSSKQRAACGS 
PLLL-LDVGFGQSWQDGSLGTG-QRSLEVKHCSELALILAQLL-TNYQLVHLPPVPGTGP 
GTQAKGYQLCCTLRSLTGLISRKEFTTPPARGTQSGRSGRSRSCATVGAYSHH-SCRHIL 
CSSYQRAACRPQQK-RR-WPTLSL-TKKKTNITYPESVLKPQRRASLDPSK--KYSVEEE 
FEQL-HHRL-SVIVIKEVKLKNLIIGRLLE-SWKKDYEIRYSWI-MLLLSLLNLNPWAFI 
IISA-PGRTTVYT-SGICLFHAGYQMAECWWRNSHNQVNGYILISLLLPRLECNGTISAH 
RNLCLPSSSDSPASAS-VAGITGAHHHARLIFCIF 
 
Translation	  of	  KM096551	  (human	  NAT	  splice	  variant	  2):	  
Frame	  1:	  
PRDTQHPQLHTLMPLCIYARNTITKELDIIRQ-IKRY-QLRLSDGPCLGFGIFA-NRDSS 
HQRQRSQGDCGL-EALPGNRNSGKVGHSKDGVDEHDQEEQEADVKQRRKGHHQSKEQRAD 
PLCSFD-T-DSANPGKTDHSEQGNRDLWR-NIALNWH-F-PSSCRPITNLSISLQCLELD 
LAHRPLAHRNS-VQPLLLLLLQAKGYQLCCTLRSLTGLISRKEFTTPPAFRLKRKQILHT 
LNLC-NHKGEHLWILPSNKNILLKKNLNSYNITDFNL-L--RRSN-KI-LLGDFWSNHGR 
KTMKSDILGFECCFYPFLT-IHGHSLSSVPNLAEPQSTHNLASVFSMLATKWLNVGGETL 
TTK-MVIF-FRSCCPGWSAMARSRLTATSASRVQAILLPQPPE-LELQAPTTMPG-FFVF 
L 
Frame	  2: 
RETPSIHNFTL-CHCVFMQEIP-LRNLTSSDSKSRGTDN-D-VMVPA-DLESLHEIGTLA 
TSDKEVRETAVSRKHFQETGIQAKLDIPKMA-MNMTRKSRRPMLNNAGRDIIKAKSSVRI 
PFAPLTRRRIRPILARRITRNRVTEISGGETLL-TGIDSSPALVDQLPTCPSPSSAWNWT 
WHTGLWLIGIHRFSLCFFSFSRQRVINCAAL-GA-PV-SLERNSPPHQPLD-KENKYYIP 
-ICAETTKESIFGSFQVIKIFC-RRI-TVITSQTLICDCDKGGQIKKSDYWETFGVIMEE 
RL-NQIFLDLNVASIPS-LKSMGIHYHQCLTWQNHSLHIIWHLSFPCWLPNG-MLVEKLS 
QPSEWLYFNFALVAQAGVQWHDLGSPQPLPPEFKRFSCLSLLSSWNYRRPPPCPANFLYF 
Frame	  3:	  
ERHPASTTSHSDAIVYLCKKYHN-GT-HHQTVNQEVLTTETE-WSLPRIWNLCMK-GL-P 
PATKKSGRLRSLGSTSRKQEFRQSWTFQRWRR-T-PGRAGGRC-TTQEGTSSKQRAACGS 
PLLL-LDVGFGQSWQDGSLGTG-QRSLEVKHCSELALILAQLL-TNYQLVHLPPVPGTGP 
GTQASGSSEFIGSASASSPSPGKGLSTVLHSEELDRFNL-KGIHHPTSL-TKKKTNITYP 
ESVLKPQRRASLDPSK--KYSVEEEFEQL-HHRL-SVIVIKEVKLKNLIIGRLLE-SWKK 
DYEIRYSWI-MLLLSLLNLNPWAFIIISA-PGRTTVYT-SGICLFHAGYQMAECWWRNSH 
NQVNGYILISLLLPRLECNGTISAHRNLCLPSSSDSPASAS-VAGITGAHHHARLIFCIF 	  
 
Figure 2-2: In-silico translation of human NAT splice variants KM096550 and KM096551 
cloned from DRG. 
Open reading frames, as shown in red, begin with a methionine residue and stop codons are 
denoted by a hyphen. The longest potential open reading frames are 67 amino acids long 
(Frame 2 of KM096550/51), which suggests the transcript is not translated into a protein. 	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Translation	  of	  KM096552	  (mouse	  NAT	  splice	  variant	  1):	  
Frame	  1:	  
SSKQAGRLRSCMEIMNQVLLFVFETFWKESYE-PRNRSHFVGRKNDQKHES-ISWQVQGT 
SLGVCSKPEGTTSPAVNS-TITSGVKEGAGEAL--MQRMLLRALVCL-LIVAKLDIPKMA 
-MNMTRKSRRPMLNSAGRDIIRAKSSVRIPLAPLIRRRIRPILARRMTRNRMLLPVFTEK 
LL-PVNDSE-RNAWLLETPRVTAACSAQEDVHILLQGSRNKAW--QEDSKSPGHRDGSYE 
ALCCTKDTINVIAAP-QRSAVGSCNTERVSIHSFIYREGPCSHIFSAEL-ATDGLWEKQT 
FSSALGPLLSSLG-TSSMLAWFCSSYAMATTARIKFIR-KDPRNITTTKKIM-VLPAARS 
VYGEQKRDMIILVIQKFH-GFYCS-YIMNVQTRYFCIILL-KDK-R-YL-GKSVLNKLFN 
IKDTALLYVH-GLIL 
Frame	  2:	  
AASRRAG-DLAWKS-TRSCFSFLKRFGRRVMNSPEIGLILWVGRMTRSMKAKSPGKCRGP 
LLECAVNPRGRLLLLSTPEPSHLE-RKGLVKPCNKCKGCC-ELWSAFNSLWQSWTSQRWR 
R-T-RGKAGGRC-TAQEGTSSEQRAACGSPWRL-SGVGFVQSWPGE-LGTGCYSQSSLRN 
CSSQ-TTVNEEMPGCSRHRE-QLRAQLRRTFISFFKALGTKRGDDRKTVRAQDIGMGAMK 
LCAVPRTQSM-SRHHNRGQQWVRAILSGSAFIHSYTERAHAATSSLLNYELPMDCGRNKH 
SLQPWAHF-VH-VKLLRCWPGSVPRTPWLPQPGSSLSGKRIPEISPRQRKSCRFCQQHAV 
SMGSKKET-LF--YKNFTKVFIAASI--MCKPDIFV-FCCRKINKDNIFEENQY-TNFLI 
-KIQHCYMYIKA-F 
Frame	  3:	  
QQAGGQAEILHGNHEPGLAFRF-NVLEGEL-IAQK-VSFCG-EE-PEA-KLNLLASAGDL 
SWSVQ-TRGDDFSCCQLLNHHIWSEGRGW-SLVINAKDAAESFGLPLTHCGKVGHPKDGV 
DEHDEEKQEADVEQRRKGHHQSKEQRADPLGAFDQA-DSSNPGQANDSEQDATPSLH-ET 
ALASERQ-MKKCLAARDTESDSCVLSSGGRSYPSSRL-EQSVVMTGRQ-EPRT-GWEL-S 
SVLYQGHNQCNRGTITEVSSGFVQY-AGQHSFIHIQRGPMQPHLLC-IMSYRWIVGETNI 
LFSLGPTSEFTRLNFFDVGLVLFLVRHGYHSQDQVYQVKGSQKYHHDKENHVGFASSTQC 
LWGAKKRHDYFSNTKISLRFLLQLVYNECANQIFLYNFVVER-IKIISLRKISIKQTF-Y 
KRYSIVICTLRLDS	  	  
Translation	  of	  KM096553	  (mouse	  NAT	  splice	  variant	  2):	  
Frame	  1:	  
SSKQAGRLRSCMEIMNQVLLFVFETFWKESYE-PRNRSHFVGRKNDQKHES-ISWQVQGT 
SLGVCSKPEGTTSPAVNS-TITSGVKEGAGEAL--MQRMLLRALVCL-LIVAKLDIPKMA 
-MNMTRKSRRPMLNSAGRDIIRAKSSVRIPLAPLIRRRIRPILARRMTRNRMLLPVFTEK 
LL-PVNDSE-RNAWLLETPRVTAACSAQEDVHILLQGSRNKAW--QEDSKSPGHRDGSYE 
ALCCTKDTINVIAAP-QSFFDVGLVLFLVRHGYHSQDQVYQVKGSQKYHHDKENHVGFAS 
STQCLWGAKKRHDYFSNTKISLRFLLQLVYNECANQIFLYNFVVER-IKIISLRKISIKQ 
TF-YKRYSIVICTLRLDS 
Frame	  2:	  
AASRRAG-DLAWKS-TRSCFSFLKRFGRRVMNSPEIGLILWVGRMTRSMKAKSPGKCRGP 
LLECAVNPRGRLLLLSTPEPSHLE-RKGLVKPCNKCKGCC-ELWSAFNSLWQSWTSQRWR 
R-T-RGKAGGRC-TAQEGTSSEQRAACGSPWRL-SGVGFVQSWPGE-LGTGCYSQSSLRN 
CSSQ-TTVNEEMPGCSRHRE-QLRAQLRRTFISFFKALGTKRGDDRKTVRAQDIGMGAMK 
LCAVPRTQSM-SRHHNRASSMLAWFCSSYAMATTARIKFIR-KDPRNITTTKKIM-VLPA 
ARSVYGEQKRDMIILVIQKFH-GFYCS-YIMNVQTRYFCIILL-KDK-R-YL-GKSVLNK 
LFNIKDTALLYVH-GLIL	  
Frame	  3:	  
QQAGGQAEILHGNHEPGLAFRF-NVLEGEL-IAQK-VSFCG-EE-PEA-KLNLLASAGDL 
SWSVQ-TRGDDFSCCQLLNHHIWSEGRGW-SLVINAKDAAESFGLPLTHCGKVGHPKDGV 
DEHDEEKQEADVEQRRKGHHQSKEQRADPLGAFDQA-DSSNPGQANDSEQDATPSLH-ET 
ALASERQ-MKKCLAARDTESDSCVLSSGGRSYPSSRL-EQSVVMTGRQ-EPRT-GWEL-S 
SVLYQGHNQCNRGTITELLRCWPGSVPRTPWLPQPGSSLSGKRIPEISPRQRKSCRFCQQ 
HAVSMGSKKET-LF--YKNFTKVFIAASI--MCKPDIFV-FCCRKINKDNIFEENQY-TN 
FLI-KIQHCYMYIKA-F 
 
 
Figure 2-3: In-silico translation of mouse NAT splice variants KM096552 and KM096553 
cloned from DRG  
 Open reading frames, as shown in red, begin with a methionine residue and stop codons are 
denoted by a hyphen. The longest potential open reading frame is 114 amino acids long (Frame 
3 of KM096552), which suggests the transcripts are not translated into a protein.  
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Expression patterns of mouse natural antisense transcript  
Mouse tissue panel 
 
To investigate the tissue expression profile of the Scn9a NAT compared with 
the sense gene (Scn9a), I ran qPCR assays across a range of mouse tissue 
cDNA samples (Figure 2-4) (see Methods 6.1.3.1). The Scn9a sense and NAT 
genes have a relatively restricted expression pattern and are co-expressed in 
adult brain, DRG and spinal cord tissues. In addition, the NAT also shows 
expression within adult eye. The co-expression of the sense and NATs in 
corresponding tissues suggests that the NAT could have a direct regulatory 
effect on Scn9a gene functions.   
 
Figure 2-4: Scn9a and NAT expression pattern.  
Mouse tissue panel real-time qPCR assays measuring the expression level relative to DRG of 
the mouse NAT (upper panel) and the Scn9a sense gene (lower panel). Both the sense and 
NAT genes are expressed in corresponding tissues. 
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To further understand the relative expression of the NAT and Scn9a within DRG 
neurons, I analysed a recent paper in which DRG neurons have been 
categorized into 11 subtypes based on single-cell RNA-seq expression data 
(Usoskin, Furlan et al. 2015). This shows that the NAT is expressed in six of the 
eleven DRG neuronal subtypes. Interestingly, in the remaining five DRG 
subtypes with no NAT expression detected, there is robust Scn9a expression 
Conversely, in the only neuronal subtype without Scn9a expression (‘NF5’), 
there is relatively high expression of the NAT, indicating that within particular 
neuronal cell populations there is contrasting expression profiles of the NAT and 
Scn9a (Figure 2-5). 
 
	   
Figure 2-5: Unbiased classification of sensory neuron types by large-scale single-cell 
RNA sequencing.  
Comprehensive RNA-seq analysis identified 11 genetically definied subtypes of DRG neurons. 
The population size and the fraction of the population that would correspond to one cell are 
shown at the top. Neuronal subclasses corresponding to the 11 subtypes are shown on the 
bottom. The NAT(Gm13629) is expressed in six neuronal subtypes with the highest expression 
in large propioceptor neurons (‘NF5’), the only subtype of DRG neurons that does not express 
Scn9a. In the remaining DRG subtypes that do not exhibit NAT expression, Scn9a is robustly 
expressed.Taken from Usoskin, Furlan et al. 2015. 
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Next, I examined if the human NAT carries known single nucleotide 
polymorphisms (SNP) that are linked to SCN9A related pain disorders (Figure 
2-6,A-C). Indeed NAT and SCN9A overlapping sequences in exon 15 and exon 
26 of SCN9A carry point mutations that have been associated with an altered 
function of Nav1.7, resulting in a painful or painless human phenotype. In the 
NAT:SCN9A overlapping region of exon 15, three mutations linked to primary 
erythromelalgia (PE) (A863P, V872G, Q875E)(Harty,Dib-hajj et al. 2006,Choi, 
Zhang et al. 2009, Stadler, O'Reilly et al. 2015, Skeik, Rooke et al. 2012) and 
two SNP’s linked to congenital insensitivity to pain (CIP) (R896Q, W897X) (Cox, 
Sheynin et al. 2010, Cox, Reimann et al. 2006) have been reported (Figure 2-
6,A). Additionally the overlapping exonic region of exon 26 in SCN9A contains 
five mutations linked to CIP (R1599X) (Mansouri, Chafai Elalaoui et al. 2014), 
PE (A1632T) (Eberhardt, Nakajima et al. 2014) cold-sensitive paroxysmal 
extreme pain disorder (PEPD) (L1612P) (Suter, Bhuiyan et al. 2015), PEPD 
(M1627K)(Dib-Hajj, Estacion et al. 2008) and to an overlapping phenotype of 
erythromelalgia and PEPD (A1632E)(Estacion, Dib-Hajj et al. 2008)(Figure 2-
6,B). However, the NAT:SCN9A overlapping regions in exon 7 and exon 17 
carry no reported disease-associated SNPs (Figure 2-6,C).	  Taken together, this 
shows that SCN9A point mutations previously shown to cause the human 
monogenic pain disorders CIP, IEM and PEPD also change the sequence of the 
NAT.	  	  
Overexpression of the human NAT specifically reduces Nav1.7 peak 
sodium currents 	  
To functionally test the effects of overexpressing the human NAT (hNAT) on 
sodium currents, HEK293 cells stably expressing either Nav1.7 or Nav1.6 were 
transfected with (1) NAT in pcDNA3 plus a GFP-expressing vector (pEGFP-N1) 
or (2) empty pcDNA3 plus pEGFP-N1 (see Methods 6.2.2) Two days after 
transfection the green fluorescing cells were patch clamped by Dr John Linley, 
Molecular Nociception Group (see Methods 6.1.4 and 6.3).  
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Exon 15 
 
SCN9A ex15   CTTAGTGTTGGCCATCATCGTCTTCATTTTTGCTGTGGTCGGCATGCAGCTCTTTGGTAA   
         |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
NAT    CTTAGTGTTGGCCATCATCGTCTTCATTTTTGCTGTGGTCGGCATGCAGCTCTTTGGTAA    
SCN9A ex15   GAGCTACAAAGAATGTGTCTGCAAGATCAATGATGACTGTACGCTCCCACGGTGGCACAT   
         |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
NAT     GAGCTACAAAGAATGTGTCTGCAAGATCAATGATGACTGTACGCTCCCACGGTGGCACAT    
SCN9A ex15   GAACGACTTCTTCCACTCCTTCCTGATTGTGTTCCGCGTG 
              |||||||||||||||||||||||||||||||||||||||| 
NAT  GAACGACTTCTTCCACTCCTTCCTGATTGTGTTCCGCGTG  
Nav1.7    
860  L V L A/P I I V F I F A V V/G G M Q/E L F G K S Y K E C V C K I N D D C T L P R/Q 
W/X H M N D F F H S F L I V F R V   912 
 
Exon 26 
 
SCN9A ex26  CCTGTTCCGAGTGATCCGTCTTGCCAGGATTGGCCGAATCCTACGTCTAGTCAAAGGAGC   
         |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
NAT  CCTGTTCCGAGTGATCCGTCTTGCCAGGATTGGCCGAATCCTACGTCTAGTCAAAGGAGC   
 
SCN9A ex26  AAAGGGGATCCGCACGCTGCTCTTTGCTTTGATGATGTCCCTTCCTGCGTTGTTTAACAT   
         |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
NAT   AAAGGGGATCCGCACGCTGCTCTTTGCTTTGATGATGTCCCTTCCTGCGTTGTTTAACAT    
SCN9A ex26  CGGCCTCCTGCTCTTCCTGGTCATGTTCATCTACGCCATCTTTGGAATGTCCAACTTTGC   
         |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
NAT   CGGCCTCCTGCTCTTCCTGGTCATGTTCATCTACGCCATCTTTGGAATGTCCAACTTTGC  	  
Nav1.7   
1597  L F R/X V I R L A R I G R I L R L /PV K G A K G I R T L L F A L M/K M S L P A/E/T L  
 F N I G L L L F L V M F I Y A I F G M S N F   1655 	  
Exon 7 and Exon 17  
 
SCN9A ex7  AATATTTTTATTACTTGGAAGGATCCAAAGATGCTCTCCTTTGTGGTTTCAGCACAGATT   
         |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
NAT    AATATTTTTATTACTTGGAAGGATCCAAAGATGCTCTCCTTTGTGGTTTCAGCACAGATT    
SCN9A ex7   CAGG   
            |||| 
NAT    CAGG    
Nav1.7  302  Y F Y Y L E G S K D A L L C G F S T D S   321 
 	  
SCN9A ex17 AGATTAAACCGGTCAAGCTCCTCAGAGTGCAGCACAGTTGATAACCCTTTGCCTGGAGAA  
         |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
NAT  AGATTAAACCGGTCAAGCTCCTCAGAGTGCAGCACAGTTGATAACCCTTTGCCTGGAGAA    
SCN9A ex17 GGAGAAGAAGCAGAGGCTGAACCTATGAATTCCGATGAGCCAGAGGC   
             ||||||||||||||||||||||||||||||||||||||||||||||| 
NAT     GGAGAAGAAGCAGAGGCTGAACCTATGAATTCCGATGAGCCAGAGGC    
Nav1.7    
1107    R L N R S S S S E C S T V D N P L P G E G E E A E A E P M N S D E P E      1141 	  	  
Figure 2-6: Alignment of NAT:SCN9A overlapping regions and reported disease-
associated SNPs in these regions  
(A) Alignment of NAT:SCN9A overlapping regions in exon 15 (A863P, V872G, Q875E, R896Q, 
W897X)  and (B) exon 26 (R1599X, L1612P, M1627K, A1632E, A1632T), linked to painful and 
painless SCN9A-Channelopathies in humans, are found in overlapping regions with the NAT 
(green highlight, original sequence; gray highlight, SNP) (C) NAT:SCN9A overlapping regions in 
exon 7 and exon 17 carry no reported disease-associated SNPs. 
A 
B 
C 
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Overexpression of the human SCN9A NAT in the Nav1.7 stable cell line resulted 
in a statistically significant reduction in the peak sodium current (Figure 2-7,C). 
In Nav1.6 stably expressing cells, overexpression of the NAT had no effect on 
the sodium current, indicating that the NAT specifically affects the activity of 
Nav1.7. To test whether the decrease in sodium current observed is related to a 
reduction in SCN9A mRNA expression, I ran a qPCR. hNav1.7 HEK293 cells 
were transfected with either hNAT or empty vector. RNA was collected 24 and 
48 hours after transfection. cDNA of non-transfected hNav1.7 stable HEK cells 
was used as a basal control (sham)(see Methods 6.1.4 and 6.3). The results 
suggest that the SCN9A mRNA levels are not altered as a result of 
overexpression of the NAT, indicating that sense mRNA is not downregulated or 
degraded (Figure 2-7 A,B). Furthermore I compared the protein expression 
levels of Nav1.7 in untransfected HEK293 hNav1.7 stable cells (Nav1.7), 
transiently NAT transfected HEK293 hNav1.7 cells (NAT) and naive HEK293 
cells (sham) (see Methods 6.2.2) 24 hours after transfection (Figure 2-7,D). 
Cells were collected and protein was isolated in RIPA buffer (see Methods 
6.5.3). Crude protein lysate was immunoblotted using an anti-Nav1.7 antibody 
(Neuromab). There was no significant change in protein expression between 
NAT transfected and untransfected HEK293 hNav1.7 stable cells 24 hours after 
transfection. However, the human HEK293 hNav1.7 stable cell line has the clear 
disadvantage that Nav1.7 is ectopically expressed from a CMV promoter. 
Therefore small changes in mRNA or protein expression can go undetected. 
Additionally, transfection efficacy might also affect the results as non-
transfected cells can also cause a false-negative qPCR and western blot result. 
To address these problems I generated a SH-SY5Y-NAT stable cell line that 
endogenously expresses Nav1.7 in order to further test the effect of NAT 
overexpression on SCN9A mRNA. However, as SH-SY5Y cells not only 
express Nav1.7 but also other voltage-gated sodium channels, I decided to also 
design a Nav1.7 TAP-tag stable cell line that allows for the detection of Nav1.7 
with commercially available antibodies. This enabled me to specifically examine 
the protein expression of Nav1.7. 
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Figure 2-7: qPCR, immunoblotting and electrophysiology recordings on hNav1.7 stable 
HEK293 cells transiently transfected with NAT. 
(A) Real-time qPCR showing that the NAT overexpression after 24 hours (n=3) or  (B) 48hrs 
does not impact the SCN9A mRNA level in hNav1.7 stable HEK293 cells relative to 
untransfected hNav1.7 stable HEK293 cells (sham)(n=3). (C) Overexpression of the human 
NAT inhibits Nav1.7 but not Nav1.6 currents. Whole cell voltage clamp recording from HEK cells 
stably expressing human Nav1.7 or human Nav1.6. Cells were transiently transfected with either 
pcDNA3 vector (black bars) or Nav1.7 NAT (white bars) along with a GFP-expressing vector and 
recorded from 48 hrs. later. Peak whole cell current (pA) was measured in response to a 10 ms 
voltage step from the holding potential of -120 mV to 0 mV and normalized to cell size (pF). N = 
17-20; * indicates p<0.05 when compared to control (unpaired t-test). Patch clamping performed 
by Dr John Linley. (D) Immunoblotting of crude lysate using an anti-Nav1.7 antibody (Neuromab) 
showed no significant difference between NAT transfected (NAT) and untransfeccted HEK293 
hNav1.7 stable cells (Nav1.7). Naïve HEK293 cells (Sham) were used as control. β-actin was 
used as a loading control. 
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Generation of a NAT-SH-SY5Y stable human neuroblastoma cell line 
The human neuroblastoma SH-SY5Y cell line endogenously expresses a range 
of voltage-gated sodium channels (Nav1.2, Nav1.3, Nav1.4, Nav1.5, Nav1.7), 
among which Nav1.7 is the one of the most abundantly expressed isoforms. 
Furthermore, beta subunit genes, SCN2B and SCN3B, are also endogenously 
expressed (Vetter, Mozar et al. 2012). However, SH-SY5Y cells show no 
endogenous expression of the hNAT (Figure 2-8,A). Here, I generated a SH-
SY5Y NAT-cell line that stably expresses the human NAT cDNA under a CMV 
promoter to further study the overexpression of hNAT on endogenously 
expressed Nav1.7 (see Methods 6.2.3). The SCN9A mRNA level in the NAT-
stable cell line was significantly downregulated compared to naïve SH-SY5Y 
cells (sham) (Figure 2-8,B). Patch clamping showed a statistically significant 
reduction in the peak sodium current compared to control SH-SY5Y cells 
(sham) that did not express the hNAT (Figure 2-8,C-D)(see Methods 6.1.3.1 
and 6.3). Voltage-current relationships appeared unaltered between the two cell 
lines.  
Next, the stable cell line was tested for the expression of SCN1A (Nav1.1), 
SCN2A (Nav1.2) and SCN3A (Nav1.3)(see Methods 6.1.3.2). Although SCN1A, 
SCN2A and SCN3A do not overlap with the NAT, they share conserved exon 
sequences (exon 15 and 26) with the antisense transcript (Figure 2-9,A). 
However SCN4A, SCN5A, SCN7A, SCN8A, SCN10A and SCN11A SCN9A 
NAT (NR_110260) do not share sequences with SCN9A NAT (NR_110260). As 
the NAT shows high expression in the brain, it is possible that the NAT may 
also regulate the Nav1.1-Nav1.3 brain-expressed sodium channels encoded by 
SCN1A-SCN3A. I was therefore interested to determine whether 
overexpression of the NAT downregulated endogenously expressed Nav1.1, 
Nav1.2 or Nav1.3 in the NAT-stable SH-SY5Y cell line. Real-time qPCR showed 
the expression level of SCN2A and SCN3A was not significantly different 
between the naïve SH-SY5Y cells (sham) and the stable-NAT SH-SY5Y cells 
(SCN1A expression could not be detected in the SH-SY5Y cell lines) (Figure 2-
9, B-C), further indicating that the functional effects of the NAT are SCN9A-
specific. 
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Figure 2-8: Overexpression of the NAT reduces Nav1.7-mRNA and currents in SH-SY5Y 
NAT stable cells.  
(A) Real-time qPCR showing that the NAT is not expressed in naïve SH-SY5Y cells (sham) but 
is expressed in the stable-NAT SH-SY5Y cell line (n=3). (B) Real-time qPCR showing that the 
endogenous SCN9A mRNA level is significantly reduced in the stable-NAT SH-SY5Y cell line 
compared to in naïve SH-SY5Y cells (sham) (n=3). (C-D) Whole cell voltage clamp recordings 
of naïve (sham) and stable-NAT SH-SYSY (Nav1.7 NAT) cells showed a significant reduction of 
the peak sodium current (D), with voltage current relationships unaltered (C) (n=16-21). * 
indicates p<0.05 when compared to control (unpaired t-test). Data shown in mean ± S.E.M 
Patch clamping by Dr Robert Werdehausen. 	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SCN1A  (NM_001165963) 
Exon 15 
SCN1A ex15 TTGGCCATCATCGTCTTCATTTTTGCCGTGGTCGGCATGCAGCTCTTTGGTAAAAGCTAC  
          |||||||||||||||||||||||||| |||||||||||||||||||||||||| |||||| 
NAT  TTGGCCATCATCGTCTTCATTTTTGCTGTGGTCGGCATGCAGCTCTTTGGTAAGAGCTAC   
SCN1A ex15 AAAGATTGTGTCTGCAAGATCGCCAG-TGATTGTCAACTCCCACGCTGGCACATGAATGA  
         ||||| |||||||||||||||    | ||| |||   |||||||| ||||||||||| || 
NAT  AAAGAATGTGTCTGCAAGATC-AATGATGACTGTACGCTCCCACGGTGGCACATGAACGA    
SCN1A ex15 CTTCTTCCACTCCTTCCTGATTGTGTTCCGCGTGCTGTGTGGGG   
            ||||||||||||||||||||||||||||||||||||| |||||| 
NAT  CTTCTTCCACTCCTTCCTGATTGTGTTCCGCGTGCTG-GTGGGG  
 
Exon 26: 
SCN1A ex26  CTACCCTGTTCCGAGTGATCCGTCTTGCTAGGATTGGCCGAATCCTACGTCTGATCAAAG 
  |||||||||||||||||||||||||||| |||||||||||||||||||||||  |||||| 
NAT  CTACCCTGTTCCGAGTGATCCGTCTTGCCAGGATTGGCCGAATCCTACGTCTAGTCAAAG   
SCN1A ex26  GAGCAAAGGGGATCCGCACGCTGCTCTTTGCTTTGATGATGTCCCTTCCTGCGTTGTTTA  
  |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
NAT  GAGCAAAGGGGATCCGCACGCTGCTCTTTGCTTTGATGATGTCCCTTCCTGCGTTGTTTA    
SCN1A ex26 ACATCGGCCTCCTACTCTTCCTAGTCATGTTCATCTACGCCATCTTTGGGATGTCCAACT  
  ||||||||||||| |||||||| |||||||||||||||||||||||||| |||||||||| 
NAT  ACATCGGCCTCCTGCTCTTCCTGGTCATGTTCATCTACGCCATCTTTGGAATGTCCAACT    
SCN1A ex26 TTGCCT   
  |||||| 
NAT   TTGCCT   	  
SCN2A  (NM_021007)  
Exon 15 
SCN2A ex15 CTTGGTATTGGCCATCATCGTCTTCATTTTTGCTGTGGTCGGCATGCAGCTCTTTGGTAA   
  ||| || ||||||||||||||||||||||||||||||||||||||||||||||||||||| 
NAT  CTTAGTGTTGGCCATCATCGTCTTCATTTTTGCTGTGGTCGGCATGCAGCTCTTTGGTAA    
SCN2A ex15 GAGCTACAAAGAATGTGTCTGCAAGATTTCCAATGATTG-TGAA--CTCCCACGCTGGCA   
  |||||||||||||||||||||||||||  | ||||||   || |  |||||||| ||||| 
NAT  GAGCTACAAAGAATGTGTCTGCAAGAT--C-AATGATGACTGTACGCTCCCACGGTGGCA    
SCN2A ex15 CATGCATGACTTTTTCCACTCCTTCCTGATCGTGTTCCGCGTGCTGTGTGG   
  |||| | ||||| ||||||||||||||||| ||||||||||||||| |||| 
NAT   CATGAACGACTTCTTCCACTCCTTCCTGATTGTGTTCCGCGTGCTG-GTGG   
	  
Exon 26: 
SCN2A ex26   CTACCCTGTTCCGAGTGATCCGTCTTGCCAGGATTGGCCGAATCCTACGTCTGATCAAAG 
  ||||||||||||||||||||||||||||||||||||||||||||||||||||  |||||| 
NAT  CTACCCTGTTCCGAGTGATCCGTCTTGCCAGGATTGGCCGAATCCTACGTCTAGTCAAAG    
SCN2A ex26 GAGCAAAGGGGATCCGCACGCTGCTCTTTGCTTTGATGATGTCCCTTCCTGCGTTGTTTA   
  |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
NAT   GAGCAAAGGGGATCCGCACGCTGCTCTTTGCTTTGATGATGTCCCTTCCTGCGTTGTTTA    
SCN2A ex26 ACATCGGCCTCCTTCTTTTCCTGGTCATGTTCATCTACGCCATCTTTGGGATGTCCAATT   
  ||||||||||||| || |||||||||||||||||||||||||||||||| |||||||| | 
NAT  ACATCGGCCTCCTGCTCTTCCTGGTCATGTTCATCTACGCCATCTTTGGAATGTCCAACT    
SCN2A ex26 TTGCCT   
  |||||| 
NAT  TTGCCT  	  
	  
SCN3A (NM_006922) 
Exon 15 
SCN3A ex15 CTTGGTGTTGGCCATCATCGTCTTCATTTTTGCTGTGGTCGGCATGCAGCTCTTTGGTAA   
  ||| |||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
NAT   CTTAGTGTTGGCCATCATCGTCTTCATTTTTGCTGTGGTCGGCATGCAGCTCTTTGGTAA    
SCN3A ex15 GAGCTACAAAGAATGTGTCTGCAAGATCAATGATGACTGTACGCTCCCACGGTGGCACAT   
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
NAT     GAGCTACAAAGAATGTGTCTGCAAGATCAATGATGACTGTACGCTCCCACGGTGGCACAT    
A 
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SCN3A ex15   GAACGACTTCTTCCACTCCTTCCTGATTGTGTTCCGCGTGCTGTGTGG   
              ||||||||||||||||||||||||||||||||||||||||||| |||| 
NAT  GAACGACTTCTTCCACTCCTTCCTGATTGTGTTCCGCGTGCTG-GTGG   
 
Exon 26: 
SCN3A ex26   CTACCTTGTTCCGAGTGATCCGTCTTGCCAGGATTGGCCGAATCCTACGTCTGATCAAAG   
          ||||| ||||||||||||||||||||||||||||||||||||||||||||||  |||||| 
NAT     CTACCCTGTTCCGAGTGATCCGTCTTGCCAGGATTGGCCGAATCCTACGTCTAGTCAAAG   
SCN3A ex26   GAGCAAAGGGGATCCGCACGCTGCTCTTTGCTTTGATGATGTCCCTTCCTGCGTTGTTTA 
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
NAT     GAGCAAAGGGGATCCGCACGCTGCTCTTTGCTTTGATGATGTCCCTTCCTGCGTTGTTTA   
SCN3A ex26  ACATCGGCCTCCTGCTCTTCCTGGTCATGTTTATCTATGCCATCTTTGGGATGTCCAACT   
  ||||||||||||||||||||||||||||||| ||||| ||||||||||| |||||||||| 
NAT     ACATCGGCCTCCTGCTCTTCCTGGTCATGTTCATCTACGCCATCTTTGGAATGTCCAACT    
SCN3A ex26   TTGCCT  
  |||||| 
NAT  TTGCCT 	   
 
Figure 2-9: Alignment of SCN1A, SCN2A and SCN3A exons with complementary 
SCN9A NAT sequence (NR_110260) and SCN1A, SCN2A and SCN3A expression 
in SH-SY5Y NAT-stable cells.  
(A) SCN1A, SCN2A and SCN3A share conserved sequences with SCN9A NAT (NR_110260) in 
exon 15 and 26 while SCN4A, SCN5A, SCN7A, SCN8A, SCN10A and SCN11A have no 
significant similarity to the SCN9A NAT. Real-time qPCR showed that SCN1A is not expressed 
in naïve SH-SY5Y cells (sham) or stable-NAT SH-SY5Y cell line. (B) While SCN2A is 
expressed but not unchanged between SH-SY5Y (sham) and stable-NAT SH-SY5Y cell line (C) 
Real-time qPCR showing that the endogenous SCN3A mRNA level is unchanged in the stable-
NAT SH-SY5Y cell line compared to in naïve SH-SY5Y cells (sham) (n=4). Data shown in mean 
± S.E.M.	  
B C 
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HEK293 hNav1.7 TAP-tag stable cell line 	  
Members of the voltage-gated sodium channel family share high sequence 
homology, which makes it generally hard to purify and access the protein 
expression level of a specific subtype. In order to test for the effect of NAT 
overexpression on the protein levels of Nav1.7, I designed a Nav1.7 tandem 
affinity purification (TAP)-tagged stable HEK293 cell line that enables me to 
specifically purify and detect Nav1.7. Here, the TAP-tag construct contains a 
Tobacco Etch Virus (TEV) cleavage site flanked by two epitope tags, namely 
FLAG and histidine affinity tag (HAT), which can be detected by commercially 
available antibodies. The HEK293 cell line stably expresses this epitope-tagged 
TAP-Nav1.7 under a CMV promoter (See Methods 6.2.3). The advantages of 
naive HEK293 cell line over a SH-SY5Y cell line are that HEK293 cells do not 
endogenously express any members of the voltage-gated sodium channel 
family and CMV promoter, unlike endogenous expression levels in SH-SY5Y, 
ensures high expression of the channel. 
 
HEK293 hNav1.7 TAP cells were tested for expression of the hNav1.7-TAP with 
co-immunostaining with anti-FLAG (green) and DAPI (blue)(see Methods 6.5.1). 
hNav1.7-TAP appears to be expressed almost exclusively in the cell membrane 
(Figure 2-10,A-B). Immunoblotting of naïve HEK293 and HEK293 hNav1.7-TAP 
showed that the Nav1.7-TAP is robustly expressed in the stable cell line (Figure 
2-10,C). Next, the effect of NAT overexpression on Nav1.7 protein levels was 
investigated. The stable cell line was transiently transfected with the human 
NAT and TAP-tagged Nav1.7 was co-immunoprecipitated with anti-FLAG 
coupled Dynabeads and immunoblotted using an anti-HAT antibody (see 
Methods 6.5.1 and 6.5.7) Comparison of NAT transfected and sham transfected 
cells showed the NAT resulted in a significant reduction in TAP-tagged Nav1.7 
protein levels in two of the western blot sets shown in Figure 2-10, D. However 
in the third set of western blot data, the housekeeping gene tubulin was not fully 
transferred onto the membrane, which prevented the quantification of Nav.17 
protein levels in this data set (Figure 2-10,D). 
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Figure 2-10: Overexpression of the NAT reduces Nav1.7 protein levels. 
Immunohistochemistry of HEK293 hNav1.7 TAP-tag stable cell line. Immunostaining of hNav1.7-
TAP (green) in (A) naïve  HEK293 (B) and HEK293 hNav1.7-TAP stable cells, blue DAPI 
staining of the nucleus. (C) Western blot of HEK293 hNav1.7-TAP and control HEK293 against 
anti-FLAG and anti-GAPDH (D) Reduction in Nav1.7-TAP tag protein levels due to 
overexpression of the NAT for 48 hrs in a Nav1.7-TAP stable HEK293 cell line. Densitometry 
readings comparing alpha-tubulin to either HAT or FLAG bands were normalized to the sham 
controls and shown below each band. Transfection of the NAT results in a 30-40% reduction in 
Nav1.7 protein. (i) Nav1.7-TAP protein detected by immunoblotting using an anti-HAT antibody 
following pull-down of Nav1.7-TAP with an anti-FLAG antibody (sham corresponds to mock 
transfected cells). (ii) Immunoblot of crude lysate using an anti-FLAG antibody confirms a 
reduction in Nav1.7 protein levels following NAT transfection. (iii) Immunoblot of crude lysate 
using an antibody to a housekeeping protein, confirming equal loading. The third western blot 
data set shown was not quantified due to incomplete tubulin transfer to the membrane. 
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Figure 2-11: Reduction in Nav1.7-TAP tag protein levels due to overexpression of the 
NAT for 48 hrs in a Nav1.7-TAP stable HEK293 cell line.  
Upper panel: (i) Immunoblot of crude lysate using an anti-pan sodium channel antibody confirms 
a reduction in Nav1.7 protein levels following NAT transfection. Lower panel: (ii) Immunoblot of 
crude lysate using an antibody to the beta actin housekeeping protein, confirming equal loading. 
 
 
 
Next, I verified these results on immunoblotting Nav1.7-TAP stable HEK293 and 
Nav1.7-TAP-NAT transfected cells with a pan-sodium channel antibody that 
recognizes all voltage-gated sodium channel subtypes (see Methods 6.5.4). 
HEK293 cells show no endogenous expression of voltage-gated sodium 
channels. Here, the stable cell line shows clear expression of the TAP-tagged 
Nav1.7. However, overexpression of hNAT shows reduced expression of the 
channel (Figure 2-11). These results confirm previous findings and suggest that 
the NAT reduces the protein levels of Nav1.7. 
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Scn9a and NAT expression in inflammatory and neuropathic pain models 
 
Electrophysiological recordings and RT-PCR analyses performed on stable cell 
lines (HEK293 Nav1.7, SH-SY5Y) strongly suggest an impact of SCN9A natural 
antisense transcript on its corresponding sense transcript. These results 
indicate that the SCN9A antisense transcript is modulating Nav1.7 sodium 
currents, leading to a decrease of sodium influx into the cells as a result of 
decreased mRNA and protein expression. A possible reason for this change in 
Nav1.7 mRNA, protein and sodium current could be that the antisense transcript 
down-regulates the expression of Nav1.7 by binding to SCN9A mRNA and 
causing it to be degraded, thus leading to a decreased amount of Nav1.7 in the 
membrane. Next, I tested whether the NAT plays a role in different pain states. 
Animal models of inflammatory pain and neuropathic pain 
 
Two different inflammatory pain models (carrageenan and complete Freund’s 
adjuvant (CFA) as well as two neuropathic pain models (chronic constriction 
injury and sciatic nerve transection) were examined. Injection of carrageenan 
into the hindpaw induces an acute and highly reproducible inflammatory 
response resulting in edema, hyperalgesia and erythema that can persist for 6 
days. Likewise, injection of CFA results in acute thermal and mechanical 
hyperalgesia that can persist for more than 2 weeks. In the chronic constriction 
injury model, sutures are tied around the sciatic nerve, which leads to thermal 
and mechanical hyperalgesia presenting within the first week and persisting for 
several weeks. In the sciatic nerve transection model (SNT) the sciatic nerve is 
completely transected (Minett, Quick et al. 2011) (See Methods 6.4.1 and 
6.4.2). I ran a qPCR to test whether the relative expression of NAT and Scn9a 
in DRG changes during inflammatory and neuropathic pain states (see Methods 
6.1.3.2). I found no significant change in relative expression of these two genes 
in DRG at different time points (2 and 24 hrs) after Carrageenan or CFA 
injection (Figure 2-12). I also found no change of expression in NAT or Scn9a in 
CCI (2 and 3 weeks) and SNT (2 weeks) at different time points (Figure 2-13). 
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Figure 2-12:  Scn9a and antisense expression in Saline (Sham), Carrageenan and CFA 
injected mice. 
L2-L5 DRG ipsilateral, and spinal cord lumbar were isolated from BL6 mice injected with saline 
or Carrageenan  (A) 2hrs (B) 24 hrs. and (C) CFA 3 days after injection. mRNA expression was 
measured by qPCR, Eppendorf realplex, Cybergreen; Relative expression normalized to 
GAPDH and shown relative to saline. Data shown in mean ± S.E.M. 
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Figure 2-13: Scn9a sense and antisense expression after neuropathic surgery (CCI and 
SNL).  
Scn9a and antisense expression levels were assessed by qPCR (A) CCI after 2 weeks and (B) 
3 weeks after surgery. DRGs L4-L6 were taken out ipsilateral of operated mice (N=5) and non-
operated mice (Black 6, n=5). (C) SNL DRGs L5-L6 ipsilateral were taken out and RNA isolated. 
Expression changes were measured via qPCR. There was no significant change in expression 
levels of sense or antisense transcript in any of the tested neuropathic pain models. Data shown 
in mean ± S.E.M. 
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2.4  Discussion 	  
I have identified, cloned and characterized a human and mouse natural 
antisense transcript for the SCN9A gene. Both human and mouse NATs are 
organised in a tail-to-tail configuration with the sense gene and both show 
evidence of alternative splicing, which is consistent with other reported NATs 
(Morris and Mattick 2014).  Although the mouse Scn9a NAT has fewer exons 
than the human NAT, both share conserved sequences with the final sense 
SCN9A/Scn9a exon. Given this conserved gene structure and the 
corresponding tissue expression profile of the sense and NAT genes, it can be 
hypothesized that the NAT may somehow regulate the function of SCN9A. To 
this end, I overexpressed the NAT in cell lines, which endogenously expressed 
Nav1.7, and also in cells which stably expressed from a CMV promoter either 
Nav1.7 or epitope-tagged Nav1.7. Real-time qPCR, immunoblotting and 
electrophysiological assays showed a significant reduction in Nav1.7 mRNA, 
protein levels and currents.  
 
How do NATs regulate the function of their sense gene counterparts? 
Characterization of other NATs have ascribed several diverse cellular functions 
including transcriptional collision, RNA interference, regulation of alternative 
splicing, RNA editing, epigenetic regulation, RNA masking, translation inhibition 
and mRNA destabilisation (Lapidot and Pilpel 2006). In this experimental set-up 
I overexpressed the processed NAT RNA from a CMV promoter in cell lines. 
This led to a reduction in sense mRNA and consequently a reduction in 
functional Nav1.7 protein. It could be speculated therefore that perhaps the NAT 
functions by downregulating SCN9A transcription, perhaps by guiding 
chromatin-modifying enzymes to the SCN9A promoter region. Alternatively, 
overexpression of the NAT could be leading to the generation of endogenous 
short RNAs (endo-siRNAs) thus leading to promotion of the RNA interference 
pathway. A third mechanism could be that the NAT: sense mRNA duplexes are 
promoting destabilisation and degradation of the sense mRNA and/or inhibiting 
translation. A greater insight into the function of the NAT in vivo could be 
gleaned from the creation of a NAT knockout mouse. In a comparable 
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experiment, Komine et al. (2006) generated a Zfhx2-AS knockout mouse 
through deletion of the transcriptional start site region for the NAT (Komine, 
Nakamura et al. 2006). Normally, the Zfhx2 expression pattern in the 
developing brain is complementary to the expression of the NAT. However in 
the Zfhx2-AS knockout mouse, the expression of the Zfhx2 homeobox-
containing transcription factor becomes dysregulated. It would be interesting to 
determine whether the expression pattern of Scn9a is altered in a Scn9a NAT 
knockout mouse. 
 
Detailed analyses of Scn9a knockout mice have shown that acute, inflammatory 
and some forms of neuropathic pain require the expression of Nav1.7 (Nassar, 
Stirling et al. 2004, Minett, Nassar et al. 2012, Minett, Falk et al. 2014). I 
hypothesized that the NAT may be downregulated in pain states, hence leading 
to upregulation of SCN9A. To test this, I assessed mRNA levels of the sense 
and NAT genes in CFA and carrageenan-induced models of inflammatory pain 
and in the chronic constriction injury neuropathic pain model. This showed that 
the mRNA level of neither the sense nor the NAT gene was significantly altered. 
The lack of change in the sense gene mRNA was a surprising finding given 
that, for example, Nav1.7 protein levels have previously been shown to increase 
following carrageenan injections (Black, Liu et al. 2004). Further work using the 
epitope-tagged Nav1.7 knock-in mice and anti-FLAG/HAT antibodies should 
help to confirm whether protein levels change in different pain models. 
Furthermore, intrathecal viral NAT overexpression experiments could help to 
determine whether the NAT is able to confer analgesia and reduce the pain 
experienced in different inflammatory and neuropathic pain states. 
 
In summary, this DRG-expressed natural antisense transcript has the potential 
to regulate pain thresholds via transcriptional and post-transcriptional regulation 
of SCN9A. Given that the presence of the NAT reduces Nav1.7 currents, then 
intuitively the lack of the NAT may increase sodium currents. This could lead to 
increased excitability of damage-sensing neurons, enabling a fine-control of 
responses to painful stimuli. It will be interesting to determine whether loss of 
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function mutations in the NAT are responsible for inherited painful disorders that 
map to human chromosome 2, and whether SNPs within the NAT alter pain 
thresholds in the general population. 
 
 
 [See Appendix A for related PlosOne article] 
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3 TAP-tagged sodium channel Nav1.7 
3.1 Summary  
 
Voltage-gated sodium channels (VGSCs) are large integral membrane proteins 
that are composed of a pore-forming alpha subunit (Nav1.1-Nav1.9 and Nax) 
and auxiliary beta subunits. The voltage-gated sodium channel Nav1.7 is 
important in the initiation and propagation of action potentials in excitable cells 
and spontaneous and inherited mutations in Nav1.7 are linked to human pain 
disorders. Here, I investigate the expression profile and protein-protein 
interaction network of Nav1.7 through an in-depth analysis of a newly generated 
TAP-tagged Nav1.7 knock-in mouse. The tandem affinity purification (TAP) tag, 
consisting of a 3XFLAG, a Tobacco Etch Virus (TEV) protease cleavage site 
and a histidine affinity tag (HAT), was fused to the C-terminus of Scn9a 
(Nav1.7). I found no altered behavior or abnormal expression of Nav1.7 protein 
in vitro and in vivo due to the expression of the TAP-tag. Furthermore the TAP 
method allowed me to isolate TAP-tagged Nav1.7 under native conditions in 
three independent single-step purifications and coupled with Liquid 
chromatography–mass spectrometry (MS/LC-MS), it revealed a list of proteins 
in complex with Nav1.7.  
3.2 Introduction  
Voltage-gated sodium channels Nav1.7, Nav1.8 and Nav1.9 (VGSC) are 
primarily found in peripheral sensory neurons and are important in the initiation 
(Nav1.7) (Klugbauer, Lacinova et al. 1995), upstroke (Nav1.8) of action 
potentials  (Renganathan, Cummins et al. 2001) and setting of the resting 
membrane potential (Nav1.9) of electrically excitable cells (Dib-Hajj, Black et al. 
2002). However neuronal transmission rests not only upon the expression of 
voltage-gated sodium channels but also on their correct transport and anchoring 
in the cell membrane of highly specialized domains such as the axon initial 
segment (AIS) and nodes of Ranvier. Assemblies of multi-molecular complexes 
are required to transport, anchor and enrich VGSCs in these highly specialized 
axonal segments (Salzer 2003, Leterrier, Brachet et al. 2010, Leterrier, Brachet 
et al. 2011). It is estimated that greater than eighty per cent of all proteins are 
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part of multi-protein complexes (Berggard, Linse et al. 2007) which are 
composed of adhesion, cytoskeletal adaptor, transport proteins and many more 
(Okuse, Malik-Hall et al. 2002, Leterrier, Brachet et al. 2010). However, very 
little is known about voltage-gated sodium channel multi-protein complex 
composition and the individual role of molecules in regulation and trafficking of 
voltage-gated sodium channels to the plasma membrane. What is known is that 
VGSC beta-subunits are involved in these processes and expression of a 
certain β-subunit with a Nav alpha subunit can promote trafficking and 
glycosylation (Laedermann, Syam et al. 2013). Other proteins that are 
implicated in the regulation and trafficking of voltage-gated sodium channels are 
Nedd4/Nedd4-like proteins (Cachemaille, Laedermann et al. 2012, 
Laedermann, Decosterd et al. 2014) ankyrins (Hedstrom and Rasband 2006), 
papin (Shao, Baker et al. 2009), ERM proteins (Malik-Hall, Poon et al. 2003), 
p11 (Okuse, Malik-Hall et al. 2002), syntrophin (Schultz, Hoffmuller et al. 1998) 
and CRMP2 (Dustrude, Wilson et al. 2013). Interestingly, CRMP2 indirectly 
regulates Nav1.7 trafficking through post-translational SUMOtylation of CRMP2. 
Dustrude et al. (2013) found that CRMP2 SUMOtylation recruits isoform specific 
voltage-gated sodium channel binding proteins that promote the trafficking of 
Nav1.7 to the plasma membrane and provides a novel mechanism for the 
modulation of Nav1.7 trafficking (Dustrude et al. 2013). 
In recent years the field of proteomics has rapidly advanced through the 
development of high-throughput methods like tandem affinity purification that 
allow large-scale protein-interaction studies. Initially TAP was developed for the 
use in Yeast proteomics (Rigaut, Shevchenko et al. 1999, Gavin, Bosche et al. 
2002) and has since been successfully adapted to other organisms including 
mammals (Angrand, Segura et al. 2006, Fernandez, Collins et al. 2009). 
Targeted tandem affinity purification combined with mass spectrometry (TAP-
MS) is a tool for mapping the organization of multi-protein complexes under 
native conditions (Berggard, Arrigoni et al. 2006, Fernandez, Collins et al. 
2009). One of the advantages of the TAP assay is that small peptide affinity 
tags do not alter function or impact the three-dimensional folding of the protein 
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and therefore do not need to be removed. The purification method itself is 
simple yet applicable to a wide range of proteins and enables identification of 
all direct and indirect interaction partners in a single experiment. Furthermore, 
the tandem affinity purification method requires no further consideration of 
abundance, composition or function of the isolated protein complex and only 
depends upon high reproducibility and accurate protein purification (Rigaut, 
Shevchenko et al. 1999, Puig, Caspary et al. 2001). Variations of the TAP-tag 
are used but the basic TAP construct consists of a TEV protease cleavage site 
that is flanked by affinity tags. 
Since there isn’t a good commercially available anti-NaV1.7 antibody for use in 
pull-down assays I instead used the TAP-MS method to characterize protein 
complexes from Nav1.7 TAP-tagged knock-in mice to allow me to isolate Nav1.7 
interaction partners in their physiological environment. I found no evidence that 
TAP-tag insertion into Nav1.7 results in an abnormal phenotype. mRNA and 
protein expression levels and electrophysiological properties of the channel 
were comparable to wildtype. Mass spectrometry analysis identified 42 proteins 
in complex with Nav1.7TAP/TAP from DRG and olfactory bulb, some of which 
(Tmed10, Aqp-1, Scn3b and mTor) have already been implicated in cellular 
trafficking, pain processing or shown to associate with other VGSCs.  
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3.3 Results 
Generation and testing of TAP-tagged Nav1.7 mouse line 	  
To investigate the protein-protein interaction and distribution of Nav1.7, Jing 
Zhao (Molecular Nociception group) generated a TAP-tagged Nav1.7 mouse 
line. Here, a tandem affinity purification (TAP)-tagged Nav1.7 targeting vector, 
which contains a HAT domain, 3x FLAG tags and a neomycin selection 
cassette (neoR) was inserted before the stop codon of exon 28 in the Nav1.7 
wild-type (WT) allele using Escherichia coli recombineering-based methods 
(Lee, Yu et al. 2001). Figure 3-1a demonstrates the structure of the NaV1.7 wild-
type (WT) allele, the TAP-tagged NaV1.7 targeting construct and the TAP-
tagged NaV1.7 targeted allele with and without the neomycin selection cassette 
(neoR).  
The final targeting construct containing a 5’-end homology arm of 3.4 kb and a 
3’-end homology arm of 5.8 kb, was transfected into 129/Sv embryonic stem 
cells (ES) (Figure 3-1a). After electroporation of the construct into embryonic 
stem cells, 346 colonies that survived selection with G418 were screened with 
3’ external probe using Southern blotting, and 12 correctly targeted colonies 
were confirmed with correct integration using 5’ external probe (targeting 
efficiency was 3.5%). Three positive ES cell lines were used to generate 
chimeras through microinjection of the cells into blastocysts. Electroporation 
and blastocysts microinjection of ES cells was performed by Dr Massimo 
Signore in JP Martinez-Barbera’s research group (UCL). Four chimeras were 
obtained and crossed with C57BL/6 mice.	   Germ line transmission from the 
chimeras was confirmed with 3’ external and 5’ external probes using Southern 
blotting (Figure 3-1,b). Furthermore F1 animals were crossed with global Cre 
mice to remove the neomycin (neoR) cassette. Southern blot analysis of 
genomic DNA from TAP-tagged Nav1.7 mice after removal of the neo cassette 
compared to wildtype is presented in Figure 3-1c. Both Southern blotting (Figure 
3-1,c) and PCR (Figure 3-3,a) results indicate that the TAP-tag was integrated 
as a whole, without deletions, into the intended location. This line of mice is 
referred to herein as Nav1.7TAP.  
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Figure 3-1: Generation of Nav1.7 TAP-tagged mouse line. 
(a) The TAP-tagged NaV1.7 targeting construct was inserted into the open reading frame in the 
3’-end before the stop codon of exon 28 of Nav1.7 using Escherichia coli recombineering-based 
methods. The figure shows the structure of the NaV1.7 wild-type (WT) allele, the TAP-tagged 
NaV1.7 targeting construct and the TAP-tagged NaV1.7 targeted allele with and without the 
neomycin selection cassette (neoR). (b) Germ line transmission from the chimeras was 
confirmed with 3’ external and 5’ external probes using Southern blotting (c) Southern blot 
analysis of genomic DNA from homozygote (homo) and heterozygote (het) TAP-tagged Nav1.7 
mice compared to wildtype after the removal of neo cassette (performed by Jing Zhao). 
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Figure 3-2: Transient transfection of HEK293 cells with Nav1.7 TAP-tag  
(a) Nav1.7 TAP-tag consisting of a 3XFLAG, a TEV protease cleavage site and a HAT 
domain. The construct was inserted at the C-terminus, just prior to the stop codon in SCN9A 
(b) Immunohistochemistry of HEK293 cells that were transiently transfected with Nav1.7 
TAP-tag and detected with an anti-FLAG antibody (red) (blue: DAPI) (c) and functional 
integrity of the sodium channel via electrophysiology analysis.   
 	  
Expression of human Nav1.7 TAP-tag in HEK293 cells  
 
To test the channel function of this TAP-tagged Nav1.7 in vitro, HEK293 cells 
were transiently transfected with the TAP-tagged Nav1.7 construct (Figure 3-
2,a) (3XFLAG tag, a TEV protease cleavage site and a HAT-domain) and 
immunostained 24 hours after transfection (Figure 3-2,b) (see Methods 6.2.2 
and 6.5.1). Nav1.7 appears to be primarily expressed in the plasma membrane 
of transfected HEK293 cells (red) and electrophysiological recordings confirmed 
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the functionality of the channel (Figure 3-2,c). To verify the protein expression of 
Nav1.7 and test for the specificity of commercially available FLAG and HAT 
antibodies, TAP-tagged Nav1.7 was immunoprecipitated from HEK293 cells and 
immunoblotted with anti-HAT antibody (see Methods 6.5.3 and 6.5.7). Western 
blot of Nav1.7 confirmed the expression of Nav1.7 TAP-tagged protein and the 
specificity of the antibodies (Figure 3-3,b-c) 
 
Nav1.7TAP/TAP tag knock-in mouse 	  
Next, I examined a newly developed Nav1.7TAP/TAP tag knock-in mouse. First 
Nav1.7TAP/+ heterozygous mice were intercrossed and I found no abnormalities 
of transmission frequency in the offspring of Nav1.7TAP/+ intercrosses (not 
shown). I then went on to PCR genotype Nav1.7TAP tag knock-in mice by 
extracting genomic DNA from littermates (control), Nav1.7TAP/+ (heterozygous) 
and Nav1.7TAP/TAP (homozygous) (see Methods 6.1.2). The samples were PCR 
genotyped using a common forward and reverse primer in Nav1.7 (see Methods 
6.1.2) that amplify the wildtype (Nav1.7+/+, 170bp, lower band) and targeted 
allele (Nav1.7TAP/TAP, 411 bp, top band) (Figure 3-3,a). Next, I looked at the 
expression of Nav1.7TAP/TAP (homozygous) in vivo to confirm protein expression 
as well as localization of the TAP-tagged protein. DRG from Nav1.7TAP/TAP and 
littermate controls were collected, immunoprecipitated in CHAPS buffer and 
immunoblotted with anti-HAT and anti-FLAG (see Methods 6.5.4 and 6.5.7). 
The band size was comparable to hNav1.7-TAP transfected HEK293 
immunoblots against these two antibodies (Figure 3-3,b-c), confirming that TAP-
tagged protein is expressed. 
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Figure 3-3: Nav1.7TAP/TAP genotyping and protein expression  
(a) PCR genotyping of Nav1.7 TAP-tagged mice using a common forward and reverse primer in 
Nav1.7 (top) that amplify the wild type (170 bp, lower band) and targeted allele (411 bp, top 
band) from gDNA. (b) Western blot detection of Nav1.7 TAP-tag with anti-FLAG antibody on 
crude lysate shows that Nav1.7 is expressed and antibodies can detect Nav1.7TAP/TAP tagged 
protein in both transgenic mice and transiently transfected HEK293 cells (c) Western blot 
detection of Nav1.7 TAP-tag with anti-HAT antibody on crude lysate shows that Nav1.7 is 
expressed and antibodies can detect Nav1.7TAP/TAP tagged in both transgenic mice and 
transiently transfected HEK cells.  	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Nav1.7TAP/TAP is highly expressed in DRG, olfactory bulb and 
hypothalamus/thalamus  
 
In mammals, ten channel isoforms (Nav1.1-1.9 and Nax) are known that share a 
greater than 50 per cent sequence homology (Catterall 2000, Goldin et al. 
2005). However this makes it challenging to only examine the distribution of one 
specific isoform. Antibodies currently in use to detect Nav1.7 are often not 
specific and therefore detect other sodium channels as well. Here, a C-terminal 
insertion of TAP-tag epitope into exon 28 of Nav1.7, allows me to purify only 
Nav1.7 and enables me to investigate its cellular and subcellular distribution. I 
have shown that transient transfection of hNav1.7 TAP-tag vector into HEK293 
cells does not alter the function and expression of the sodium channel (Figure 
3-1,b-c).  
In rodents and humans, Nav1.7 is primarily expressed in DRG neurons and the 
olfactory bulb (Toledo-Aral, Moss et al. 1997, Weiss, Pyrski et al. 2011). 
Therefore protein lysates from DRG neurons of TAP-tagged Nav1.7 knock-in 
mice were immunoprecipitated with anti-FLAG and blotted with an anti-HAT 
antibody. Western blot confirmed the expression of Nav1.7TAP/TAP tag in vivo 
(Figure 3-3,b-c). Next, I compared the levels of expression of TAP-tagged 
Nav1.7 from DRG neurons in homozygote (Nav1.7TAP/TAP) and heterozygote 
(Nav1.7TAP/+) mice and found that the band height is similar but intensity varies 
(Figure 3-4,a). To investigate the tissue specific distribution of Nav1.7, 14 
different tissues from a Nav1.7TAP/TAP mouse were collected and protein lysates 
prepared then co-immunoprecipitated with anti-FLAG and immunoblotted with 
anti-HAT antibody (see Methods 6.5.5 and 6.5.7). I found that Nav1.7 is highly 
expressed in DRG neurons and the hypothalamus/thalamus but the highest 
expression was detected in the olfactory bulb (Figure 3-4,b). Besides these 
three tissues, Nav1.7 expression was also detected in spinal cord, sciatic nerve 
and testis but was absent in tissues such as lung, liver, spleen, eye, kidney, 
brain* and cerebellum. Next, the expression of Nav1.7 in the pancreas was 
examined. Zhang et al. (2014) reported that Nav1.7 is expressed in pancreatic 
islets where it is suspected to trigger glucose-stimulated insulin secretion 
(Zhang, Chibalina et al. 2014). However under two experimental conditions, 
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Nav1.7 protein in mouse pancreas tissue was not detected (Figure 3-4, c). As 
shown in Figure 3-5, Jing Zhao performed immunohistochemistry against TAP-
tagged Nav1.7 with anti-FLAG antibody (green) in spinal cord, olfactory bulb and 
DRG sections (see Methods 6.5.2), which showed that Nav1.7TAP/TAP was 
expressed only in the knock-in mice and not in the control (Nav1.7+/+) mice. 
 
 
Figure 3-4: Nav1.7TAP/TAP is highly expressed in olfactory bulb, DRG and 
hypothalamus/thalamus. 
(a) Co-immunoprecipitation of Nav1.7TAP/TAP, Nav1.7TAP/+ and control (wildtype) from DRG 
neurons with anti-FLAG antibody covalently coupled to Dynabeads and immunoblotted with 
anti-HAT antibody (b) Nav1.7TAP/TAP tissue panel. Nav1.7 TAP-tagged protein is highly expressed 
in olfactory bulb, DRG and hypothalamus/thalamus, with expression also detected in spinal 
cord, testis and sciatic nerve (c) Co-immunoprecipitation of Nav1.7TAP/TAP in pancreas, DRG, 
brain and wildtype pancreas in modified Ripa (w/o SDS) and Ripa buffer (SDS). Nav1.7TAP/TAP, 
and control (wildtype) were co-immunoprecipitated with anti-FLAG antibody covalently coupled 
to Dynabeads and immunoblotted with anti-HAT antibody. 
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Figure 3-5: Nav1.7 expression in the spinal cord, olfactory bulb and DRG.  
Analysis of Nav1.7TAP/TAP expression via immunohistochemistry in spinal cord, olfactory bulb and 
DRG section from Nav1.7TAP/TAP and wildtype mice (Wt). Sections of Nav1.7TAP/TAP and Wt from 
olfactory bulb and DRG were stained with anti-FLAG and visualized with Alexa Fluor-488 and in 
spinal cord with Alexa Fluor-594 (performed by Jing Zhao). 
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Optimization of single step and tandem affinity purification of Nav1.7TAP/TAP  
Tandem affinity purification is a four-step process to purify a TAP-tagged protein 
from crude lysate through two consecutive affinity purifications. Here, the TAP-
tag epitope inserted into Nav1.7 contains a TEV site flanked by a 3XFLAG tag 
and a HAT domain (Figure 3-6,a). In the first steps, the specificity of the 
3XFLAG binding sites and a unique TEV protease cleavage site are exploited. 
For the solubilisation of Nav1.7TAP/TAP tag protein from DRG and olfactory 
neurons, 1% CHAPS buffer was experimentally evaluated to be the most 
suitable detergent. CHAPS is a non-denaturating zwitterionic detergent, 
commonly used to extract membrane proteins in their native conformation. In 
comparison to strong anionic detergents like SDS, CHAPS preserves protein-
protein interactions and is compatible with downstream applications such as 
mass spectrometry. Protein was extracted from DRG and olfactory bulb neurons 
and Nav1.7TAP/TAP captured from crude DRG/olfactory bulb lysates with magnetic 
M290 Epoxy-Dynabeads covalently bound to anti-FLAG antibody. This step 
allows the rapid first purification of Nav1.7 TAP-tag complex from the crude 
lysate while preserving its native conformation. In the second step, the 
expression of a unique Tobacco Etch Virus (TEV) protease cleavage site within 
the TAP-tag is exploited to elute the Nav1.7TAP/TAP tagged complex from the 
beads (Figure 3-6,b). A modified TEV protease with enhanced temperature 
stability (AcTEV) is incubated with the Nav1.7 TAP-anti-FLAG complex. Addition 
of TEV releases the Nav1.7TAP/TAP complex from the beads through site-specific 
cleavage and completes the single purification. In the third step, magnetic Ni-
NTA beads capture the recovered Nav1.7 TAP-tag complex, which also 
contains a poly-histidine affinity tag (HAT). Ni-NTA beads contain immobilized 
Nickel ions on their surface that have a high selectivity and affinity for 
polyhistidine residues independent of the three dimensional confirmation. In the 
last step Nav1.7TAP/TAP complex is eluted from the beads with SDS and DTT, 
completing the tandem affinity purification process (see Methods 6.5.6). All 
steps where monitored with immunoblotting with anti-HAT (Figure 3-6,b).  
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Figure 3-6: Single and tandem affinity purification. 
(a) Schematic overview of the four-step tandem affinity purification protocol. In the first step, 
Nav1.7 TAP-tag protein is captured with anti-FLAG coupled Dynabeads and released by the 
addition of AcTEV protease, completing the single step purification. In the third and fourth steps 
of the tandem affinity purification, the HAT domain is exploited and Nav1.7-TAP protein is 
captured by Ni2+ beads and released by boiling in SDS and DTT (b) Tandem affinity purification 
of Nav1.7TAP/TAP steps were monitored using Western blot and immunoblotted with anti-HAT 
antibody (1:500) (c) Silver staining of protein isolated from Nav1.7TAP/TAP mice (red arrow) and 
littermate controls after a single purification from DRG/olfactory bulb pooled sample. 
 
 
 
Next, single affinity purified Nav1.7TAP/TAP complexes were silver stained (see 
Methods 6.5.8) (Figure 3-6c, red arrow). Three independent single (n=3) and 
tandem purifications (n=3) from pooled DRG/olfactory bulb samples were 
performed and sent for Liquid chromatography–mass spectrometry (LC-MS) 
analyses. 
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Mass spectrometry analysis of single-step purified Nav1.7 TAP-tag protein 
 
LS-MS/MS of single-step purified Nav1.7-tap tag complexes was performed by 
Honglei Huang (University of Oxford) (see Methods 6.6). All raw MS data were 
processed to generate MGF files (200 most intense peaks) using the 
Proteowizard v.2.1.2476 software. The identification of proteins was performed 
using MGF files with the central proteomics facilities pipeline. A homo sapiens 
database containing entries from UniProtKB was used in the CPF Proteomics 
pipeline for data analysis. This pipeline combines data from three search 
engines (Mascot, OMSSA and X! tandem k-score). The search was carried out 
using the following parameters. Trypsin was the enzyme used for the digestion 
of the proteins and only one missed cleavage was allowed. The accepted 
tolerance for the precursor was 50 ppm and 0.1 Da for the fragment. The 
search encompassed 1+, 2+ and 3+ charge states, fixed modification for 
cysteine carbamidomethyl and variable modification for asparagine and 
glutamine deamidation, and methionine oxidation. All trypsin fragments were 
added to an exclusion list. False discovery rate was calculated by 
peptide/proteinprophet or estimated empirically from decoy hits, identified 
proteins were filtered to an estimated 1% FDR. The label-free analysis was 
carried out using the normalized spectral index (SINQ). 
Functional protein-interaction partners of Nav1.7  
Proteins were manually clustered through use of PHANTER 
(http://www.pantherdb.org/), IPA (Quiagen) and UniProt. PHANTER and UniProt 
are online protein annotation tools that analyse high throughput, genome wide 
data from proteomic and expression studies (Mi, Muruganujan et al. 2013). 
Group data analysis of DRG/olfactory bulb proteins isolated from wildtype (n=3) 
mice compared to Nav1.7TAP homozygous knock-in mice (n=3, single 
purification) determined that in total 201 proteins were two-fold increased in the 
knock-in mice, 77 of which were specific for Nav1.7TAP/TAP tag samples after a 
single-step purification (Table 1). 164 proteins out of 201 proteins were 2-fold 
increased and came up in at least 2 out of 3 of the single purification runs for 
Nav1.7TAP/TAP (Table 2,white). In three separate LS-MS/MS runs of Nav1.7TAP/TAP, 
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42 proteins come up only in the Nav1.7TAP/TAP group but not in wildtype controls 
(Table 2, light green). Proteins that were not only enriched in Nav1.7TAP/TAP mice 
but were more than 8-fold increased in Nav1.7TAP/TAP compared to the wildtype 
group are shown in light blue in Table 2. 
Additionally, proteins were grouped into Channels/receptors/transporters, 
Enzymes, Vesicular/trafficking/transport, Cytoskeletal/structural/cell-adhesion, 
Nuclei acid binding protein/transcription factor and unclassified. Unclassified 
proteins include uncharacterized proteins and proteins with unknown GO 
function/Protein class annotation in any annotation tools (Table 2). Furthermore, 
Table 2 shows the spectral index, hence the relationship between peptide 
lengths, spectral counts and fragment-ion intensity. 
Proteins specific for Nav1.7TAP/TAP were also grouped by GO Components 
(UniProt) (Table 3). Table 3 gives an overview of all proteins only enriched in 
Nav1.7TAP/TAP (2 out of 3 runs, > 2-fold increase) and proteins that were at least 
8-fold increased in Nav1.7TAP/TAP group compared to the wildtype group, and 
their location in subcellular compartments/cellular component.  
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Table 1: Full list of mass spectrometry data: 201 proteins at least 2 fold 
increase 
Protein 
 
 
Description Abbreviate KI/WT 
or FI 1 
Q5SX40 Myosin-1 Myh1 KI Only 
A6H8H5 Potassium voltage-gated channel subfamily 
B member 2 
Kcnb2 KI Only 
E9Q8I9-2| Isoform 2 of Protein furry homolog Fry KI Only 
O09111 NADH dehydrogenase [ubiquinone] 1 beta 
subcomplex subunit 11, mitochondrial 
Ndufb11 KI Only 
O35668-2 Isoform A of Huntingtin-associated protein 1 Hap1 KI Only 
O88384 Vesicle transport through interaction with t-
SNAREs homolog 1B 
Vti1b KI Only 
O88951 Protein lin-7 homolog B Lin7b KI Only 
O89112 LanC-like protein 1 Lancl1 KI Only 
P02088 Hemoglobin subunit beta-1 Hbb-b1 KI Only 
P02089 Hemoglobin subunit beta-2 Hbb-b2 KI Only 
P39054-2 Isoform 2 of Dynamin-2 Dnm2 KI Only 
P40240 CD9 antigen Cd9 KI Only 
P48320 Glutamate decarboxylase 2 Gad2 KI Only 
P62192 26S protease regulatory subunit 4 Psmc1 KI Only 
P62821 Ras-related protein Rab-1A Rab1A KI Only 
P70452 Syntaxin-4 Stx4 KI Only 
Q3U1J4 DNA damage-binding protein 1 Ddb1 KI Only 
Q3UJU9 Regulator of microtubule dynamics protein 3 Rmdn3 KI Only 
Q3ULD5 Methylcrotonoyl-CoA carboxylase beta 
chain, mitochondrial 
Mccc2 KI Only 
Q3V3R1 Monofunctional C1-tetrahydrofolate 
synthase, mitochondrial 
Mthfd1l KI Only 
Q5DTL9-2 Isoform 2 of Sodium-driven chloride 
bicarbonate exchanger 
Slc4a10 KI Only 
Q60631-2 Isoform 2 of Growth factor receptor-bound 
protein 2 
Grb2 KI Only 
Q61029-2 Isoform Delta of Lamina-associated 
polypeptide 2, isoforms 
beta/delta/epsilon/gamma 
Tmpo KI Only 
Q61234 Alpha-1-syntrophin Snta1 KI Only 
Q62205 Sodium channel protein type 9 subunit alpha Scn9a KI Only 
Q62383 Transcription elongation factor SPT6 Supt6h KI Only 
Q64133 Amine oxidase [flavin-containing] A Maoa KI Only 
Q6IRU2 Tropomyosin alpha-4 chain Tpm4 KI Only 
Q6P5F6 Zinc transporter ZIP10 Slc39a10 KI Only 
Q6ZPS2-2 Isoform 2 of Carnosine synthase 1 Carns1 KI Only 
Q7M729 Sodium channel subunit beta-4 Scn4b KI Only 
Q7TME0 Lipid phosphate phosphatase-related protein 
type 4 
Lppr4 KI Only 
Q7TPD3-2 Isoform 2 of Roundabout homolog 2 Robo2 KI Only 
Q7TQH0-2 Isoform 2 of Ataxin-2-like protein Atxn2l KI Only 
Q80VC9-2 Isoform 2 of Calmodulin-regulated spectrin- Camsap3 KI Only 
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associated protein 3 
Q80WM4 Hyaluronan and proteoglycan link protein 4 Hapln4 KI Only 
Q80WM5 Hyaluronan and proteoglycan link protein 3 Hapln3 KI Only 
Q811P8-2 Isoform 2 of Rho GTPase-activating protein 
32 
Arhgap32 KI Only 
Q8BGH2 Sorting and assembly machinery component 
50 homolog 
Samm50 KI Only 
Q8BHK2 Sodium channel subunit beta-3 Scn3b KI Only 
Q8BK64 Activator of 90 kDa heat shock protein 
ATPase homolog 1 
Ahsa1 KI Only 
Q8BYR1-2 Isoform 2 of tRNA wybutosine-synthesizing 
protein 4 
Lcmt2 KI Only 
Q8C419 Probable G-protein coupled receptor 158 Gpr158 KI Only 
Q8CGY8-2 Isoform 2 of UDP-N-acetylglucosamine--
peptide N-acetylglucosaminyltransferase 110 
kDa subunit 
Ogt KI Only 
Q8K019-2 Isoform 2 of Bcl-2-associated transcription 
factor 1 
Bclaf1 KI Only 
Q99KG3-2 Isoform 2 of RNA-binding protein 10 Rbm10 KI Only 
Q99MI1-2 Isoform 2 of ELKS/Rab6-interacting/CAST 
family member 1 
Erc1 KI Only 
Q99PJ0 Neurotrimin Ntm KI Only 
Q9CQ75 NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex subunit 2 
Ndufa2 KI Only 
Q9CQJ8 NADH dehydrogenase [ubiquinone] 1 beta 
subcomplex subunit 9 
Ndufb9 KI Only 
Q9CQZ5 NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex subunit 6 
Ndufa6 KI Only 
Q9CR51 V-type proton ATPase subunit G 1 Atp6v1g1 KI Only 
Q9CZT8 Ras-related protein Rab-3B Rab3b KI Only 
Q9D0R8 Protein LSM12 homolog Lsm12 KI Only 
Q9D1D4| Transmembrane emp24 domain-containing 
protein 10 
Tmed10 KI Only 
Q9D517 1-acyl-sn-glycerol-3-phosphate 
acyltransferase gamma 
Agpat3 KI Only 
Q9D855 Cytochrome b-c1 complex subunit 7 Uqcrb KI Only 
Q9D8W5 26S proteasome non-ATPase regulatory 
subunit 12 
Psmd12 KI Only 
Q9DCJ1 Target of rapamycin complex subunit LST8 Mlst8 KI Only 
Q9DCZ4 Apolipoprotein O Apoo KI Only 
Q9EPK2-2 Isoform 2 of Protein XRP2 Rp2 KI Only 
Q9JJ28| Protein flightless-1 homolog Flii KI Only 
Q9JLI8| Squamous cell carcinoma antigen 
recognized by T-cells 3 
Sart3 KI Only 
Q9JLN9 Serine/threonine-protein kinase mTOR Mtor KI Only 
Q9QWK4 CD5 antigen-like Cd5l KI Only 
Q9QWW1-2 Isoform 2 of Homer protein homolog 2 Homer2 KI Only 
Q9WTS6-2 Isoform 2 of Teneurin-3 Tenm3 KI Only 
Q9WV34-2 Isoform 2 of MAGUK p55 subfamily member 
2 
Mpp2 KI Only 
Q9WV85 Nucleoside diphosphate kinase 3 Nme3 KI Only 
Q9Z0P4 Paralemmin-1 Palm KI Only 
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Q9Z0V2 Potassium voltage-gated channel subfamily 
D member 2 
Kcnd2 KI Only 
B1APX2 Protein 5031439G07Rik 5031439G07Ri
k 
KI Only 
|D3YWG1 Uncharacterized protein Gm7964 KI Only 
G3UZJ2 Microtubule-associated protein (Fragment) Map2 KI Only 
H3BJD0 Protein Ppp1r9a Ppp1r9a KI Only 
Q0VGU4 MCG18019 Vgf KI Only 
Q3U422 NADH dehydrogenase [ubiquinone] 
flavoprotein 3, mitochondrial 
Ndufv3 KI Only 
Q8CF89 TGF-beta-activated kinase 1 and MAP3K7-
binding protein 1 
Tab1 43.63 
Q9DBZ5 Eukaryotic translation initiation factor 3 
subunit K 
Eif3k 32.97 
Q9WTT4 V-type proton ATPase subunit G 2 Atp6v1g2 19.16 
O70439| Syntaxin-7 Stx7 18.61 
Q9JME5 AP-3 complex subunit beta-2 Ap3b2 15.09 
Q99MR8 Methylcrotonoyl-CoA carboxylase subunit 
alpha, mitochondrial 
Mccc1 13.76 
P97450 ATP synthase-coupling factor 6, 
mitochondrial 
Atp5j 11.15 
Q9JJY3 Sphingomyelin phosphodiesterase 3 Smpd3 11.15 
Q80Y17 Lethal (2) giant larvae protein homolog 1 Llgl1 10.64 
P48193-2 Isoform 2 of Protein 4.1 Epb41 8.86 
Q9ER00 Syntaxin-12 Stx12 7.31 
Q91ZU6-2 Isoform 1 of Dystonin Dst 7.05 
Q3UGC7 Eukaryotic translation initiation factor 3 
subunit J-A 
Eif3j1 7.02 
P12787 Cytochrome c oxidase subunit 5A, 
mitochondrial 
Cox5a 6.83 
Q9ESN9-2 Isoform 1a of C-Jun-amino-terminal kinase-
interacting protein 3 
Mapk8ip3 6.37 
Q9JKK7 Tropomodulin-2 Tmod2 6.30 
Q14BI2 Metabotropic glutamate receptor 2 Grm2 5.98 
Q921I1 Serotransferrin Tf 5.80 
P62334 26S protease regulatory subunit 10B Psmc6 5.67 
Q80TL0 Protein phosphatase 1E Ppm1e 5.65 
Q9Z127 Large neutral amino acids transporter small 
subunit 1 
Slc7a5 5.53 
Q8QZY1 Eukaryotic translation initiation factor 3 
subunit L 
Eif3l 5.19 
Q9R0N7 Synaptotagmin-7 Syt7 5.07 
Q9D6J6 NADH dehydrogenase [ubiquinone] 
flavoprotein 2, mitochondrial 
Ndufv2 5.06 
Q5DTY9 BTB/POZ domain-containing protein 
KCTD16 
Kctd16 5.01 
Q61335 B-cell receptor-associated protein 31 Bcap31 5.01 
Q91XD7 Cysteine-rich with EGF-like domain protein 1 Creld1 4.62 
Q3UH68-3 Isoform 3 of LIM and calponin homology 
domains-containing protein 1 
Limch1 4.60 
Q9QXV0 ProSAAS Pcsk1n 4.60 
Q9DBR7-2 Isoform 2 of Protein phosphatase 1 
regulatory subunit 12A 
Ppp1r12a 4.50 
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Q61330 Contactin-2 Cntn2 4.42 
P70414 Sodium/calcium exchanger 1 Slc8a1 4.41 
Q8JZR6-2 Isoform 2 of Electroneutral sodium 
bicarbonate exchanger 1 
Slc4a8 4.35 
Q7TMF3 NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex subunit 12 
Ndufa12 4.32 
O70194 Eukaryotic translation initiation factor 3 
subunit D 
Eif3d 4.30 
Q7TQ95 Protein lunapark Lnp 4.22 
S4R2K9 Ankyrin-3 (Fragment) Ank3 4.12 
Q0VE82 Copine-7 Cpne7 4.03 
Q9DBG6 Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase subunit 2 
Rpn2 4.00 
Q8R5H1-2 Isoform 2 of Ubiquitin carboxyl-terminal 
hydrolase 15 
Usp15 3.88 
Q9QUR8 Semaphorin-7A Sema7a 3.74 
Q9Z1P6 NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex subunit 7 
Ndufa7 3.71 
Q80TS3-3 Isoform 3 of Latrophilin-3 Lphn3 3.69 
O35526| Syntaxin-1A Stx1a 3.64 
A2ALS5-2 Isoform 2 of Rap1 GTPase-activating protein 
1 
Rap1gap 3.60 
P55012 Solute carrier family 12 member 2 Slc12a2 3.58 
Q8R5C5 Beta-centractin Actr1b 3.58 
E9PVU0 Unconventional myosin-VI Myo6 3.48 
Q7TPR4 Alpha-actinin-1 Actn1 3.47 
Q78IK2 Up-regulated during skeletal muscle growth 
protein 5 
Usmg5 3.45 
P48771 Cytochrome c oxidase subunit 7A2, 
mitochondrial 
Cox7a2 3.44 
E9Q3L2 Protein Pi4ka Pi4ka 3.40 
P62812 Gamma-aminobutyric acid receptor subunit 
alpha-1 
Gabra1 3.30 
B8QI35 Liprin-alpha 3 Ppfia3 3.28 
P63137-2 Isoform 2 of Gamma-aminobutyric acid 
receptor subunit beta-2 
Gabrb2 3.25 
Q9WTR5 Cadherin-13 Cdh13 3.18 
Q8BW75 Amine oxidase [flavin-containing] B Maob 3.16 
Q8C522 Endonuclease domain-containing 1 protein Endod1 3.13 
Q9DC69 NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex subunit 9, mitochondrial 
Ndufa9 3.10 
P01631 Ig kappa chain V-II region 26-10 Ig kappa chain 
V-II region 26-
10 OS=Mus 
musculus 
3.07 
P28738 Kinesin heavy chain isoform 5C Kif5c 3.06 
Q9DB77 Cytochrome b-c1 complex subunit 2, 
mitochondrial 
Uqcrc2 3.03 
Q61768 Kinesin-1 heavy chain Kif5b 3.01 
Q8R366 Immunoglobulin superfamily member 8 Igsf8 2.98 
Q9WTS5 Teneurin-2 Tenm2 2.94 
P23116| Eukaryotic translation initiation factor 3 
subunit A 
Eif3a 2.91 
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Q9JI91 Alpha-actinin-2 Actn2 2.91 
P32037| Solute carrier family 2, facilitated glucose 
transporter member 3 
Slc2a3 2.88 
Q6PDL0 Cytoplasmic dynein 1 light intermediate 
chain 2 
Dync1li2 2.88 
B2RUJ5-3 Isoform 3 of Amyloid beta A4 precursor 
protein-binding family A member 1 
Apba1 2.81 
Q99LC3 NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex subunit 10, mitochondrial 
Ndufa10 2.79 
P18242 Cathepsin D Ctsd 2.78 
Q6WVG3 BTB/POZ domain-containing protein 
KCTD12 
Kctd12 2.78 
Q60931 Voltage-dependent anion-selective channel 
protein 3 
Vdac3 2.77 
Q9ERG2 Striatin-3 Strn3 2.73 
Q8R1B4 Eukaryotic translation initiation factor 3 
subunit C 
Eif3c 2.72 
Q80SW1 Putative adenosylhomocysteinase 2 Ahcyl1 2.70 
Q9WTM5 RuvB-like 2 Ruvbl2 2.68 
P01837| Ig kappa chain C region Ig kappa chain 
C region 
OS=Mus 
musculus 
2.67 
E9Q7C9 Kinesin light chain 1 Klc1 2.66 
O70252 Heme oxygenase 2 Hmox2 2.58 
Q8BG32 26S proteasome non-ATPase regulatory 
subunit 11 
Psmd11 2.58 
Q8BGN3 Ectonucleotide 
pyrophosphatase/phosphodiesterase family 
member 6 
Enpp6 2.57 
P14685 26S proteasome non-ATPase regulatory 
subunit 3 
Psmd3 2.54 
Q61735-2 Isoform 2 of Leukocyte surface antigen 
CD47 
Cd47 2.51 
O88737-2 Isoform 2 of Protein bassoon Bsn 2.39 
O88741 Ganglioside-induced differentiation-
associated protein 1 
Gdap1 2.39 
Q60598 Src substrate cortactin Cttn 2.38 
Q9QY76 Vesicle-associated membrane protein-
associated protein B 
Vapb 2.37 
Q8K3J1 NADH dehydrogenase [ubiquinone] iron-
sulfur protein 8, mitochondrial 
Ndufs8 2.34 
Q8K400 Syntaxin-binding protein 5 Stxbp5 2.34 
Q8CAQ8-2 Isoform 2 of Mitochondrial inner membrane 
protein 
Immt 2.33 
P23927 Alpha-crystallin B chain Cryab 2.33 
Q9JHU4 Cytoplasmic dynein 1 heavy chain 1 Dync1h1 2.33 
O08917 Flotillin-1 Flot1 2.32 
Q3V132 ADP/ATP translocase 4 Slc25a31 2.32 
Q91WK2 Eukaryotic translation initiation factor 3 
subunit H 
Eif3h 2.26 
Q9JIS5 Synaptic vesicle glycoprotein 2A Sv2a 2.26 
A2AQ25-2 Isoform 2 of Sickle tail protein Skt 2.25 
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Q99MN1| Lysine--tRNA ligase Kars 2.24 
O55143 Sarcoplasmic/endoplasmic reticulum calcium 
ATPase 2 
Atp2a2 2.22 
tr|E9Q6P5 Protein Ttc7b Ttc7b 2.21 
P97390 Vacuolar protein sorting-associated protein 
45 
Vps45 2.20 
Q9DB05 Alpha-soluble NSF attachment protein Napa 2.20 
P04919-2 Isoform Kidney of Band 3 anion transport 
protein 
Slc4a1 2.19 
P46097 Synaptotagmin-2 Syt2 2.19 
Q9DCX2 ATP synthase subunit d, mitochondrial Atp5h 2.19 
Q8CCT4 Transcription elongation factor A protein-like 
5 
Tceal5 2.18 
Q6PGE7 Sodium-dependent proline transporter Slc6a7 2.17 
Q8CBY8-2 Isoform 2 of Dynactin subunit 4 Dctn4 2.16 
Q9CZW5 Mitochondrial import receptor subunit 
TOM70 
Tomm70a 2.15 
Q8BFZ9 Erlin-2 Erlin2 2.11 
Q8CGU1 Calcium-binding and coiled-coil domain-
containing protein 1 
Calcoco1 2.10 
E9Q5J9 Tropomyosin alpha-3 chain Tpm3 2.08 
P31324 cAMP-dependent protein kinase type II-beta 
regulatory subunit 
Prkar2b 2.07 
P62715 Serine/threonine-protein phosphatase 2A 
catalytic subunit beta isoform 
Ppp2cb 2.06 
B1AWC8 Protein Pde4b Pde4b 2.05 
E9PUL5 Proline-rich transmembrane protein 2 Prrt2 2.04 
Q9R1L5 Microtubule-associated serine/threonine-
protein kinase 1 
Mast1 2.04 
Q9D0M3-2 Isoform 2 of Cytochrome c1, heme protein, 
mitochondrial 
Cyc1 2.03 
P60229 Eukaryotic translation initiation factor 3 
subunit E 
Eif3e 2.03 
Q3TXX4 Vesicular glutamate transporter 1 Slc17a7 2.03 
Q8VEK0 Cell cycle control protein 50A Tmem30a 2.02 
P62196 26S protease regulatory subunit 8 Psmc5 2.00 
1 KI: knock in; WT: wild type; KI only: only found in knock in; FI: Fold increase compared to 
wildtype  
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Table 2: Functional protein-interaction partners of Nav1.7 (single 
purification) 
 
MGI 
symbol 
Protein name Function 
(GO-family/ 
PHANTER 
protein class) 
UniPr
ot Acc 
SPECTRAL 
INDEX  
MIC SIn 
 
    S1 S2 S3 
 
Channels/receptor/transporters 
 
Adrm1	   Proteasomal	  ubiquitin	  
receptor	  ADRM1	  
Proteasomal	  
ubiquitin	  receptor	  
Q9JKV1	   	   1.37
E-­‐07	  
1.52
E-­‐07	  
Aqp1	   Aquaporin-­‐1	   Transporter	  
Transfer/carrier	  
protein 
Q02013	   	  
1.31
E-­‐06	  
1.03
E-­‐06	  
Atp2a2	   Sarcoplasmic/endoplasm
ic	  reticulum	  calcium	  
ATPase	  
Cation	  transporter;	  	  
Ion	  channel	  
O55143	  
	   1.82
E-­‐06	  
8.86
E-­‐07	  
8.71
E-­‐07	  
Atp6v1g2	   V-­‐type	  proton	  ATPase	  
subunit	  G	  2	  
ATP	  synthase	   Q9WTT4	   1.95
E-­‐06	   	  	  
1.81
E-­‐07	  
Bcap31	   B-­‐cell	  receptor-­‐
associated	  protein	  31	  
Transporter	  
Membrane	  traffic	  
protein 
Q61335	  
1.07
E-­‐06	  
8.57
E-­‐07	  
4.92
E-­‐07	  
Cd47	   Leukocyte	  surface	  
antigen	  CD47	  
Immunoglobulin	  
receptor	  
superfamily	  
Q61735	  
2.99
E-­‐07	  
3.29
E-­‐07	  
5.09
E-­‐07	  
Fxyd7	   FXYD	  domain-­‐containing	  
ion	  transport	  regulator	  7	  
Anion	  channel;	  
Enzyme	  modulator	  
P59648	   	   1.27
E-­‐05	  
1.57
E-­‐05	  
Gabra1	   Gamma-­‐aminobutyric	  
acid	  receptor	  subunit	  
alpha-­‐1	  
GABAreceptor;	  
Acetylcholine	  
receptor 
P62812	  
1.27
E-­‐06	  
2.64
E-­‐07	  
3.65
E-­‐07	  
Kcnj10	   ATP-­‐sensitive	  inward	  
rectifier	  potassium	  
channel	  10	  
Voltage-­‐gated	  ion	  
channel	  	  
Q9JM63	   	  
1.23
E-­‐06	  
4.59
E-­‐07	  
Lpar1	   Lysophosphatidic	  acid	  
receptor	  1	  
G-­‐protein	  coupled	  
receptor 
P61793	   	   4.23
E-­‐08	  
4.58
E-­‐08	  
Lphn3	   Latrophilin-­‐3	   G-­‐protein	  coupled	  
receptor	  
Q80TS3	   1.16
E-­‐06	  
3.05
E-­‐08	  
	  
Scn3b	   Sodium	  channel	  subunit	  
beta-­‐3	   
Voltage-­‐gated	  ion	  
channel 
Q8BHK2	   3.48
E-­‐06	  
5.27
E-­‐06	  
2.68
E-­‐06	  
Scn4b	   Sodium	  channel	  subunit	  
beta-­‐4	   
Voltage-­‐gated	  ion	  
channel	  
Cell	  adhesion	  
molecule	  
Q7M729	  
1.58
E-­‐06	   	  	  
2.39
E-­‐06	  
Scn9a	   Sodium	  channel	  protein	  
type	  9	  subunit	  alpha	   
Voltage-­‐gated	  ion	  
channel	  
Q62205	   2.84
E-­‐06	  
5.08
E-­‐06	  
2.67
E-­‐06	  
Sema7a	   Semaphorin-­‐7A	   Membrane-­‐bound	  
signaling	  molecule	  
Q9QUR8	   3.38
E-­‐07	   	  	  
3.13
E-­‐08	  
Slc12a2	   Solute	  carrier	  family	  12	  
member	  2	  
Cation	  transporter E9QM38	   9.85
E-­‐07	  
1.17
E-­‐06	  
1.26
E-­‐06	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Slc2a3	   Solute	  carrier	  family	  2,	  
facilitated	  glucose	  
transporter	  member	  3	  
Carbohydrate	  
transporter	  
P32037	  
2.12
E-­‐07	   	  	  
1.75
E-­‐06	  
Slc30a9	   Zinc	  transporter	  9	   Transporter	   Q5IRJ6	   	   1.48
E-­‐07	  
1.06
E-­‐07	  
Slc4a1	   Band	  3	  anion	  transport	  
protein	  
Transporter	   P04919	   1.47
E-­‐06	  
2.92
E-­‐07	  
3.16
E-­‐07	  
Slc4a8	   Electroneutral	  sodium	  
bicarbonate	  exchanger	  1	  
Cation	  transporter	   Q8JZR6	   1.62
E-­‐07	   	  	  
5.42
E-­‐08	  
Slc6a5	   Sodium-­‐	  And	  Chloride-­‐
Dependent	  Glycine	  
Transporter	  2	  
Cation	  transporter	   B2RQX9	   	  
3.02
E-­‐08	  
1.29
E-­‐07	  
Slc7a5	   Large	  neutral	  amino	  
acids	  transporter	  small	  
subunit	  1	  
Amino	  acid	  
transporter	  
Q9Z127	  
4.43
E-­‐08	  
3.88
E-­‐07	  
4.47
E-­‐07	  
Slc8a1	   	   Sodium/calcium	  
exchanger	  1	  
Cation	  transporter G3X9J1	   3.51
E-­‐07	  
1.92
E-­‐07	  
4.70
E-­‐07	  
Tf	   Serotransferrin	   Type	  I/II	  cytokine	  
receptor	  
P20352	   1.30
E-­‐07	  
5.38
E-­‐07	  
 
Vdac3	   Voltage-­‐dependent	  
anion-­‐selective	  channel	  
protein	  3	  
Anion	  channel;	  
Voltage-­‐gated	  ion	  
channel	  
Q60931	  
3.08
E-­‐06	  
1.37
E-­‐06	  
1.19
E-­‐06	  
 
Enzymes 
	  
Kinases	  
Csnk2a1	   Casein	  kinase	  II	  subunit	  
alpha	  
Serine/threonine	  
protein	  kinase	  
Q60737	   3.66
E-­‐07	  
4.73
E-­‐07	  
1.02
E-­‐06	  
Mapk8ip3	   C-­‐Jun-­‐amino-­‐terminal	  
kinase-­‐interacting	  
protein	  3	  
Kinase	  modulator	   Q9ESN9	  
9.47
E-­‐09	  
2.02
E-­‐07	  
5.11
E-­‐07	  
Mpp2	   MAGUK	  p55	  subfamily	  
member	  2	  
Nucleotide	  kinase	   Q9WV34
-­‐2	  
	   1.27
E-­‐07	  
2.38
E-­‐07	  
Mtor	   Serine/threonine-­‐protein	  
kinase	  mTOR	  
Serine/threonine	  
protein	  kinase	  
Q9JLN9	   	   4.82
E-­‐09	  
2.42
E-­‐08	  
Ndufa10	   NADH	  dehydrogenase	  
[ubiquinone]	  1	  alpha	  
subcomplex	  subunit	  
10,mitochondrial	  
Nucleotide	  kinase	   Q99LC3	  
8.82
E-­‐07	  
1.77
E-­‐06	  
8.84
E-­‐07	  
Pi4ka	   Phosphatidylinositol	  4-­‐
Kinase	  Alpha	  
Kinase	   E9Q3L2	   	   4.92
E-­‐07	  
4.18
E-­‐07	  
RP2	   Protein	  retinitis	  
pigmentosa	  2,	  XRP2	  
Nucleotide	  kinase	   Q9EPK2-­‐
2	  
3.89
E-­‐06	  
1.21
E-­‐06	  
2.98
E-­‐07	  
Sgk223	   Tyrosine-­‐protein	  kinase	  
SgK223	  
Protein	  kinase	   Q571I4	    2.02
E-­‐08	  
1.87
E-­‐08	  
Tab1	   TGF-­‐beta-­‐activated	  
kinase	  1	  and	  MAP3K7-­‐
binding	  protein	  1	  
Kinase	  inhibitor	  
Protein	  
phosphatase	  
Q8CF89	    
1.94
E-­‐06	  
2.16
E-­‐07	  
Tek	   Angiopoietin-­‐1	  receptor	   Transmembrane	  
tyrosine	  kinase	  
protein	  
Q02858	    
1.35
E-­‐06	  
1.21
E-­‐06	  
Phosphatase	  
Enpp6	   Ectonucleotide	   Nucleotide	   Q8BGN3	   9.66 	   1.16
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pyrophosphatase/phosp
hodiesterase	  family	  
member	  6	  
phosphatase	   E-­‐07	   E-­‐07	  
Lppr3	   Lipid	  phosphate	  
phosphatase-­‐related	  
protein	  type	  3	  
Phosphatase	   Q7TPB0	  
1.09
E-­‐07	  
2.48
E-­‐07	  
1.89
E-­‐07	  
Ppp1r9a	  	   Neurabin-­‐1,	  Protein	  
protein	  phosphatase	  1,	  
regulatory	  subunit	  9A	  
Phosphatase	   H3BJD0	   	  
2.65
E-­‐07	  
1.06
E-­‐07	  
Ligase	  
Carns1	   Carnosine	  synthase	  1,	  
Isoform	  2	  	  
Other	   Q6ZPS2-­‐
2	  
 1.47
E-­‐06	  
1.02
E-­‐06	  
Kars	   Lysine-­‐-­‐tRNA	  ligase	   RNA	  binding	  
protein;aminoacyl-­‐
tRNA	  synthetase	  
Q99MN1	    
1.85
E-­‐07	  
2.95
E-­‐07	  
Mccc1	   Methylcrotonoyl-­‐CoA	  
carboxylase	  subunit	  
alpha;	  Mitochondrial	  
Ligase	   Q99MR8	    
1.31
E-­‐07	  
9.25
E-­‐07	  
Mccc2	  	   Methylcrotonoyl-­‐CoA	  
carboxylase	  beta	  chain;	  
Mitochondrial	  
Ligase	   Q3ULD5	    
1.98
E-­‐07	  
3.80
E-­‐08	  
Mthfd1l	  	   Monofunctional	  C1	  
tetrahydrofolate	  
synthase;	  Mitochondrial	  
Ligase	   Q3V3R1	    
1.79
E-­‐07	  
5.02
E-­‐08	  
Neurl4	   Neuralized-­‐like	  protein	  4	   Ubiquitin-­‐protein	  
ligase	  
Q5NCX5	    2.02
E-­‐08	  
1.23
E-­‐08	  
Isomerase/lhydrolase/protease	  
Ahcyl1	   Putative	  
adenosylhomocysteinase	  
2	  
Hydrolase	   Q80SW1	   	  
3.13
E-­‐07	  
8.18
E-­‐07	  
Cox5a	   Cytochrome	  c	  oxidase	  
subunit	  5A,	  
mitochondrial	  
Oxidase	   P12787	  
2.95
E-­‐05	   	  	  
4.09
E-­‐07	  
Hmox2	   Heme	  oxygenase	  2	   Oxygenase	   O70252	   5.10
E-­‐07	   	  	  
3.62
E-­‐07	  
Ndufa8	   NADH	  dehydrogenase	  
[ubiquinone]	  1	  alpha	  
subcomplex	  subunit	  8	  
Dehydrogenase	  
	  
Q9DCJ5	  
1.52
E-­‐05	   	  	  
1.50
E-­‐07	  
Ndufa9	   NADH	  dehydrogenase	  
[ubiquinone]	  1	  alpha	  
subcomplex	  subunit	  9,	  
mitochondrial	  
Dehydrogenase	  
Reductase	  
Q9DC69	  
9.46
E-­‐06	  
1.03
E-­‐06	  
8.71
E-­‐07	  
Ndufv2	   NADH	  dehydrogenase	  
[ubiquinone]	  
flavoprotein	  2,	  
mitochondrial	  
Dehydrogenase;	  
Reductase	  
Q9D6J6	  
3.83
E-­‐06	  
9.37
E-­‐07	  
	  
Ndufa3	   NADH	  dehydrogenase	  
[ubiquinone]	  1	  alpha	  
subcomplex	  subunit	  3	  
Oxidoreductase	  
	  
Q9CQ91	  
4.92
E-­‐06	   	  	  
1.28
E-­‐06	  
Ndufa7	   NADH	  dehydrogenase	  
[ubiquinone]	  1	  alpha	  
subcomplex	  subunit	  7	  
Oxidoreductase	  
	  
Q9Z1P6	  
1.37
E-­‐06	  
1.83
E-­‐06	  
1.64
E-­‐06	  
Ndufs8	   ADH	  dehydrogenase	  
[ubiquinone]	  iron-­‐sulfur	  
protein	  8,	  mitochondria	  
Oxidoreductase	  
	  
Q8K3J1	   	  
2.66
E-­‐06	  
9.24
E-­‐07	  
7.46
E-­‐07	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Ndufv3	   	   NADH	  dehydrogenase	  
[ubiquinone]	  
flavoprotein	  3,	  
mitochondrial	  
Oxidoreductase	  
	  
Q8BK30	  
4.32
E-­‐06	  
1.57
E-­‐06	  
	  
Pde4b	   Camp-­‐Specific	  3',5'-­‐
Cyclic	  Phosphodiesterase	  
4b	  
Phosphodiesterase	   B1AWC9	   	  
3.29
E-­‐07	  
1.96
E-­‐07	  
Psmc1	   26S	  protease	  regulatory	  
subunit	  4	  
Hydrolase	   P62192	   	   2.64
E-­‐07	  
4.02
E-­‐07	  
Psmc5	   26S	  protease	  regulatory	  
subunit	  8	  
Hydrolase	   P62196	   	   4.77
E-­‐07	  
2.90
E-­‐07	  
Psmc6	   26S	  protease	  regulatory	  
subunit	  10B	  
Hydrolase	   P62334	   	   1.25
E-­‐06	  
8.12
E-­‐07	  
Uqcrc2	   Cytochrome	  b-­‐c1	  
complex	  subunit	  2,	  
mitochondrial	  
Metalloprotease	  
Reductase	  
Q9DB77	  
1.20
E-­‐05	  
1.76
E-­‐06	  
2.63
E-­‐06	  
Transferase	  
Agpat3	  	   1-­‐acyl-­‐sn-­‐glycerol-­‐3-­‐
phosphate	  
acyltransferase	  gamma	  	  
Acyltransferase	   Q9D517	   	  
1.27
E-­‐07	  
3.66
E-­‐07	  
Maob	  	  
	  
Amine	  oxidase	  [flavin-­‐
containing]	  A	  
Methyltransferase	   Q64133	   2.00
E-­‐07	  
1.61
E-­‐07	  
	  
Mat2a	   	  S-­‐adenosylmethionine	  
synthase	  isoform	  type-­‐2	  
Nucleotidyltransfer
ase	  
Q3THS6	   	   1.17
E-­‐07	  
4.80
E-­‐08	  
Ogt	   Isoform	  2	  of	  UDP-­‐N-­‐
Acetyl	  glucosamine-­‐
peptide	  
Nacetylglucosaminy-­‐
ltransferase	  	  
Glycosyltransferase	   Q8CGY8-­‐
2	  
	  
1.19
E-­‐07	  
1.65
E-­‐07	  
Ttc7b	   Tetratricopeptide	  Repeat	  
Protein	  7b	  
Glycosyltransferase	   E9Q6P5	   	   2.61
E-­‐07	  
1.16
E-­‐07	  
Modulators/	  Regulators/Signalling	  	  
Kctd16	   BTB/POZ	  domain-­‐
containing	  protein	  
KCTD16	  
Enzyme	  modulator	   Q5DTY9	  
2.61
E-­‐07	   	  	  
3.71
E-­‐08	  
Psmd12	   26S	  proteasome	  non-­‐
ATPase	  regulatory	  
subunit	  12	  
Enzyme	  modulator	   Q9D8W5	   	  
1.32
E-­‐07	  
7.89
E-­‐07	  
Psmd3	   26S	  proteasome	  non-­‐
ATPase	  regulatory	  
subunit	  3	  
Enzyme	  modulator	  
	  
P14685	  
5.47
E-­‐08	  
1.06
E-­‐06	  
7.76
E-­‐07	  
Ccar2	   Cell	  cycle	  and	  apoptosis	  
regulator	  protein	  2	  
Enzyme	  inhibitor	  	   Q8VDP4	   	   1.45
E-­‐07	  
5.97
E-­‐08	  
 
Vesicular/trafficking/transport 
 
Ap3b2	   AP-­‐3	  complex	  subunit	  
beta-­‐2	  
Membrane	  traffic	  
protein	  
Q9JME5	   1.47
E-­‐06	  
1.14
E-­‐06	  
2.01
E-­‐07	  
Apba1	   Amyloid	  beta	  A4	  
precursor	  protein-­‐
binding	  family	  A	  member	  
1	  
Membrane	  
trafficking	  
regulatory	  protein	  
B2RUJ5	   	  
8.35
E-­‐08	  
3.29
E-­‐07	  
Cope	   Coatomer	   subunit	  
epsilon	  
Vesicle	  coat	  protein	   Q9D1D4	   	  
2.49 2.42
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E-­‐07	   E-­‐07	  
Cpne7	   Copine-­‐7	   Membrane	  traffic	  
protein	  
Q0VE82	   	   	   1.81
E-­‐07	  
7.79
E-­‐07	  
Flot1	   Flotillin-­‐1	   Membrane	  traffic	  
protein	  
O08917	   3.18
E-­‐07	  
3.15
E-­‐07	  
4.73
E-­‐07	  
Llgl1	   Lethal(2)	  giant	  larvae	  
protein	  homolog	  1	  
Membrane	  
trafficking	  
regulatory	  protein	  
Q80Y17	   	  
2.83
E-­‐07	  
1.45
E-­‐07	  
Napa	  
	  
Alpha-­‐soluble	  NSF	  
attachment	  protein	  
Membrane	  traffic	  
protein	  
Q9DB05	   8.07
E-­‐07	  
6.77
E-­‐07	  
1.39
E-­‐06	  
Osbpl6	   Oxysterol-­‐binding	  
protein-­‐related	  protein	  6	  
Transfer/carrier	  
protein	  
Q8BXR9	   	   2.71
E-­‐08	  
1.46
E-­‐08	  
Sec22b	   Vesicle-­‐trafficking	  
protein	  SEC22b	  
SNARE	  protein	   O08547	   1.21
E-­‐06	  
5.26
E-­‐07	  
2.35
E-­‐07	  
Stx12	   	   Syntaxin-­‐12	   SNARE	  protein	   Q9ER00	   1.20
E-­‐07	  
6.97
E-­‐07	  
5.05
E-­‐07	  
Stx1a	   	   Syntaxin-­‐1A	   SNARE	  protein	   O35526	   1.70
E-­‐05	   	  	  
2.10
E-­‐06	  
Stx7	   Syntaxin	  7	   SNARE	  protein	   Q8BH40	   4.01
E-­‐06	   	  	  
1.62
E-­‐07	  
Stxbp5	   Syntaxin-­‐binding	  protein	  
5	  
Membrane	  
trafficking	  
regulatory	  protein	  
Q8K400	  
2.12
E-­‐06	   	  	  
3.37
E-­‐09	  
Sv2a	   Synaptic	  vesicle	  
glycoprotein	  2A	  
Transfer/carrier	  
protein	  
Q9JIS5	   7.41
E-­‐06	  
2.76
E-­‐06	  
5.56
E-­‐06	  
Syt2	   Synaptotagmin-­‐2	   Membrane	  
trafficking	  
regulatory	  protein	  
P46097	  
2.25
E-­‐05	  
1.86
E-­‐06	  
1.64
E-­‐06	  
Tmed10	  	   Transmembrane	  emp24	  
domain-­‐containing	  
protein	  10	  	  
Transfer/carrier	  
protein	  
Vesicle	  coat	  protein	  
Q9D1D4	  
1.08
E-­‐06	   	  	  
9.98
E-­‐08	  
Vapb	   Vesicle-­‐associated	  
membrane	  protein,	  
associated	  protein	  B	  and	  
C	  
Membrane	  
trafficking	  
regulatory	  protein	  
Q8BH80	  
4.55
E-­‐06	   	  	  
1.33
E-­‐07	  
 
Cytoskeletal/structural/cell adhesion 
 
Actr1b	   Beta-­‐centractin	   Actin	  and	  actin	  
related	  protein	  
Q8R5C5	   	   1.05
E-­‐06	  
4.41
E-­‐07	  
Ank3	   Ankyrin-­‐3	   Cytoskeletal	  
protein	  
G5E8K5	   1.44
E-­‐06	  
4.38
E-­‐07	  
1.30
E-­‐07	  
Arhgap32	   RhoGTPase-­‐activating	  
protein	  32	  
Cytoskeletal	  
regulator	  protein	  
Q811P8	   	   	   4.69
E-­‐08	  
1.81
E-­‐08	  
Cdh13	   Cadherin-­‐13	   Cell	  junction	  
protein	  
Q9WTR5	   1.39
E-­‐07	  
7.25
E-­‐08	  
2.54
E-­‐07	  
Chaperones	  	  
Ckap5	   Cytoskeleton-­‐associated	  
protein	  5	  
Non-­‐motor	  
microtubule	  
binding	  protein	  
A2AGT5	  
6.00
E-­‐07	  
1.18
E-­‐06	  
	  
Cttn	   Src	  substrate	  cortactin	   Non-­‐motor	  actin	  
binding	  protein	  
Q60598	   	   1.91
E-­‐07	  
1.57
E-­‐06	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Dnajb6	   DnaJ	  homolog	  subfamily	  
B	  member	  6	  
Chaperonin	   O54946	   	   8.15
E-­‐07	  
9.65
E-­‐07	  
Dst	   Dystonin	   Non-­‐motor	  actin	  
binding	  protein	  
E9Q9X1	   1.45
E-­‐08	  
9.94
E-­‐09	  
6.52
E-­‐08	  
Dync1h1	   Cytoplasmic	  dynein	  1	  
heavy	  chain	  1	  
Microtubule	  family	  
cytoskeletal	  protein	  
Q9JHU4	   	   5.70
E-­‐07	  
1.19
E-­‐06	  
Dync1li2	   Cytoplasmic	  dynein	  1	  
light	  intermediate	  chain	  
2	  
Microtubule	  family	  
cytoskeletal	  protein	  
Q6PDL0	   	  
3.32
E-­‐07	  
3.63
E-­‐07	  
Flii	   Protein	  flightless-­‐1	  
homolog	  	  
	  
Non-­‐motor	  actin	  
binding	  protein 
Q9JJ28 	  
2.63
E-­‐08	  
4.03
E-­‐08	  
Fry	   Protein	  furry	  homolog,	  
Isoform	  2	  	  
Structural/scaffold	  	   E9Q8I9-­‐2	   	   5.41
E-­‐09	  
7.10
E-­‐09	  
Gdap1	   Ganglioside-­‐induced	  
differentiation-­‐
associated	  protein	  	  
Cytoskeletal	  
protein	  
	  
O88741	   	  
2.29
E-­‐06	  
1.78
E-­‐06	  
Hepacam	   Hepatocyte	  cell	  adhesion	  
molecule	  
Cell-­‐adhesion	  
molecule	  
Q640R3	   	   2.89
E-­‐07	  
3.19
E-­‐07	  
Hspb1	   Heat	  shock	  protein	  beta-­‐
1	  
Structural	  protein	  
Chaperone	  
P14602	   	   5.96
E-­‐07	  
4.94
E-­‐07	  
Kif5b	   Kinesin-­‐1	  heavy	  chain	   Microtubule	  
binding	  motor	  
protein	  
Q61768	  
1.30
E-­‐07	  
2.81
E-­‐07	  
1.04
E-­‐06	  
Kif5c	   Kinesin	  heavy	  chain	  
isoform	  5C	  
Microtubule	  
binding	  motor	  
protein	  
P28738	  
2.64
E-­‐08	   	  	  
3.89
E-­‐08	  
Klc1	   Kinesin	  light	  chain	  1	   Microtubule	  family	  
cytoskeletal	  protein	  
E9Q7C9	  
	  	  
4.38
E-­‐07	  
1.40
E-­‐06	  
Limch1	   LIM	  and	  calponin	  
homology	  domains-­‐
containing	  protein	  1	  
Actin	  family	  
cytoskeletal	  protein	  
Q3UH68	  
5.36
E-­‐07	   	  	  
1.27
E-­‐07	  
Mlst8	   Target	  of	  rapamycin	  
complex	  subunit	  LST8	  
Actin	  cytoskeleton	  
and	  mTor	  regulator	  
Q9DCJ1	   	   1.50
E-­‐06	  
6.75
E-­‐07	  
Myo6	   Unconventional	  myosin-­‐
VI	  
G-­‐protein	  
modulator;	  
actin	  binding	  motor	  
protein	  
E9Q174	   	  
1.47
E-­‐06	  
6.20
E-­‐07	  
Ntm	   Neurotrimin	   Cell	  adhesion	  
molecule	  
Q99PJ0 4.27
E-­‐07	   	  	  
7.61
E-­‐08	  
Tmod2	   Tropomodulin-­‐2	   Non-­‐motor	  actin	  
binding	  protein 
Q9JKK7	   7.03
E-­‐08	  
8.19
E-­‐07	  
1.13
E-­‐05	  
Tomm70a	   Mitochondrial	  import	  
receptor	  subunit	  TOM70	  
Chaperone	   Q9CZW	   	   5.32
E-­‐07	  
3.93
E-­‐07	  
Tubg1	   Tubulin	  gamma-­‐1	  chain	   Tubulin	   P83887	   	   1.82
E-­‐07	  
1.87
E-­‐07	  
Ca2+/	  Calmodulin	  binding	  
Camsap3	   Calmodulin-­‐regulated	  
spectrin-­‐associated	  
protein	  3	  	  
Microtubule	  
dynamics	  
Calmodulin-­‐
regulated	  
Q80VC9-­‐
2	  
	  
2.63
E-­‐07	  
6.61
E-­‐08	  
Creld1	   Cysteine-­‐rich	  with	  EGF-­‐
like	  domain	  protein	  1	  
Calcium	  binding	  
	  
Q91XD7	   	   2.21
E-­‐07	  
7.58
E-­‐07	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Epb41	   Protein	  4.1	   Calmodulin	  binding	  
Actin	  cytoskeleton	  
organization	  
P48193	  
4.62
E-­‐07	   	  	  
1.21
E-­‐07	  
Ppp1cc	   Serine/threonine-­‐protein	  
phosphatase	  PP1-­‐
gamma	  catalytic	  subunit	  
Protein	  
phosphatase;	  
Calcium-­‐binding	  
protein	  
P63087	  
6.62
E-­‐07	  
1.16
E-­‐06	  
8.77
E-­‐07	  
Ppp2cb	   	   Serine/threonine-­‐protein	  
phosphatase	  2A	  catalytic	  
subunit	  beta	  isoform	  
Protein	  
phosphatase;	  
Calcium-­‐binding	  
protein	  
P62715	   	  
5.66
E-­‐07	  
9.02
E-­‐07	  
Slc9a1	   Sodium/hydrogen	  
exchanger	  1	  
Calmodulin	  binding	  
Antiporter	  	  
Q6116	   3.00
E-­‐07	   	  	  
2.84
E-­‐07	  
Strn	   Striatin	   Calmodulin	  binding	   O55106	   	   2.23
E-­‐07	  
1.42
E-­‐07	  
Strn3	   Striatin-­‐3	   Calmodulin	  binding	   Q9ERG2	   	   3.36
E-­‐07	  
1.13
E-­‐07	  
Strn4	   Striatin-­‐4	   Calmodulin	  binding	   P58404	   	   2.11
E-­‐07	  
1.01
E-­‐07	  
 
Nuclei acid binding protein/Transcription factor 
 
Agap3	   Arf-­‐GAP	  with	  GTPase,	  
ANK	  repeat,	  PH	  domain-­‐
containing	  protein	  3	  
Nucleic	  acid	  
binding;	  
G-­‐protein	  
modulator	  
F8VQE9	   	  
1.02
E-­‐06	  
1.09
E-­‐07	  
Atxn2l	   Ataxin-­‐2-­‐like	  protein;	  	   RNA	   binding	  
protein	  
Q7TQH0-­‐
2	  
 8.76
E-­‐08	  
5.64
E-­‐08	  
Calcoco1	   Calcium-­‐binding	  and	  
coiled-­‐coil	  domain-­‐
containing	  protein	  1	  
DNA	  binding	  
	  
Q8CGU1	    
2.13
E-­‐07	  
3.09
E-­‐07	  
Ddb1	  	   DNA	  damage-­‐binding	  
protein	  1	  	  
mRNA	  
polyadenylation	  
factor	  
Q3U1J4	    
1.82
E-­‐07	  
2.01
E-­‐07	  
Eif3a	   Eukaryotic	  translation	  
initiation	  factor	  3	  
subunit	  A	  
Translation	  
initiation	  factor	  
P23116	  
	   
1.25
E-­‐06	  
3.40
E-­‐06	  
Eif3b	   Eukaryotic	  translation	  
initiation	  factor	  3	  
subunit	  B	  
Translation	  
initiation	  factor	  
Q8JZQ9	  
	   
2.17
E-­‐06	  
2.54
E-­‐06	  
Eif3c	   Eukaryotic	  translation	  
initiation	  factor	  3	  
subunit	  C	  
Translation	  
initiation	  factor	  
Q8R1B4	  
	   
8.12
E-­‐07	  
1.47
E-­‐06	  
Eif3d	   Eukaryotic	  translation	  
initiation	  factor	  3	  
subunit	  D	  
Translation	  
initiation	  factor	  
O70194	  
	   
1.44
E-­‐06	  
1.85
E-­‐06	  
Eif3e	   Eukaryotic	  translation	  
initiation	  factor	  3	  
subunit	  E	  
Translation	  
initiation	  factor	  
P60229	  
	   
2.94
E-­‐06	  
3.83
E-­‐06	  
Eif3h	   Eukaryotic	  translation	  
initiation	  factor	  3	  
subunit	  H	  
Transcription	  factor	   Q91WK2	  
	   
2.02
E-­‐07	  
1.17
E-­‐06	  
Eif3k	   Eukaryotic	  translation	  
initiation	  factor	  3	  
subunit	  K	  
Translation	  
initiation	  factor	  
Q9DBZ5	  
	   
1.08
E-­‐06	  
1.33
E-­‐06	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Eif3l	   Eukaryotic	  translation	  
initiation	  factor	  3	  
subunit	  L	  
Translation	  
initiation	  factor	  
Q8QZY1	  
	  	  
4.25
E-­‐07	  
2.18
E-­‐06	  
Eif4b	   Eukaryotic	  translation	  
initiation	  factor	  4B;	  
Translation	  
initiation	  factor	  
Q8BGD9	   5.03
E-­‐07	  
2.53
E-­‐05	  
1.10
E-­‐05	  
Igf2bp2	   Insulin-­‐like	  growth	  factor	  
2	  mRNA-­‐binding	  protein	  
2	  
mRNA	  splicing	  
factor;	  
Ribonucleoprotein;	  
Q5SF07	  
2.60
E-­‐06	  
7.96
E-­‐07	  
1.76
E-­‐06	  
Prrc2c	   Protein	  PRRC2C	   Transcription	  
factor;	  
Nuclease	  	  
Q3TLH4	   	  
5.81
E-­‐08	  
3.46
E-­‐08	  
Rpl19	   60S	  ribosomal	  protein	  
L19	  
Ribosomal	  protein	   P84099	   	   1.77
E-­‐06	  
8.94
E-­‐07	  
Sart3	  	   Squamous	  cell	  
carcinoma	  antigen	  
recognized	  by	  T-­‐cells	  3	  	  
Nuclease	   Q9JLI8	   	  
2.22
E-­‐07	  
2.38
E-­‐07	  
Tardbp	   TAR	  DNA-­‐binding	  protein	  
43	  
DNA	  binding	  
protein;	  
Q921F2	   	   1.46
E-­‐06	  
4.75
E-­‐07	  
Zranb2	   Zinc	  finger	  Ran-­‐binding	  
domain-­‐containing	  
protein	  2	  
RNA	  binding	  	   Q9R020	   	  
2.61
E-­‐07	  
2.50
E-­‐07	  
 
Unclassified 
 
Apoo	  	   Apolipoprotein	   O;	  
protein	  FAM121B	  
Uncharacterised	   Q9DCZ4	   	   1.33
E-­‐06	  
1.06
E-­‐06	  
Atp5h	   ATP	  synthase	  subunit	  d,	  
mitochondrial	  
Transmembrane	  
transporter	  
Q9DCX2	   1.30
E-­‐05	  
3.55
E-­‐06	  
2.63
E-­‐06	  
Atp5j	   ATP	  synthase-­‐coupling	  
factor	  6,	  mitochondrial	  
Transmembrane	  
transporter	  	  
P97450	   1.70
E-­‐05	   	  	  
3.14
E-­‐06	  
BC068157	   Protein	  BC068157	   Uncharacterised	   E9PV26	   	   3.35
E-­‐08	  
2.18
E-­‐08	  
Chchd6	   Coiled-­‐coil-­‐helix-­‐coiled-­‐
coil-­‐helix	  domain-­‐
containing	  protein	  6,	  
mitochondrial	  
Unclassified/	  
function	  unknown	  
	  
Q91VN4	  
2.42
E-­‐06	  
3.67
E-­‐07	  
6.08
E-­‐07	  
Cyc1	   Cytochrome	  c1,	  heme	  
protein,	  mitochondrial	  
	   Q9D0M3	   5.74
E-­‐06	  
7.47
E-­‐07	  
8.62
E-­‐07	  
Dctn4	   Dynactin	  subunit	   Putative	  
uncharacterised	  
Protein	  
Q8CBY8	   	  
3.56
E-­‐06	  
3.37
E-­‐06	  
Endod1	   Endonuclease	  domain-­‐
containing	  1	  protein	  
Putative	  
uncharacterised	  
Protein	  
Q8C522	  
8.30
E-­‐06	  
5.00
E-­‐08	  
2.02
E-­‐07	  
Erlin2	   Erlin-­‐2	   Protein	  binding	  /	  
function	  unknown	  
Q8BFZ9	   7.46
E-­‐07	  
1.60
E-­‐07	  
9.27
E-­‐08	  
1Ig	  heavy	  
chain	  V	  
region	  
AC38	  
205.12	  
Ig	  heavy	  chain	  V	  
region	  AC38	  205.12	  
Uncharacterised	   P06330	  
2.78
E-­‐05	  
7.71
E-­‐06	  
2.50
E-­‐06	  
Ig	  kappa	  
chain	  C	  
region	  
Ig	  kappa	  chain	  C	  
region	  
Uncharacterised	   P01837	  
6.72
E-­‐05	  
8.17
E-­‐05	  
8.27
E-­‐05	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Ig	  kappa	  
chain	  V-­‐II	  
region	  26-­‐
10	  
Ig	  kappa	  chain	  V-­‐II	  
region	  26-­‐10	  
Uncharacterised	   P01631	  
6.19
E-­‐04	  
7.58
E-­‐05	  
5.59
E-­‐05	  
Igsf8	   Immunoglobulin	  
superfamily	  member	  8	  
Function	  unknown	   Q8R366	   5.32
E-­‐06	  
2.17
E-­‐06	  
1.16
E-­‐06	  
Immt	   Mitochondrial	  inner	  
membrane	  protein	  
Function	  unknown	   Q8CAQ8	   8.80
E-­‐06	  
7.09
E-­‐07	  
9.05
E-­‐07	  
Kctd12	  
BTB/POZ	  domain-­‐
containing	  protein	  
KCTD12	  	  
Auxiliary	  subunit	  of	  
GABA-­‐B	  receptors	  
Q6WVG	  
1.82
E-­‐06	  
3.56
E-­‐07	  
6.69
E-­‐07	  
Kctd16	  
BTB/POZ	  domain-­‐
containing	  protein	  
KCTD16	  	  
Auxiliary	  subunit	  of	  
GABA-­‐B	  receptors	  
Q5DTY9	  
2.61
E-­‐07	   	  	  
3.71
E-­‐08	  
Lnp	   Protein	  lunapark	   Uncharacterised	   Q7TQ95	   1.07
E-­‐07	  
8.69
E-­‐08	  
4.28
E-­‐07	  
	  
Phb2	  
Prohibitin-­‐2	   Protein	  binding	   O35129	   3.58
E-­‐06	  
4.19
E-­‐06	  
1.74
E-­‐06	  
Plp2	   Plp2	   Function	  unknown	  	   Q9R1Q7	   7.88
E-­‐07	   	  	  
7.70
E-­‐07	  
Ppfia3	   Liprin-­‐alpha	  3	   Function	  unknown	   B8QI35	   4.14
E-­‐07	  
5.76
E-­‐07	  
2.63
E-­‐07	  
Prrt2	   Proline-­‐rich	  
transmembrane	  protein	  
2	  
Function	  unknown	   E9PUL5	  
7.51
E-­‐07	  
6.43
E-­‐07	  
1.03
E-­‐06	  
Psmd11	   26S	  proteasome	  non-­‐
ATPase	  regulatory	  
subunit	  11	  
Function	  unknown	   Q8BG32	   	  
2.88
E-­‐06	  
2.75
E-­‐06	  
Psmd7	   26S	  proteasome	  non-­‐
ATPase	  regulatory	  
subunit	  7	  
Proteosome	  
complex	  	  
P26516	   	  
1.11
E-­‐06	  
4.89
E-­‐07	  
Samm50	  	   Sorting	   and	   assembly	  
machinery	   component	  
50	  homolog	  	  
Possibly	  
mitochondrial	  
protein	  binding	  
Q8BGH2	  
2.58
E-­‐07	  
2.74
E-­‐07	  
2.00
E-­‐07	  
Smpd3	   Sphingomyelin	  
phosphodiesterase	  3	  
Uncharacterised	   Q9JJY3	   1.04
E-­‐07	   	  	  
1.29
E-­‐07	  
Spef2	   	   Sperm	  flagellar	  protein	  2	   Uncharacterised	   Q8C9J3	   	   1.05
E-­‐07	  
1.05
E-­‐07	  
Wfs1	   Wolframin	   Uncharacterised	   P56695	   	   1.03
E-­‐07	  
1.26
E-­‐07	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Table 3: Protein-interaction1 partners of Nav1.7 by subcellular location 
MGI 
symbol	  
Protein Name	   Subcelluar 
localisation 
(GO Component2) 
 
	  
Plasma	  membrane	  
	  
Aqp1	   Aquaporin-­‐1	   Plasma	  membrane	  
Kcnj10	   ATP-­‐sensitive	  inward	  rectifier	  potassium	  channel	  10	   Plasma	  membrane	  
Lppr3	   Lipid	  phosphate	  phosphatase-­‐related	  protein	  type	  3	   Membrane	  
Mpp2	   MAGUK	  p55	  subfamily	  member	  2	   Plasma	  membrane	  
Ntm	  	   Neurotrimin	   Plasma	  membrane	  
Osbpl6	   Oxysterol-­‐binding	  protein-­‐related	  protein	  6	   Plasma	  membrane	  
Plp2	   Plp2	   Plasma	  membrane	  
Ppp1r9a	  	   Neurabin-­‐1,	  Protein	  protein	  phosphatase	  1,	  
regulatory	  subunit	  9A	  
Plasma	  membrane	  
Scn3b	  	   Sodium	  channel	  subunit	  beta-­‐3	   Plasma	  membrane	  
Scn4b	  	   Sodium	  channel	  subunit	  beta-­‐4	   Plasma	  membrane	  
Scn9a	  	   Sodium	  channel	  protein	  type	  9	  subunit	  alpha	   Plasma	  membrane	  
Slc30a9	   Zinc	  transporter	  9	  
	  
Plasma	  membrane	  
Slc6a5	   Sodium-­‐and	  Chloride-­‐Dependent	  Glycine	  
Transporter	  2	  
Plasma	  membrane	  
Slc9a1	   Sodium/hydrogen	  exchanger	  1	   Plasma	  membrane	  
Stx7	   Syntaxin	  7	   Plasma	  membrane	  
SNARE	  complex	  
	  
Nucleus	  
	  
Ddb1	  	   DNA	  damage-­‐binding	  protein	  1	   Nucleus	  
Eif3k	   Eukaryotic	  translation	  initiation	  factor	  3	  subunit	  K	   Nucleus,	  Cytoplasm	  
Flii	  	   Protein	  flightless-­‐1	  homolog	   Nucleus	  
Mtor	   Serine/threonine-­‐protein	  kinase	  mTOR	   Nucleus;	  TORC1	  complex; 
TORC2	  complex	  
Psmc1	   26S	  protease	  regulatory	  subunit	  4	   Nucleus	  
Proteasome	  complex	  
Sart3	  	   Squamous	  cell	  carcinoma	  antigen	  recognized	  by	  T-­‐
cells	  3	  
Nucleus	  
Zranb2	   Zinc	  finger	  Ran-­‐binding	  domain-­‐containing	  protein	  2	   Nucleus	  
	  
Cytoplasm	  
	  
Agpat3	  	   1-­‐acyl-­‐sn-­‐glycerol-­‐3-­‐phosphate	  acyltransferase	  
gamma	  
Cytoplasm	  
Arhgap32	   RhoGTPase-­‐activating	  protein	  32	   Cytoplasm	  
Atp5j	   ATP	  synthase-­‐coupling	  factor	  6,	  mitochondrial	   Cytoplasm	  
Mitochondrial	  membrane	  
Atp6v1g2	   V-­‐type	  proton	  ATPase	  subunit	  G2	   Cytoplasm	  
Integral	  component	  of	  synaptic	  
vesicle	  membrane	  
Camsap3	   Calmodulin-­‐regulated	  spectrin-­‐associated	  protein	  3	   Cytoplasm	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Cope	   Coatomer	  subunit	  epsilon	   Cytoplasm	  
Vesicle	  coat	  protein	  
Llgl1	   Lethal(2)	  giant	  larvae	  protein	  homolog	  1	   Cytoplasm	  
Mat2a	   S-­‐adenosylmethionine	  synthase	  isoform	  type-­‐2	   Cytoplasm	  
Mccc1	   Methylcrotonoyl-­‐CoA	  carboxylase	  subunit	  alpha;	  
Mitochondrial	  
Cytoplasm	  
Mitochondrial	  membrane	  
Mccc2	  	   Methylcrotonoyl-­‐CoA	  carboxylase	  beta	  chain;	  
Mitochondrial	  
Cytoplasm	  
Mitochondrial	  membrane	  
Mlst8	   Target	  of	  rapamycin	  complex	  subunit	  LST8	   Cytoplasm	  
TORC1	  complex; TORC2	  
complex	  
Mthfd1l	  	   Monofunctional	  C1	  tetrahydrofolate	  synthase;	  
Mitochondrial	  
Cytoplasm	  
Mitochondrial	  membrane	  
Ndufa3	   NADH	  dehydrogenase	  [ubiquinone]	  1	  alpha	  
subcomplex	  subunit	  3	  
Cytoplasm	  
Mitochondrial	  membrane	  
Ndufv3	   	   NADH	  dehydrogenase	  [ubiquinone]	  flavoprotein	  3,	  
mitochondrial	  
Cytoplasm	  
Mitochondrial	  membrane	  
Neurl4	   Neuralized-­‐like	  protein	  4	   Cytoplasm	  
Ogt	   Isoform	  2	  of	  UDP-­‐N-­‐Acetyl	  glucosamine-­‐-­‐peptide	  
Nacetylglucosaminyltransferase	  
Cytoplasm	  
Pde4b	   Camp-­‐Specific	  3',5'-­‐Cyclic	  Phosphodiesterase	  4b	   Cytoplasm	  
Voltage-­‐gated	  calcium	  channel	  
complex;	  Z-­‐	  disc,	  cell	  pheriphery	  
Psmd12	   26S	  proteasome	  non-­‐ATPase	  regulatory	  subunit	  12	   Cytoplasm	  
Proteasome	  complex	  
Psmd7	   26S	  proteasome	  non-­‐ATPase	  regulatory	  subunit	  7	   Cytoplasm	  
Proteasome	  complex	  
RP2	   Protein	  retinitis	  pigmentosa	  2,	  XRP2	   Cytoplasm;	  cytoplasmatic	  
vesicle	  
Samm50	  	  
	  
Sorting	  and	  assembly	  machinery	  component	  50	  
homolog	  
Cytoplasm	  
Mitochondrial	  membrane	  
Strn4	   Striatin-­‐4	   Cytoplasm	  
Tab1	   TGF-­‐beta-­‐activated	  kinase	  1	  and	  MAP3K7-­‐binding	  
protein	  1	  
Cytoplasm	  
Tmed10	  	   Transmembrane	  emp24	  domain-­‐containing	  protein	  
10	  
Cytoplasm	  
Copi-­‐coated	  Vesicle	  
Tubg1	   Tubulin	  gamma-­‐1	  chain	   Cytoplasm;	  Cytoskeleton	  
	  
Other	  
	  
Ap3b2	   AP-­‐3	  complex	  subunit	  beta-­‐2	   Other	  
Apoo	  	   Apolipoprotein	  O;	  protein	  FAM121B	   Extracellular	  Space	  
Carns1	   Carnosine	  synthase	  1,	  Isoform	  2	   Other	  
Sgk223	   Tyrosine-­‐protein	  kinase	  SgK223	   Other	  
Tf	   Serotransferrin,	  F3	   Extracellular	  Space	  
1 all proteins specific for Nav1.7 TAP/TAP and/or had more than 8-fold increase  
2 UniProt and IPA analysis 
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LS-MS/MS of tandem affinity purified TAP-tagged Nav1.7TAP/TAP  
 
Tandem affinity purification is a consecutive four-step purification protocol. In 
the first steps, Nav1.7TAP/TAP tag is captured with anti-FLAG coupled Dynabeads 
and released by the addition of TEV protease, completing the single-step 
purification. The third and fourth steps of the tandem affinity purification exploit 
the specificity of the HAT domain, Nav1.7TAP/TAP is captured by Ni2+ beads and 
released by boiling in SDS and DTT. However, my tandem affinity purification 
(TAP) of Nav1.7TAP/TAP was not successful. LC-MS runs were not enriched in 
Nav1.7TAP/TAP and beta subunits, although immunoblotting with anti-HAT showed 
a strong band at 260-280kDa after tandem affinity purification (Figure 3-5,b). 
This suggests that Nav1.7TAP/TAP was present and enriched through the tandem 
purification protocol. However, it is unclear why Nav1.7 was detectable on a 
western blot but not through mass spectrometry, particularly given the high 
sensitivity of this technique. One possible explanation might be that the protein 
storage before the mass spectrometry was not sufficient to stabilize and prevent 
protein degradation.  
Verification of a Nav1.7TAP/TAP interaction partner Scn3b 
Scn3B 
Next the obtained mass spectrometry data was verified. One of the interaction 
partners found on the list is Navβ3 subunit, a small (~ 40 kDa) transmembrane 
protein that is non-covalently linked to Nav alpha subunits and regulates its 
functional activity. In contrast to Navβ4, Navβ3 forms trimers in the plasma 
membrane and is believed to act as a scaffold to cluster and facilitate 
interaction with various signaling molecules and other ion channels (Namdurai 
et al. 2014). Recent studies discovered the role of Scn3b in the intracellular 
trafficking of Nav alpha subunits. Laedermann et al. (2013) showed that β1 and 
β3, but not β2 or β4 associate with Nav1.7 in the ER/Golgi and mediate from 
there the channels’ glycosylation state and membrane expression 
(Laedermann, Syam et al. 2013). Furthermore, a recent study by Ishikawa et al. 
(2013) showed that certain mutations in SCN3B lead to dysregulated trafficking 
of Nav1.5, which is linked to Brugada syndrome. Alex Kanellopoulos performed 
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a reverse Co-IP of Nav1.7TAP/TAP and β3-subunit from DRG/olfactory bulb with 
anti-FLAG antibodies and immunoblotting with anti-SCN3B antibody to verify 
the interaction of Nav1.7 with the β3-subunit (see Methods 6.5.5) and showed 
that Nav1.7 and β3-subunit are interacting. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-7: Validation of Nav1.7 interaction partner Scn3b.  
Upper panel: Co-immunoprecipitation of Nav1.7TAP/TAP from DRG and olfactory bulb with anti-
FLAG and immunoblotting with anti-HAT. Lower panel: Co-immunoprecipitation of Nav1.7-TAP 
from DRG and olfactory bulb with anti-FLAG and immunoblotting with anti-SCN3B (performed 
by Alex Kanellopoulos). 
 
Other interaction partners 
mTOR 
The serine/thereonine kinase, mammalian target of rapamycin (mTOR), is an 
important regulator of cell growth, maintenance and synaptic plasticity. There 
are two known mTOR complexes (mTORC1 and mTORC2) that differ in 
activation stimuli, protein composition, sensitivity to rapamycin and subcellular 
localization (Ma and Blenis 2009). Functionally mTOR controls local protein 
Na
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synthesis and translation in neuronal and non-neuronal cells via intracellular 
signaling and phosphorylation (activation) of transcription initiation factors and 
ribosomal protein kinases (Li, Kim et al. 2014). Chronic pain states are 
characterized by increased excitability of primary afferents and by short and 
long-term changes in protein expression leading to peripheral and central 
sensitization. TTXs voltage-gated sodium channel Nav1.7 expression is 
upregulated during acute and chronic pain states (Matzner and Devor 1994, 
Omana-Zapata, Khabbaz et al. 1997). Wada et al. (2004) found that inhibition of 
mTOR in chromaffin cells increases the number of plasma membrane localized 
voltage-gated sodium channels via increased trafficking of Na+ channels from 
the trans-Golgi (Wada, Yanagita et al. 2004). Inhibition of mTOR through 
intracethecal injection or direct application of rapamycin in inflammatory and 
neuropathic animal pain models attenuates mechanical hypersensitivity 
(Asante, Wallace et al. 2009, Liang, Tao et al. 2013). Given the contradicting 
effects of mTOR inhibition, this might indicate a tissue specific regulation of the 
protein. However, it also shows that mTOR plays a role in mediating 
inflammatory (Norsted Gregory, Codeluppi et al. 2010) and neuropathic pain 
states (Zhang, Sun et al. 2013, Lisi, Aceto et al. 2015). In my Nav1.7TAP/TAP 
single step purification, mTOR was significantly enriched in Nav1.7TAP/TAP but 
not in the wildtype samples.  
Aquaporin-1 (AQP-1) 
Aquaporins are small (24-30 kDa) pore-forming membrane proteins ubiquitously 
expressed in most tissues and fundamental in selective transport of water and 
solute molecules across membranes. Aquaporins are members of a large major 
intrinsic protein family. Structurally aquaporins are homotetrameric complexes, 
comprised of 6 transmembrane and one pseudo-transmembrane segment. In 
mammals at least 13 isoforms are known that differ in expression pattern and 
water/solute transport selectivity. AQP1, AQP2, AQP3, AQP4, AQP5, AQP8 
and AQP9 are expressed in the peripheral or central nervous system (Agre, 
King et al. 2002, Zhang and Verkman 2010). Furthermore some isoforms, 
AQP1, AQP2 and AQP4 have been implicated in pain processing. Aquaporin-1 
(AQP1) is robustly expressed in the somata and in peripheral and central 
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branches of small diameter nociceptive DRG neurons. Aquaporin-1 (AQP1) was 
also found in small diameter sensory neurons in the trigeminal and nodose 
ganglia (Oshio, Watanabe et al. 2006, Shields, Mazario et al. 2007). This 
expression coincides with the expression pattern of peripherally located Na+ 
channels. Indeed Aquaporin-1-/-mice exhibit a decreased response in thermal 
and cold inflammatory pain tests and Aqp1 was shown to directly interact with 
Nav1.8. The decrease in inflammatory pain response in Aqp1 knockouts was 
due to impaired Nav1.8 activity in DRG neurons (Zhang and Verkman 2010).  
Tmed 10 (or TMP21or p23) 
The intracellular secretory pathway consists of a number of consecutive steps 
to ensure the correct synthesis/folding, transport and secretion of proteins. This 
transport is achieved through selective packing of newly synthesized, correctly 
folded proteins into COP-II coated vesicles in the ER that bud off and transport 
the cargo to the Golgi. Escaped ER resident proteins are transported back from 
the Golgi in COP-I-coated vesicles. In the Golgi, proteins are subject to 
extensive post-translational modification and when matured, exit the Golgi 
through the TGN (trans Golgi exit). However, from the TGN, there are two 
routes for a protein 1) the consecutive secretory pathway and 2) the regulated 
secretory pathway. The regulated secretory pathway is common in highly 
specialized cell types, like neurons, where the protein cargo is only released 
upon strong extracellular stimulation (Strating and Martens 2009). 
Transmembrane emp24 domain (TMED) or p24 protein family of trafficking 
proteins are important regulators of protein-cargo selection and bidirectional 
vesicular transport from the ER to the Golgi apparatus (Nickel, Sohn et al. 1997, 
Dominguez, Dejgaard et al. 1998). TMED family members are small (24kDa) 
type I transmembrane proteins primarily found in COP-I and COP-II coated 
vesicles in ER and Golgi that consist of four functional domains: an ER 
membrane targeting sequence, a N-terminal GOLD domain (Golgi dynamics) 
that is important in cargo selectivity and C-terminal COPI and COPII vesicle- 
binding domains. Structurally TMED proteins can form monomers, dimers, 
oligomers or hetero-oligomer complexes (Gommel, Orci et al. 1999, Strating 
and Martens 2009). 
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Tmed 10 also known as Tmp21 or p23 is predominately found in COP-I and 
COP-II coated vesicles in the ER and Golgi apparatus but also the plasma 
membrane of secretory granules in the pancreatic beta cells (Hosaka, 
Watanabe et al. 2007, Strating and Martens 2009). Additionally Tmed10 is 
associated with presenilin/γ-secretase complex in the plasma membrane and 
shown to be an important regulator of the γ-secretase. Chen et al. (2006) 
showed that Tmed10 specifically modulates γ-secretase activity and not the 
complex assembly or stability (Chen, Hasegawa et al. 2006). It is believed that 
Tmed10 luminal domain is responsible for its efficient trafficking to the cell 
surface (Blum and Lepier 2008). Recently, it was also reported that Tmed10 
interacts with PKC isoforms via their C1 domain. The C1 domain in PKC is 
highly conserved and present in all isoforms and is important in plasma 
membrane targeting of PKC (Wang and Kazanietz 2010, Wang, Xiao et al. 
2011). 
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3.4  Discussion  	  
Voltage-gated sodium channels (VGSC) are large glycoprotein complexes that 
reside in the plasma membrane and consist of a pore-forming Nav α-subunit 
and an associated β-subunit(s). Similar to other proteins, voltage-gated sodium 
channels are subject to transcriptional and translational regulations and 
intracellular trafficking that controls the electrophysiological properties and 
functional expression of Na+ channels. However very little is known about which 
proteins are involved in the trafficking of Nav channels to the plasma membrane 
and through which mechanisms the transport is achieved with regards to 
specific isoforms.  
 
Here, I focused on the voltage-gated sodium channel Nav1.7, which is important 
in initiation and propagation of action potentials in excitable cells and has 
emerged as key player in human pain pathways. Therefore investigating Nav1.7 
protein-protein interaction partners and channel trafficking can provide insights 
into the nature of pain signaling. Therefore, I analyzed a newly synthesized 
Nav1.7TAP tagged mouse. The clear advantages of using a knock-in TAP-tagged 
mice over methods like Yeast-2-Hybrid is that background noise is reduced and 
sensitivity is increased as the endogenous expression of RNA and protein is 
mimicked in vivo, which limits the possibility of artefactual interactions. Also, the 
use of a small terminally located TAP-tag allows the detection of the tagged 
protein and interaction partners without further consideration of post-translation 
modifications or protein interactions. Additionally, through the use of the TAP-
tag method instead of Yeast 2-hybrid assays, all interaction partners can be 
detected in one experiment (Puig, Caspary et al. 2001, Fernandez, Collins et al. 
2009). 
 
In the case of voltage-gated sodium channels, where family members share a 
high degree of sequence homology, the TAP method allows isoform specific 
isolation of Nav1.7. Targeted insertion of a TAP-tag into Nav1.7 enables us to 
breed homozygous mice (Nav1.7TAP/TAP). Here, Nav1.7TAP/TAP mice have a 
normal phenotype and I found no evidence that TAP-tag insertion into Nav1.7 
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alters RNA, protein expression or the electrophysiological properties of the 
channel. I examined the expression of the Nav1.7TAP/TAP   in various tissues, and 
found it to be highly expressed in DRG, olfactory bulb and to a lower extent in 
spinal cord, sciatic nerve and testis. However, I also found Nav1.7 to be 
expressed in the hypothalamus/thalamus. This is consistent with recent findings 
from Black et al. (2013) that Nav1.7 is present in supraoptic nuclei in the 
hypothalamus and is upregulated in response to osmotic stress (Black, 
Hoeijmakers et al. 2013). I also looked at the expression of TAP-tagged Nav1.7 
in the pancreas and could not detect any expression. This is in contradiction 
with findings from previous studies (Zhang, Chibalina et al. 2014), however as 
the pancreas is loaded with digestive enzyme, I cannot preclude that Nav1.7 
was not degraded prior to the analysis. 
 
Until now, only a few protein-interaction partners of Nav1.7 are known and it is 
unclear how the channel is trafficked to the plasma membrane. Through the use 
of a knock-in TAP-tag fused to Nav1.7, I was able to isolate multiprotein 
complexes from primary DRG and olfactory neurons of Nav1.7TAP/TAP mice. I 
identified a total of 164 proteins that were more than two-fold increased in 
Nav1.7TAP/TAP samples compared to wild-type, 42 of which were specific in the 
Nav1.7TAP/TAP group. I grouped the proteins according to their functional classes 
and cellular localization. Nav1.7TAP/TAP samples were enriched in plasma 
membrane located ion channels, receptors and transporters as well as 
cytoplasmic resident enzymes but also uncharacterized proteins. In particular, 
Scn3b, mTOR, Tmed10 and Aquaporin-1 that were highly enriched in 
Nav1.7TAP/TAP sparked my interest. These genes have previously been reported 
to play a crucial role in protein synthesis, intracellular trafficking and pain 
processing. 
β1-and β3-subunits are believed to associate with Nav1.7 in the ER/Golgi and 
can mediate different glycosylation states and plasma membrane expression 
(Laedermann, Syam et al. 2013). The data revealed that Nav1.7 is in complex 
with β3 and β4 but not β1 or β2 and through Co-IP, β3 (Scn3b) was verified as 
direct interaction partner of Nav1.7. This is consistent with findings from Ho et 
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al. (2012) that in small diameter DRG neurons Nav1.7 primarily interacts and co-
localizes with β3 subunits in the periphery. As for Scn4b (β4), mRNA 
expression is low in both small and large diameter DRG neurons and does not 
correlate with expression of Scn9a in DRG (Ho, Zhao et al. 2012).  However, as 
the samples contained pooled DRG and olfactory bulb extracts it is possible that 
Nav1.7 in the olfactory bulb is associated with β3 and β4.  
Strikingly, the mass spectrometry data obtained did not indicate an interaction 
between Nav1.7 and Nedd-4 as reported by Laedermann et al., (2013). I can 
only speculate that the lysis buffer (CHAPS) might have disrupted the 
interaction. Interestingly, mass spectrometry identified an E3 ubiquitin ligase, 
namely Neurl4, to be in complex with Nav1.7. 
 
In summary, I achieved the first purification of the Nav1.7 protein-protein 
interaction complexes in vivo under native conditions and obtained a list of 164 
enriched proteins, 42 of which were only found in Nav1.7-TAP knock-in 
samples. Among those interaction partners, I identify and verified a previously 
described interaction partner of Nav1.7. Additionally, I identified proteins in 
complex with Nav1.7 that are implicated in pain processing but have not been 
described as interaction partners of Nav1.7 before. For instance, I identified 
Aquaporin-1, a plasma membrane localized pore-forming protein that is found in 
the somata and in the peripheral and central branches of damage sensing 
neurons and has recently been implicated in nociception. Aqp1-/- mice exhibit 
decreased inflammatory and noxious cold responses as Nav1.8 is a direct 
interaction partner of the channel. While Nav1.8 mRNA and protein is 
significantly upregulated, Zhang and Verkman et al. (2010) did not find changes 
in Scn9A expression. They concluded that the impaired electrophysiological 
properties of Nav1.8 but not Nav1.7 are responsible for the Aqp1-/- phenotype in 
mice (Zhang and Verkman 2010). However, as seen in chapter 2, mRNA 
expression levels of Scn9a are unaltered in pain models of inflammatory and 
neuropathic pain (Koenig, Werdehausen et al. 2015) although it is reported that 
Nav1.7 levels are increased. This may indicate that Scn9a is not newly 
transcribed but mRNA is stored intracellularly and released and translated 
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locally upon external stimulation, possibly through mTOR, another protein highly 
enriched in my TAP experiment.  
Mass spectrometry also revealed uncharacterized proteins that interact with 
Nav1.7. In the future, it will be interesting to further study the functionally known 
and uncharacterized interaction partners to gain a comprehensive picture of 
their significance in the Nav1.7 interactome. Additionally it will be interesting to 
purify Nav1.7 complexes from different tissues and under normal and 
pathological conditions, which may shed light on why seemingly genetically 
similar mutations have different phenotypes i.e. PE and PEPD and may help to 
understand if during chronic pain states different signal transduction complexes 
are recruited. Furthermore, a comprehensive understanding of which proteins 
normally interact with Nav1.7 may help in the development of a new class of 
analgesic drugs. 
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4 A mouse model of inherited Primary Erythromelalgia  
4.1  Summary  
 
Inherited Primary Erythromelalgia (PE) is a rare autosomal dominant disease 
that is characterized by recurring episodes of excruciating pain, redness and 
swelling in the lower extremities that are induced by moderate exercise, warmth 
and humidity (Finley, Lindsey et al. 1992). PE is caused by SCN9A (Nav1.7) 
gain-of-function mutations that alter the channel’s electrophysiological 
properties and render the dorsal root ganglia neurons hyperexcitable. The line 
of treatment for congenital PE patients is very limited and to date the most 
effective strategy to alleviate pain is cooling of the affected areas. One of most 
common and best-studied PE mutations is L858F in Nav1.7, which was first 
identified in a Chinese (Han, Rush et al. 2006) and Canadian family (Drenth, te 
Morsche et al. 2005). To further understand and investigate possible drug 
treatments for PE and chronic pain disorders that map to the SCN9A locus, I 
analyzed a newly developed transgenic mouse carrying the human Nav1.7 
L858F mutation (together with a C-terminal TAP-tag) that recapitulates the 
human primary erythromelalgia phenotype. 
 
4.2  Introduction  
 
Inherited primary erythromelalgia is a rare autosomal dominant neuropathy 
characterized by an early onset phenotype with painful reddened feet and 
hands. Painful episodes are induced by moderate physical exercise, long 
periods of standing and exposure to warm temperatures. In the later stages of 
inherited PE, affected individuals experience reoccurring episodes of persistent 
pain, redness and elevated temperatures of lower extremities, upper legs, feet, 
and also the hands (Cohen and Samorodin 1982, Finley, Lindsey et al. 1992, 
van Genderen, Michiels et al. 1993). Genome-wide linkage analysis in a three-
generation Chinese family (Yang, Wang et al. 2004) first identified mutations in 
SCN9A to cause Primary Erythromelalgia. To date, all known PE mutations are 
gain-of-function mutations that lead to increased Nav1.7 activity (Dib-Hajj, Rush 
et al. 2005, Harty, Dib-Hajj et al. 2006, Cheng, Dib-Hajj et al. 2008). The Nav1.7 
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L858F mutation was first identified in a Chinese (Han, Rush et al. 2006) and 
Canadian family (Drenth, te Morsche et al. 2005) and is so far the most reported 
PE mutation. Here, a leucine residue at position 858 that encodes for a segment 
in the DII/S4-S5 pore region of Nav1.7, is substituted for phenylalanine. Leucine 
in this position is highly conserved in all VGSCs and related sub-mammalian 
sodium channels (Han, Rush et al. 2006, Cregg, Cox et al. 2014). For instance, 
a mutation in Nav1.4 in this region has been linked to cold-sensitive 
paramyotonia congenita (Plassart, Eymard et al. 1996). Voltage-clamp 
recordings show that functionally the Nav1.7 L858F mutation lowers the 
channel’s activation threshold. This in turns makes it easier to activate Nav1.7. 
Simultaneously, L858F slows Nav1.7 deactivation kinetics and increases the 
channel’s response to slow ramp stimuli, thereby allowing more channels to be 
open for longer at a given time (Cummins, Dib-Hajj et al. 2004). Additionally, 
various reported mutations including L858F boost Nav1.7’s recovery from 
inactivation (Han, Rush et al. 2006, Harty, Dib-Hajj et al. 2006, Cheng, Dib-Hajj 
et al. 2008). This renders DRG neurons hyperexcitable with activation 
thresholds shifting towards hyperpolarized potentials, increased frequency of 
repetitive firing and prolonged opening of the channel (Dib-Hajj, Rush et al. 
2005). A correlation of clinical severity, age of PE onset and mutation has been 
reported with the greater the hyperpolarization shift due to the mutation, the 
earlier the PE age of onset (Han, Dib-Hajj et al. 2009, Cregg, Cox et al. 2014). 
Patients carrying a PE mutation, including L858F, report that cooling of the 
affected areas alleviates pain. Han et al. (2007) found that cooler temperatures 
(16°C) shift the activation threshold of Nav1.7 L858F to more depolarized 
potentials. Most likely this effect is responsible for the cold mediated pain relief 
in PE (Han, Lampert et al. 2007). 
Here, I ran a duplex Taqman assay for TAP and GAPDH to determine the 
transgenic hNav1.7 L858F copy number of founders and offspring. I found that 
the transgene was present in all founders with the highest number of integration 
in founder A. Immunoblotting showed that hNav1.7 L858F is only present in the 
transgenic animals and it is highly expressed in olfactory bulb, dorsal root 
ganglia and in lower levels in spinal cord. Behavioural tests on hNav1.7 L858F 
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mice show that motor function and levels of behavioural responses to acute 
noxious pain tests are normal. However, hNav1.7 L858F mice show increased 
nociceptive and inflammatory behavioural responses to the formalin test and 
elevated temperatures of the affected areas. Taken together, the human 
Nav1.7-L858F mice mimic aspects of the human Primary Erythromelalgia 
phenotype. 
4.3  Results  
Generation of TAP-tagged Nav1.7 L858F mouse  
 
Transgenic mice carrying human Nav1.7 with a L858F mutation (hNav1.7-
L858F) were generated by Yury Bogdanov (Post-doctoral fellow, Molecular 
Nociception Group) using a recombineering protocol (Copeland, Jenkins et al. 
2001). The backbone for the shuttle vector was constructed using a pCreERT2 
plasmid (a kind gift from P. Chambon, Collège de France) (Metzger and 
Chambon 2001). The pCreERT2 plasmid was modified using PCR to insert 
mouse Nav1.7 5’-and 3’-homology arms that span from exon 2 to intron 2-3. The 
CreERT2 sequence was then excised while preserving a FRT-flanked 
Kanamycin selection cassette. The L858F mutation was induced in human 
Nav1.7 cDNA using PCR with primers carrying the point mutation, before being 
inserted into the shuttle vector (Figure 4-1,a) The resulting shuttle vector 
contained a cassette expressing hNav1.7-L858F cDNA and a kanamycin 
resistance gene in place of mouse Nav1.7 exon 2. The complete shuttle vector 
was fully sequenced before being incorporated into BAC clone RP23-304D3, 
which contains exons 1 to 7 of the mouse Nav1.7 gene as well as regulatory 
sequence 5’-upstream of the gene. The integrity and the absence of 
recombination within the BAC clone was confirmed by PCR, restriction analysis 
and pulse-field gel electrophoresis (Figure 4-1, b-c). The BAC vector containing 
hNav1.7-L858F was purified and sent to Cyagen Biosciences for microinjection 
into mouse oocytes. A total of 4 founders were identified using PCR screening, 
with the progeny of founder ‘A’ being used for subsequent experiments. 
	   137	  
 
 
Figure 4-1: Generation of TAP-tagged Nav1.7 L858F mouse. 
(a) Shuttle vector containing a cassette expressing hNav1.7-L858F cDNA and kanamycin 
resistance gene was inserted in mouse Nav1.7 exon 2. The integrity and the absence of 
recombination within the BAC clone was confirmed by (b) PCR (c) restriction analysis and 
pulse-field gel electrophoresis. Performed by Dr. Yury Bogdanov. 
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Transgenic copy number estimation using real-time qPCR 	  
Traditionally, Southern blotting is used to estimate DNA copy numbers in 
transgenic animals. However this method strongly depends on a variety of 
parameters and optimization of these parameters can be a time consuming and 
costly procedure. Real-time PCR based estimation of transgenic copy numbers 
provides a fast, inexpensive and high throughput tool to assess copy numbers 
in transgenic animals and plants (Ingham, Beer et al. 2001, Alexander, Erwin et 
al. 2004, Chandler, Chandler et al. 2007, Yuan, Burris et al. 2007). Here, I used 
the quantitative ΔΔCt method (Livak and Schmittgen 2001) to determine the 
transgenic copy number of human Nav1.7 L858F-TAP in mice by comparing the 
genomic TAP integration to a calibrator with a known TAP copy number. The 
ΔΔCt method requires a similar amplification efficacy of transgene (TAP) and 
internal reference gene (Gapdh), and a calibrator with known copy number 
(TAP) (Ballester, Castello et al. 2004, Yuan, Burris et al. 2007). I determined the 
efficiency of the customized TaqMan primers for TAP tag (FAM, labeled) and 
TaqMan assay Gapdh (VIC/MGB labeled, limited) by setting up a standard 
curve of genomic DNA (see Methods 6.1.3.3). The efficiencies were calculated 
from the standard curve with ETAP (2.15) and EGapdh (1.97) (Figure 4-2, Top). As 
calibrator I used a Southern blot verified heterozygous one copy TAP tagged 
Nav1.7 knock-in mouse. Copy number was calculated by comparing ΔCt values 
of TAP in PE mice to the ΔCt value of TAP calibrator (see Method 6.1.3.2), 
resulting in a specific ΔΔCT value. The final copy number was calculated as 2X 
RQ (RQ = 2 –ΔΔCT) 
 
In total four founders (A, C, D, E) and 34 transgenic mice from breeding lines 
A2, A3 and F1 were tested by multiplex qPCR for TAP and Gapdh expression. 
ΔCt values for each transgenic mouse and the calibrator were determined by 
normalization of TAP Ct (threshold cycle) to the reference gene Gapdh Ct: 
 
ΔCt (TAP) = Ct (TAP, FAM) – Ct (Gapdh, VIC/MGB) 
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ΔΔCt was calculated by subtraction of the calibrator ΔCt from the average ΔCt 
for each sample (from duplicates):  
 
ΔΔCt (TAP) = ΔCt (TAP, unknown) – ΔCt (TAP, calibrator) 
 
The fold-change in copy number for the transgenic samples was evaluated 
using relative quantification (RQ) = 2-ΔΔCt and final copy number is 2X RQ (Livak 
and Schmittgen 2001) (Figure 4-2, bottom).	   
Based on the ΔΔCt method I estimated the copy numbers of founder A to be 7 
copies (± 0.42SD), founder C 3 copies (±0.34SD), founder D 1 copy (± 0.01SD) 
and founder E 3 copies (± 0.18SD) (Figure 4-2,bottom). 34 transgenic Nav1.7 
L858F mice were tested from line A2, A3 and F1 and around 20 per cent (n=6) 
had no detectable copies of Nav1.7 L858F TAP, more than 30 per cent (n=12) 
had 1-2 copies, 20 per cent (n=7) had 3-4 copies of the transgene and around 
30 per cent of the mice had > 5 copies of the transgene (n=9) (Figure 4-3,A). 
Furthermore, I verified the expression of TAP-tagged SCN9A by PCR 
genotyping (Figure 4-3, B). 
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Founder 
Avg. 
ΔΔCt 
ΔCt (TAP) - ΔCt 
(calibrator) 
Avg. 
2- ΔΔCt  
(RQ) 
Estimated 
Copy number 
2 X (RQ) ± SD 
A  -1.84 3.584 7 ± 0.42 
C -0.56 1.479 3 ± 0.34 
D 1.71 0.306 1 ± 0.01 
E -0.61 1.52 3 ± 0.18 
 
 
Figure 4-2: Standard curve and transgenic copy number estimation  
Top | Standard curve TAP (red) and Gapdh (black) TaqMan primers. Delta Ct plotted against 
the log (concentration/ng). Bottom | Copy number estimation of Nav1.7 L858F founders using 
relative quantification ΔΔCt method. Copy number is determined by a series of calculations. 
ΔCt is calculated by subtracting the Gapdh Ct from the TAP Ct for each replicate. The average 
ΔCt from the 3 replicates was then calculated. Nav1.7 TAP-tag knock-in mouse with a single 
copy was used as calibrator for the Nav1.7 L858F TAP-tag copy number estimation. ΔCt from 
each unknown DNA sample was normalized to the calibrator to determine the ΔΔCt. Relative 
quantity (RQ) is 2-ΔΔCt, and finally copy number was obtained by 2 X RQ and ± 2 X SD (Livak 
and Schmittgen 2001). 
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Co-Immunoprecipitation of hNav1.7 L858F  
 
Next, I examined the protein expression in the newly developed hNav1.7 L858F 
TAP-tagged mouse line through the use of the integrated TAP-tag. The TAP-tag 
construct consists of a 3XFLAG tag, a TEV protease cleavage site and a HAT-
domain (Puig, Caspary et al. 2001) that was inserted C-terminally before the 
stop coding of exon 28 in human Nav1.7. Up to now it has been very 
challenging to examine the distribution of specific subtypes of voltage-gated 
sodium channels due to the high degree of homology among family members. 
Hence, this Nav1.7 L858F TAP-tagged mouse allows the isoform specific 
isolation of Nav1.7. 
 
First, I compared the DRG protein expression of a transgenic TAP-tagged 
hNav1.7 mouse to a littermate control. I found that TAP-tagged Nav1.7 is only 
expressed in the transgenic animal and can be detected with antibodies (Figure 
4-3, c).  
 
Next, I examined the channel’s expression in different tissues. It was previously 
reported that in rodents and humans, Nav1.7 is mainly expressed in small 
diameter nociceptive DRG neurons (Toledo-Aral, Moss et al. 1997) and 
olfactory neurons (Weiss, Pyrski et al. 2011) but was also found in lower 
expression levels in other peripheral tissues. Therefore I collected six tissues 
including DRG and olfactory bulb from a hNav1.7 L858F TAP-tagged mouse, 
co-immunoprecipitated the samples with anti-FLAG and immunoblotted them 
with an anti-HAT antibody (see Methods 6.5.4, 6.5.5 and 6.5.7). I found that 
Nav1.7 is highly expressed in olfactory bulb and to a lower extent in DRG and 
spinal cord but besides these three tissues, expression of Nav1.7 was absent in 
tissues such as heart, liver and cerebellum (Figure 4-3,d). Interestingly, 
immunoblotting of Nav1.7 in dorsal root ganglia showed two band sizes (at 260 
and 280 kDa) that are believed to be the result of glycosylation states 
(Laedermann, Syam et al. 2013). 
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Figure 4-3: hNav1.7L858F TAP mice show normal expression of RNA and protein  
(A) Transgenic copy number estimation for offspring of Founder A. In total 4 founders and 34 
animals were tested for the expression of hNav1.7 L858F TAP-tag. 20 per cent were negative 
for the transgene, more than a third had the transgene integrated in 1-2 copies, 20 per cent had 
3-4 copies and more than 30 per cent of all tested animals had >5 copies (B) Genotyping of 
hNav1.7 L858F TAP founders and offspring (C) Co-Immunoprecipitation of hNav1.7 TAP-tagged 
protein from DRGs of transgenic and littermate control mice (D) Co-Immunoprecipitation of 
human Nav1.7 L858F TAP-tag with anti-FLAG and immunoblotting with anti-HAT shows that 
Nav1.7L858F TAP-tagged protein is only expressed in transgenic hNav1.7 L858F TAP-tag mice 
with an estimated size of 260-280 kDa. Nav1.7 is expressed in olfactory bulb, dorsal root ganglia 
and spinal cord, besides these three tissues expression of Nav1.7 was not detected in tissues 
such as heart, liver and cerebellum. 
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Behavioural tests of hNav1.7 L858F mice  
Behavioural tests were performed by Mike Minett, Post-doctoral fellow, 
Molecular Nociception group (see Methods 6.4.3) to determine whether the pain 
phenotype seen in the transgenic mice recapitulates primary erythromelalgia. 
The Rotarod test showed that hNav1.7 L858F mice have normal motor function 
when compared to wildtype littermate mice (Figure 4-4,A). Behavioural 
responses of hNav1.7 L858F (red columns, n=8) and littermate (white columns, 
n=11) mice to the: von Frey test – hindpaw and abdomen (Figure 4-4,B), 
Randall-Selitto test applied to the tail and hindpaw (Figure 4-4,C), Hargreaves’ 
test – 0.6°C.s-1 and 2.0°C.s-1 heat ramps (Figure 4-4,D), Hotplate test – 50°C 
and 55°C (Figure 4-4,E) and Acetone test (Figure 4-4,F) all showed no 
significant difference between transgenic and littermate control mice. 
Furthermore the body weight of hNav1.7 L858F mice and core body 
temperature were also not significantly different from littermate controls (Figure 
4-4,G-H).  However, hNav1.7 L858F mice showed a significant avoidance of 
stimuli approaching the noxious heat threshold in comparison to littermate 
controls in the thermal place preference test (Figure 4.4,I). The hNav1.7 L858F 
mice also showed significantly more nociceptive behaviours following 
intraplantar injection of formalin in both the first and second phase (Figure 4-
5,A-B)(see Methods 6.4.1). Also, hNav1.7 L858F mice showed an increase in 
hind paw temperatures (Figure 4-4,H and 4-5,C).  
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Figure 4-4: hNav1.7 L858F mice show normal behavioural responses to acute noxious 
pain tests.  
Behavioural responses of hNav1.7 L858F (red columns, n=8) and littermate (white columns, 
n=11) mice to the: (A) Rotarod test, (B) von Frey test – hindpaw and abdomen, (C) Randall-
Selitto test – tail and hindpaw, (D) Hargreaves’ test – 0.6°C.s-1 and 2.0°C.s-1 heat ramps, (E) 
Hotplate test – 50°C and 55°C, (F) Acetone test, (G) body weight. (H) hNav1.7 L858F mice (red 
columns, n=6) show an increased hindpaw skin temperature but not core body temperature in 
comparison to littermate mice (white columns, n=6). (I) hNav1.7 L858F mice (red squares, n=7) 
significantly avoid pre-noxious heat temperature in the thermal place preference test in 
comparison to littermate mice (white squares, n=9). Data analysed by t-test, except (i) analysed 
by two-way analysis of variance followed by a Bonferroni post-hoc test. Results are presented 
as mean ± S.E.M.  
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Figure 4-5: hNav1.7 L858F mice show increased nociceptive behaviours in response to 
the formalin test.  
(A) hNav1.7 L858F mice (red columns, n=6) show increased nociceptive behaviours in 
comparison to littermate mice (white columns, n=6) following intraplantar injection of formalin. 
(B) hNav1.7 L858F mice (red columns, n=6) show increased nociceptive behaviours during both 
phase I & II in comparison to littermate mice (white columns, n=6).  (C) hNav1.7 L858F mice 
(red columns, n=6) show increased hindpaw skin temperature at baseline and throughout the 
formalin test in comparison to littermate mice (white columns, n=6). Data analysed by two-way 
analysis of variance followed by a Bonferroni post-hoc test. Results are presented as mean ± 
S.E.M. * P < 0.05, *** P < 0.001 
 	  
Next, I was interested if the number of integrated transgenic Nav1.7L858F 
copies impacts the pain thresholds of hNav1.7L858F mice. Nav1.7L858F is an 
autosomal dominant mutation and individuals who carry one copy of the 
mutated gene suffer from painful episodes. I hypothesized that a high number of 
transgenic hNav1.7 L858F copies might translate into an increased number of 
mutant Nav1.7 channels expressed. This in turn could potentially increase the 
pain-related behaviour in transgenic animals. Therefore the behavioural 
responses of hNav1.7 L858F mice with high (more than 5 copies) and low (1-2 
copies) transgenic copy numbers were compared to littermate controls.  
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Figure 4-6: hNav1.7 L858F mice show normal behavioural responses to acute noxious 
pain tests independently of transgenic copy number 
Behavioural responses of hNav1.7 L858F mice with high copy number (red columns, more than 
5 copies, n=5), low copy number (pink column, 1-2 copies, n=5) and littermate control (white 
columns, n=5) mice to the (A) Rotarod test, (B) von Frey test – hindpaw and abdomen, (C) 
Hargreaves’ test – 0.6°C.s-1 and 2.0°C.s-1 heat ramps, (D) Hotplate test – 50°C and 55°C, (E) 
Randall-Selitto test – tail and hindpaw, (F) Acetone test. Data were analysed by t-test and 
results are shown as mean ± S.E.M. (Experiments were performed by Michael Minett.) 
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In the Rotarod test hNav1.7 L858F mice, independently of the transgenic copy 
number, showed normal motor function when compared to wildtype littermate 
mice (Figure 4-6,A). Furthermore, the behavioural responses of hNav1.7 L858F 
with a high number of transgene copies (red columns, n=5), low number of 
copies (pink columns, n=5) and littermate (white columns, n=5) mice to the von 
Frey test – hindpaw and abdomen (Figure 4-6,B), Hargreaves’ test – 0.6°C.s-1 
(Figure 4-6,D) Randall-Selitto test applied to the tail and hindpaw (Figure 4-6,E), 
Hotplate test – 50°C and 55°C (Figure 4-6,D) and Acetone test (Figure 4-6,F) all 
showed no significant difference between transgenic, and littermate control 
mice independently of the transgenic copy number. However, in the 
Hargreaves’ test at 2.0°C.s-1, heat ramps (Figure 4-6,C) hNav1.7L858F mice 
with a low but not a high number of copies showed an increase in behavioural 
response when compared to the littermate control. 
 
Humans with PE suffer from on-going and/or episodic pain that is triggered by 
heat and moderate exercise, while Quantitative Sensory Testing shows that 
sensory detection and pain thresholds are within two standard deviations of 
unaffected individuals (Segerdahl, Xie et al. 2012). The data suggest that TAP 
tagged hNav1.7 L858F mice have a phenotype that resembles aspects of the 
human PE phenotype. Akin to human PE patients with L858F, as well as other 
gain-of-function mutations, report that pain is exacerbated by warmth, exercise 
and local exposure to heat (Yang, Wang et al. 2004, Segerdahl, Xie et al. 2012) 
and skin temperature of the affected area during painful episodes is measurably 
increased (Samuels, te Morsche et al. 2008). 
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4.4  Discussion  
 
Inherited Primary Erythromelalgia (PE or IEM) is a rare autosomal dominant 
disease caused by mutations in SCN9A. To date, all known SCN9A-related PE 
mutations are gain-of-function mutations that shift the Nav1.7 threshold of 
activation and increase neuronal excitability. The best-studied and most 
commonly reported mutation in hNav1.7 is L858F (Cummins, Dib-Hajj et al. 
2004, Drenth, te Morsche et al. 2005, Han, Rush et al. 2006). Here, a 
conserved leucine residue at position 858 within exon 15 of SCN9A (segment in 
the DII/S4-S5 pore region) is substituted for phenylalanine (Han, Rush et al. 
2006, Cregg, Cox et al. 2014). Functionally the L858F mutation in Nav1.7 lowers 
the channel’s activation threshold, slows its deactivation kinetics while 
simultaneously boosts recovery from inactivation and increases the channel’s 
response to slow ramp stimuli, thereby allowing more channels to be activated 
easier and to be open for longer (Cummins, Dib-Hajj et al. 2004, Han, Rush et 
al. 2006, Harty, Dib-Hajj et al. 2006, Cheng, Dib-Hajj et al. 2008). This in turn 
leads to hyperexcitability of DRG neurons. A correlation of clinical severity, age 
of PE onset and mutation has been reported and the greater the 
hyperpolarization shift induced by the mutation, the earlier the PE age of onset 
and severity (Han, Dib-Hajj et al. 2009, Cregg, Cox et al. 2014). 
 
Clinical symptoms and treatment of inherited primary erythromelalgia  
Clinically, inherited primary erythromelalgia (PE) is characterized by recurring 
episodes of painful reddened feet, lower legs and in some cases the upper 
extremities. Painful episodes are accompanied by elevated skin temperature 
and swelling of the affected areas. Other symptoms may include dry mouth, 
eyes and gastro-intestinal problems (Drenth and Waxman 2007). Generally, 
episodes are provoked by moderate exercise, warmth, eating hot, spicy food, 
wearing tight shoes or drinking alcohol (Samuels, te Morsche et al. 2008). 
Typically the first symptoms appear in early childhood or adolescence (Mandell, 
Folkman et al. 1977, Michiels, te Morsche et al. 2005) but there are rare cases 
of late onset PE (Gaur and Koroscil 2009). Over the course of PE, the 
symptoms, length and intensity of episodes steadily increase (Finley, Lindsey et 
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al. 1992, van Genderen, Michiels et al. 1993). hNav1.7 L858F is a temperature 
sensitive mutation and reportedly patients cool the affected areas (i.e. ice 
buckets or fan) to alleviate pain. Han et al. (2007) showed that cooler 
temperatures (below 16°C) shift the activation threshold of Nav1.7 L858F to 
more depolarized potentials (Han, Lampert et al. 2007). Although cooling is a 
very effective analgesic, possible secondary complications include skin 
infections and in severe cases gangrene (Gaur and Koroscil 2009). Besides the 
severe pain, PE patients exhibit no neurological deficiency and quantitative 
sensory testing (QST) is within 2SD of unaffected individuals. However 
Segerdahl et al. (2012) found that affected individuals exhibit decreased 
sensitivity to deep pressure and vibration in the feet. It was concluded that 
these altered thresholds were caused by thickened skin, a phenomena which is 
commonly observed in PE patients (Segerdahl, Xie et al. 2012). 
 
In common with human PE individuals, the newly generated hNav1.7 L858F 
TAP tagged mice exhibit normal weight and no obvious neurological deficiency. 
Furthermore, there was no altered response to acute pain tests or any evidence 
of motor coordination deficiencies. However, hNav1.7 L858F TAP mice show 
avoidance of pre-noxious temperatures, which is consistent with previous 
reports of human PE patients, as warm temperatures are a known trigger of 
painful episodes. Strikingly, withdrawal latency in hotplate testing (50-55oC) for 
noxious heat was unchanged between littermate controls and hNav1.7 L858F 
mice. One possible explanation is that at noxious temperatures of around 50-55 
degrees, a distinct molecular mechanism is in place that is independent of 
Nav1.7. This is contradictory to prior findings in Nav1.7Nav1.8 mice (Nassar, 
Stirling et al. 2004, Minett, Nassar et al. 2012). However, I cannot be sure that 
this randomly inserted human gene will be regulated and processed in the same 
way as the endogenous gene (e.g. the SCN9A NAT is not included in the 
transgenic design). Although I showed that the transgene exhibits a normal 
transmission pattern, and SCN9A mRNA and Nav1.7L858F protein are normally 
expressed, the question remains whether the human protein was sufficiently 
trafficked and correctly inserted into the membrane. Strikingly, I also did not find 
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a correlation between copy number and severity of pain related behaviour 
(Figure 4-6). PE is an autosomal dominant disease, therefore one copy of the 
gene should be sufficient to see a pain related phenotype.  
 
However, hNav1.7 L858F mice show significantly increased pain related 
behavior and increased hindpaw temperatures compared to littermate controls 
in the first and second phase of formalin, which supports the idea that the 
human Nav1.7 L858F transgene produces a functional membrane localized 
protein. Therefore an initial trigger might be required to see the full spectrum of 
behaviour responses in Nav1.7 L858F mice. 
 
In summary, I analyzed a transgenic hNav1.7 L858F TAP-tag mouse that 
resembles aspects of the human inherited Primary Erythromelalgia phenotype. 
This mouse model (hNav1.7 L858F-TAP) will allow us to further study the 
effects of drug treatments. Current medical treatment of inherited primary 
erythromelalgia is challenging and no single effective drug treatment is 
available. Generally individuals suffering from painful episodes often receive 
individualized treatment and medication depending on their medical history 
(Davis, Sandroni et al. 2003). Drugs that are most commonly used and proven 
effective in some PE patients are: Aspirin, SNRIs (serotonin-norepinephrine 
reuptake inhibitors) and SSRI (selective serotonin reuptake inhibitors) and other 
anti-depressants, sodium channel blockers, carbamazepine and others 
(Hisama, Dib-Hajj et al. 1993). This mouse model of human primary 
erythromelalgia will allow us to further our understanding of the molecular 
mechanisms underlying pain processing. The TAP tag inserted in the final exon 
of the transgene will allow the tissue specific purification of Nav1.7 L858F and 
protein interaction partners and might shed light on why PE and PEPD, two 
inherited pain disorders linked to gain of function SCN9A mutations, affect 
different areas and why clinical symptoms vary significantly between PE and 
PEPD. 	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5  Conclusions and Future work 	  
The work in this thesis has aimed to provide a more detailed understanding of 
the functional regulation and expression of SCN9A/Nav1.7. Firstly, in Chapter 2, 
I showed that SCN9A/Nav1.7 expression is specifically controlled by a naturally 
occurring, long non-coding RNA (or NAT), which might be physiologically 
relevant in human pain disorders that map to the SCN9A locus. I demonstrated 
that in vitro the NAT regulates SCN9A/Nav1.7 expression and 
electrophysiological properties in an isoform specific manner. Therefore, in vivo 
study of the NAT i.e. through injection of a viral construct containing the mouse 
natural antisense transcript, will be necessary to determine if overexpression of 
the transcript potentially reduces pain related behaviour. Studies in humans and 
mice have shown that Nav1.7 is crucial for initiation and propagation of action 
potentials. The channel functions as a threshold and amplifier of initial 
membrane depolarisations and is required for the activation of Nav1.8 which is 
non-redundant in the uprising phase of the action potential. A 30 percent 
decrease in Nav1.7 expression, as shown in chapter 2, could prove sufficient to 
prevent the activation of Nav1.8 and in this way inhibit the action potential from 
firing off. Additionally, through the use of CRISPR/Cas9 technolgy a NAT 
knockout mouse line will be generated where exon 1 in NAT is deleted. This 
deletion will disrupt the NAT transcription and enables us to study the impact on 
NAT ablation on Scn9a RNA and protein distribution in vivo. Based on my 
findings highlighted in Chapter 2, I speculate that ablation of NAT in vivo will 
result in a painful phenotype in the NAT knockout mice.  
Another aspect that merits further investigation is NAT splice variants and their 
individual role in Scn9A expression. Scn9a is alternatively spliced in two 
mutually exclusive sites in exon 11 and exon 5 (Raymond, Castle et al 2009). 
For instance, the alternative splice variants 5N and 5A from exon 5, are 
significantly different in their electrophysiological properties and expression 
patterns i.e. 5N is a neonatal splice variant. The exact purpose of a neonatal 5N 
splicing variant is not yet fully understood. Although splicing patterns of NAT 
and Scn9a do not appear to be coupled as reported for other NATs i.e. Kcna2 
antisense RNA and Kcn2a (Zhao, Tang et al 2013). There is the possibility that 
	   152	  
the alternative splicing of NAT potentially shifts the splicing events in SCN9A. 
The proposed mechanism is that the expression of a particular antisense 
transcript variant could either stabilize the neonatal or adult sense transcript in a 
tissue specific manner, or binding may mask the splicing site of the sense 
mRNA and therefore represses the neonatal splicing variant in favor of the adult 
one.   
Strikingly, my in vivo studies showed no change in total expression of NAT or 
Scn9a in neuropathic and inflammatory models. This is interesting given the fact 
that the protein levels of Nav1.7 are reportedly increased in carrageenan 
induced inflammatory pain (Black, Liu et al. 2004). Zhao, Tang et al (2013) 
found that Kcna2 antisense transcript is expressed in medium sized DRG 
neurons. However, nerve injury not only upregulated the expression of the 
Kcna2 NAT in vivo but also shifted the NAT distribution in DRG subpopulations 
from mostly medium, to medium and large sized damage sensing neurons. 
Hence this shift in subpopulation distribution could potentially be the case for 
Scn9a NAT and would explain the unchanged mRNA levels in the pain induced 
mouse models. Therefore, using RNA-seq could be most helpful to study the 
distribution patterns of the NATs and Scn9a with the aim of understanding the 
dynamic expression of NAT and Scn9a within subpopulations of damage-
sensing neurons in pathological pain states.  
Finally, how is the expression of the NAT induced in vivo? In this thesis I 
examined the regulatory effects of NAT expression on SCN9A/Nav1.7. 
However, in the future it will be important to understand what induces the 
transcription of the NAT itself. To answer this question, further structural 
investigation is required to identify transcription start sites and promoter regions 
in the transcripts. In-silico analysis of NAT sequences through online search 
tools such as TFsearch could give clues on possible transcriptional activators 
that bind to these regions. 
 
In Chapter 3, I describe a newly developed TAP-tagged Nav1.7 knock-in line 
that enabled me to purify Nav1.7 and its protein-interaction partners under 
physiological conditions. This study provides the first comprehensive large-
	   153	  
scale analysis of Nav1.7 protein complexes. This is particularly exciting as until 
now very little was known about the Nav1.7 protein interactome and the role 
these interaction partners play in the trafficking and regulation of the channel. 
As shown in chapter 3, some protein interaction partners found through my TAP 
experiment have previously been shown to be implicated in nociception and 
pain processing i.e. mTor and Aquaporin-1, but have not been associated with 
Nav1.7. However, as tandem affinity purification isolates all direct and indirect 
interaction partners of the TAP-tagged protein, the isolated proteins need to be 
verified as direct interaction partners of Nav1.7. There are various ways to test 
for the direct interaction of proteins. One possible approach, as shown in 
chapter 3, is Co-IP of Nav1.7 and immunostaining against the protein of interest. 
This allowed for the confirmation of the direct interaction between Nav1.7 and 
Scn3b and also validated our TAP-tagged approach as Scn3b has previously 
been shown to directly interact with the channel to influence trafficking and 
glycosylation of Nav1.7 (Laedermann, Syam et al. 2013). Other approaches to 
verify and study direct interaction between two proteins are Yeast 2-hybrid and 
fluorescence resonance energy transfer (FRET). Notably, my mass 
spectrometry data also revealed various mitochondrial proteins in complex with 
Nav1.7. There are no reports of Nav1.7 being expressed in the mitochondrial 
membrane or Nav1.7 interactions with mitochondrial proteins. I speculate that 
these proteins are possibly indirect interaction partners of the channel. 
However, as some mitochondrial proteins are encoded by nuclear genes and 
also translated and folded in the ER/Golgi, they could potentially directly 
assemble with Nav1.7 in the ER/Golgi and in this way influence the channels’ 
trafficking and function. Further investigation into the direct interaction of Nav1.7 
with these proteins will shed light on a possible mechanism. 
Taken together, studying these interaction partners will help to gain insights into 
how Nav1.7 is trafficked to the plasma membrane under normal and 
pathological conditions and may lead to the discovery of a potential new 
analgesic drug target. 
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Finally, Chapter 4 of this thesis described the characterization of a newly 
developed transgenic mouse model of human primary erythromelalgia (PE), a 
rare pain disorder. In this chapter I investigated the transgenic integration of 
hNav1.7L858F and corresponding behavioral response to acute, neurogenic 
and inflammatory pain and found that the PE mouse model resembles in some 
aspects the human PE phenotype. Akin to human PE patients, in transgenic PE 
mice an initial trigger is required to induce painful episodes. For instance, 
injection of formalin increases the pain-mediated behavioral response in 
transgenic PE mice. However, it is still unclear why the transgenic mice did not 
respond to the hotplate test. In human PE sufferers, warm temperatures are the 
most common trigger for a painful episode. Another finding was that the number 
of transgenic hNav1.7L858F copies had not impact the response to acute pain. 
The question remains if the transgene is processed and integrated in a similar 
manner to the endogenous Nav1.7. Further investigation into the expression 
and function of hNav1.7L858F via immunohistochemistry and 
electrophysiological recordings will be necessary to answer these questions.  
In the past, transgenic animal studies have provided pivotal insights into the 
molecular and cellular mechanisms underlying nociception. This in turn has 
opened up exciting prospects in the design of new analgesic drugs. Therefore, 
a transgenic PE model offers the advantage of an in-depth analysis of the 
molecular mechanisms underlying nociception and pain sensation in PE, as well 
as the opportunity to test newly developed analgesic drugs in vivo.  
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6  Material and Methods  
6.1 Molecular biology  
6.1.1 Reagents, cloning and kits  
Gels, LB and plates 
• Agarose gel 1%, 1.8 g agarose (Sigma) in 180ml 1x TAE Buffer 
• LB 10 g LB broth (Sigma) in 500ml ddH2O and autoclaved for 20 min at 
121 degrees 
• LB Agar 10 g LB (Sigma)  and 7.5 g Agar (Sigma) broth in 500 ml ddH2O 
autoclaved for 20 min at 121 degrees; Antibiotics (Ampicillin, 100μg/ml 
or Kanamycin, 25μg/ml) added to LB or LB+Agar   
DNA and protein ladders  
• Spectra™ Multicolor High Range Protein Ladder (Fermentas, SM1859) 
• Thermo Scientific PageRuler Plus Prestained Protein Ladder (Invitrogen, 
26619) 
• 1 kb Plus DNA Ladder (Invitrogen, 10787-018) 
• 100 bp DNA Ladder (Invitrogen, 15628-050) 
Competent cells  
• OneShot© Top10 chemically competent cells (Invitrogen C4040-10) 
• XL10-Gold ultracompetent Cells (Stratagene C-200314) 
Purification kits  
• Miniprep (Spin Miniprep kit, Qiagen) 
• Maxiprep (High speed Maxiprep kit, Qiagen)   
• Gel purification (Gel purification kit, Qiagen) 
• PCR Purification  (Qiagen) 
• DreamTaq Green DNA polymerase kit (Invitrogen) 
Restriction digests 
• Single Digest: 15 μL of H2O, 2 μL of appropriate restriction 
 enzymebuffer, 2 μL of DNA (200ng), 1 μL of restriction enzyme. Leave 
 3 hours at 37 or 65 °C 
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• Double Digest for 2 restriction enzymes: 1 μL of each enzyme with 2 
 μL of buffer, 2 μL of DNA (200 ng) and 14 μL of H2O. Enzymes used 
 EcoRI, BamHI, BstBI, BsaAI, KpnI, HindIII (New England Biolabs) 
Cloning the human and mouse NATs 	  
Human dorsal root ganglia total RNA was purchased from Clontech; Mouse 
total RNA was isolated from DRGs dissected from wild-type black6 mice using 
the RNeasy MinElute Kit (Qiagen). Total RNA was reverse transcribed into 
cDNA using Superscript III (Life Technologies) and oligo d(T), according to the 
manufacturer's instructions. The human SCN9A NAT was PCR-amplified from 
DRG cDNA using KAPA HiFi DNA polymerase (Kapa Biosystems) or LA Taq 
(TaKaRa) in three overlapping fragments using the following primers: Fragment 
1, 5' GAA TGA AAT TTA GTG TTT CCC ATC C, 5' AGC AAT GTT TCA CCT 
CCA GAG ATC; Fragment 2, 5' GGA ATT CAG GCA AAG TTG GA, 5' CAC 
CAA CAT TCA GCC ATT TG; Fragment 3, 5' CTG ATT ATT GGG AGA CTT 
TTG GAG, 5' GCT CCT ATT TCT GAG TTT ATA CTG TG. The mouse Scn9a 
NAT was PCR-amplified using the primers 5' AGC AAG AGT AAG AAG TAT 
TGG c, 5' CAT TAT ATT TCA TTT TAA TG. PCR products were cloned using 
the Zero Blunt TOPO PCR Cloning Kit  (Life Technologies). Individual colonies 
were Sanger sequenced and submitted to GenBank under the accession 
numbers KM096550 (clone LA5), KM096551 (clone LA8), KM096552 (clone 
3.2) and KM096553 (clone 3.1). 
6.1.2 DNA and RNA isolation  
Genomic DNA isolation and genotyping  
 
Ear tissue was collected and genomic DNA extracted according to the 
manufacturer’s protocol using the Pure Link Genomic DNA Purification Kit 
(Invitrogen). Primers for genotyping were designed using the Primer3 Plus 
software. The PCR reaction consisted of 95 °C for 5 min followed by 35 cycles 
of 1 min at 95 °C, 30 sec at 57 °C and 2 min at 72 °C (Thermocycler PeqStar). 
The products were separated on a 1.5% agarose gel to verify that the  
reaction products yielded the expected fragment size.  
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Table 6-1 Genotyping primers 	  
	  	  
RNA isolation in primary cells 
Mice were deeply anaesthetized with CO2 and terminated through neck 
breaking, DRGs were taken out and brought into RNAlater (Ambion) for storage 
up to one week at 4oC. DRGs were transferred into Precellys ceramic kit 4.1 
(Peqlab) with TriZol (Ambion). Homogenized samples were transferred into 
QIAshredder mini column (Qiagen). Supernatant from QIAshredder was 
separated in PLG tubes (VWR) by addition of chloroform isopropanol alcohol 
24:1 (Sigma) via centrifugation for 15 min,16000g  at 4oC. The upper colourless 
aqueous layer was removed and mixed with 70% EtOH and spun down in an 
RNeasy MinElute spin column (Qiagen). The spin column was washed with 
RPE Buffer (Qiagen). DNaseI/Buffer RDD (Qiagen) was added onto the 
membrane and left for 15min at RT. The spin column was washed with RPE 
Buffer and 80% EtOH. RNA  was eluted in RNAse free water (Ambion). 
RNA isolation HEK293 and SH-SY5Y 
HEK293 cells were pelleted and washed in 1XPBS (Gibco) and resuspended in 
TriZol (Ambion). Chloroform (VMR) was added and the sample was centrifuged 
at 11,000 g, 15 minutes at 4oC. Top phase supernatant containing RNA was 
mixed with isopropyl alcohol (Sigma), shortly incubated and centrifuged at 
11,000 g for 10 min at 4oC. The pellet was washed in 75% EtOH and 
centrifuged at 7,500 g, 5 min at 4oC. After a short incubation, the pellet was 
resuspended in ultra-pure water. 
Primer Name  Sequence (5’-3’) Description  
Nav1.7L858F TTCATCCACCACCTCTCCAC RefSeq, 
NM_002977.3 
TAP-L858F ATCTTGTTGTGGGCATGAGCGT L858F-TAP-tag  
5aR4  CCGAGGCCAGGGAACAAATTCC Nav1.7  5’ UTR 
3aR4 AACACGAGTGAGTCACCTTCGC Nav1.7 3’UTR 
TAP-R1 ATCTTGTTGTGGGCATGAGCGT TAP-tag 
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Reverse transcription  
• SuperScript III RT First Strand (Invitrogen) performed according to 
manufacturer’s protocol. 
6.1.3 qPCR  
6.1.3.1 qPCR for mouse tissue panel and cell lines 
One ug of total RNA derived from a range of tissues (Clontech) or prepared in-
house (DRG) were reverse-transcribed into cDNA using Superscript III (Life 
Technologies) and oligo d(T). SYBR Green assay (Bio-Rad) was performed 
according to the manufacturer’s protocol using primers to Scn9a, the NAT and 
β-actin.  
Relative expression of the target gene was calculated using the comparative 
∆∆CT method (Livak and Schmittgen et al. 2001,Pfaffel et al, 2001). Expression 
of the test gene was compared with that of β-actin measured on the same 
sample, giving a CT difference (∆CT) for β-actin minus the test gene. The 
relative expression of Scn9A and NAT in specific tissues was calculated in 
relation to the expression levels in DRG using the comparative ∆∆CT method 
(Livak and Schmittgen et al. 2001). ∆CT values of individual tissues were 
compared to ∆CT of DRG, giving ∆∆CT values of a specific tissue and relative 
expression was calculated as 2-∆∆CT. Mean, S.E.M. and statistics were 
calculated from the ∆∆CT method. Data were analyzed using Microsoft Excel, 
and statistics were performed using GraphPad Prism 5.01 software (GraphPad 
Software, San Diego, CA). 
 
qPCR analysis of animal models 
Total RNA was isolated from dissected L2-L6 ipsilateral DRGs from 
Carrageenan, CFA and CCI treated mice and L5-L6 DRG from SNT treated 
mice using the RNeasy MinElute Kit (Qiagen). Real-time qPCR was performed 
using SYBR Green (Applied Biosystems) and the following primers: Scn9a 
(efficiency 1.91), NAT (efficiency 1.96) and Gapdh (efficiency 1.76). Relative 
expression levels of mRNA were calculated using the comparative ΔΔCt (Ct) 
method and statistical significance was determined using an unpaired t-test. 
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6.1.3.2 Taqman Assays 
SCN1A, SCN2A and SCN3A expression in NAT-SH-SY5Y stable cell line 
NAT-SH-SY5Y stable and untreated SH-SY5Y cell line samples were tested for 
the expression of SCN1A, SCN2A and SCN3A using TaqMan assays for hm 
SCN1A (Hs00374696_m1), hm SCN2A (Hs01109877_m1) and hm SCN3A 
(Hs00366902_m1) and hm GAPDH (Hs02758991_g1). TaqMan assays were 
performed according to manufacturer’s protocol in an Eppendorf Realplex under 
the following thermal cycling conditions: 50°C for 2 minutes, 95°C for 10 
minutes, and 40 cycles of 95°C for 15 seconds and 60°C for 1 minute. All 
reactions were performed on biological and technical triplicates. Relative 
expression was calculated using the comparative ∆∆CT Method (Livak and 
Schmittgen et al. 2001,Pfaffel et al. 2001). ∆CT was obtained by subtraction of 
GAPDH Ct values from Ct values of the target gene. Next, ∆CT values of the 
target gene were compared between groups, giving ∆∆CT. Relative expression 
was calculated using 2-∆∆CT indicating the fold change in expression of the target 
gene in the NAT-stable cell line compared to untreated SH-SY5Y. Mean, SEM 
and statistics were calculated from the ∆∆CT method. Data were analyzed 
using Microsoft Excel, and statistics were performed using GraphPad Prism 
5.01 software (GraphPad Software, San Diego, CA). 
TaqMan Mulitplex Assays  
 
Nav1.7 L858F TAP-tag copy number was determined using TaqMan copy 
number assays (Life Technologies) according to the manufacturer's instructions. 
Isolated genomic DNA (40 ng) was mixed with 2×TaqMan Expression Master 
Mix and 20XTaqMan probes in a 96 well plate (Bio-Rad). Custom Taqman 
Assays-by-Design tool (Invitrogen) was used to a generate a primer and probe 
set for the TAP tag (inserted in Nav1.7 L858F gene, Assay Id: AJPADNX) and 
TaqMan Mouse GAPDH (GAPDH, NM_008084.2) as endogenous control 
(VIC/MGB) in a 20µl reaction volume. The TaqMan multiplex assay was 
performed using the Eppendorf Realplex and the following thermal cycling 
conditions: 50°C for 2 minutes, 95°C for 10 minutes, and 40 cycles of 95°C for 
15 seconds and 60°C for 1 minute. All reactions were performed in duplicate or 
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triplicate. Copy numbers were estimated by relative quantification. TAP Ct 
values for PE mice were normalized to endogenous GAPDH Ct values and 
compared to a calibrator TAP sample known to have 1 copy of the target 
sequence using the comparative Ct (ΔΔCt) method. Data were analyzed and 
statistics performed using Microsoft Excel. 
Table 6-1.2: Overview SYBR Green and TaqMan PCR primers 
 
Primer 
name 
Sequence (5’-3’) / Assay ID Description 
Scn9a F GAGGGGCAAACTGACTACA Mouse tissue panel, 
animal models 
Scn9a R AGAAACATTCCTACAATGGAG Mouse tissue panel,  
animal models 
NAT F TGCTGTCAACTCCTGAACCA Mouse tissue panel, 
animal models 
NAT R TCCAACTTTGCCACAATGAG Mouse tissue panel 
animal models 
β-actin F TTCTTTGCAGCTCCTTCGTT Mouse tissue panel, 
animal models 
β-actin R ATGGAGGGGAATACAGCCC Mouse tissue panel, 
animal models 
Gapdh F TGC GAC TTC AAC AGC AAC TC  
 
Mouse tissue panel, 
animal models 
Gapdh R CTT GCT CAG TGT CCT TGC TG Mouse tissue panel, 
animal models 
SCN9A F AGA GGG GTA CAC CTG TGT GAA SH-5YSY 
SCN9A R CCC AGG AAA ATC ACT ACG ACA 
AA 
SH-5YSY 
hNAT F GGA GTC ACT GGG ATT AAA GGC 
AT 
SH-5YSY 
hNAT R TTC TTT GTC GCT GGT GGC TAG 
AG 
SH-5YSY 
b-ACT F CGC CGC CAG CTC ACC ATG SH-5YSY 
b-ACT R CAC GAT GGA GGG GAA GAC GG SH-5YSY 
TAP AJPADNX L858F-TAP 
GAPDH GAPD NM_008084.2 
SCN1A Hs00374696_m1 NM_001165963.1 
NM_001165964.1 
NM_001202435.1 
NM_006920.4 
SCN2A Hs01109877_m1 NM_001040142.1 
NM_001040143.1 
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NM_021007.2 
SCN3A Hs00366902_m1 NM_001081676.1 
NM_001081677.1 
NM_006922.3 
GAPDH Hs02758991_g1 NM_001256799.1 
NM_002046.4 
 
6.1.3.3.Standard curve -Transgenic Nav1.7 L858F mice copy number 
estimation  
A dilution series of purified gDNA (neat, 1/10,1/100,1/1000,1/10000) was 
prepared and 4 μl of each sample was set up in a 96-well plate (Bio-Rad) for a 
Taqman assay according to the manufacturer’s protocol. Obtained threshold 
cycles (Ct) were plotted against Log10 concentration (ng/ul) for each sample. 
Efficiency was calculated as followed: E = 10 [–1/slope] (Pfaffle et al. 2001). 
Efficiencies for TAP and GAPDH are 1.97 and 2.15 respectively. Data were 
analyzed and statistics performed using Microsoft Excel. 
6.1.4 Expression vectors 
Human and mouse antisense expression vector  
Human full length, BC051759, was amplified from a cDNA clone: IMAGE human 
cDNA clone, BC051759 Clone ID 5582690. Mouse full length transcript 
AK138532 was amplified from Fantom FLS clone A330052F22. DNA was 
isolated using Miniprep protocol (Qiagen) and used as template in Phusion PCR 
(NEB) using the primers: hm AS HINDIII FWD 
5’CCCAAGCTTGTCTTAGTCCTCTGAATATTTT-3’, hm AS KpnI REV5’-CGG 
GGTACC CCA ATTGATGGAGAATTTTAT-3’ and ms HindIII FWD 5’-
CCCAAGCTT GAGCAAGAGT AAGAAGTA-3’, ms AS KpnI REV 5’- CGG 
GGTACC GCCATTATATTTCAT-3’. Amplified DNA was further gel purified 
(Qiagen). pcDNA3 (Invitrogen) mammalian expression vector and purified full 
length human/mouse SCN9A and Scn9a NAT were double digested overnight 
at 37oC with KpnI and HindIII (NEB), linearized pcDNA3 vector was also treated 
with SAP (NEB) before ligation. Ligation of full length Scn9a/SCN9A NAT to 
pcDNA3 vector was carried out with T4 DNA Ligase (Fermentas). Ligation 
reactions were transformed into XL10 Gold ultracompetent cells (Agilent). 
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Single positive colonies were picked and inoculated in LB+Ampicillin and grown 
overnight at 220 rpm at 37oC. The bacterial cells were then pelleted by 
centrifugation at 5000 rpm for 10 min. DNA was isolated using Miniprep and 
Maxiprep kits (Qiagen). The expression vectors were then sequenced (Source 
Bioscience) and sequences were compared against reference sequence 
databases using the Genome UCSC (http://genome.ucsc.edu/) and NCBI 
BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi) web tools. Nucleotide blast (Data 
base: Reference genomic sequences (refseq_genome), organism: mus 
musculus taxid: 10090 or Homo sapiens taxid: 9606) identified the sequenced 
inserts as full length human BC051759 and mouse AK138532 full length 
SCN9A NAT. Herein these are referred to as human and mouse NAT in 
pcDNA3. 
6.2 Cell culture  
6.2.1 Cell culture maintenance  
Table 6.2: Cell culture medium 
Cell line  Medium  
HEK293 DMEM (GIBCO), 10% FBS, 1%Pen/Strep  
HEK293 hm Nav1.7 
TAP tag  
stable cell line 
DMEM (GIBCO), 10% FBS, 1% Pen/Strep, 0.5% G418 
(Sigma) 
Nav1.7/Nav1.6 
stable cell line 
MEM (Sigma), 2mM L- Glutamine (Sigma ), 10% FBS 
(Invitrogen), 2μg/ml Blastocydin (calbiochem), 
0.6mg/ml Geneticin (Invitrogen), 10ml/L Penicillin –
streptomycin (Sigma) 
SH-SY5Y Ham’s F12: EMEM (1:1) 2 mM glutamine (Life 
technologies) 1% non essential amino acids and 10% 
FBS (Life technologies) 
SH-SY5Y-NAT  
stable cell line 
Ham’s F12: EMEM (1:1) 2 mM glutamine (Life 
technologies) 1% non essential amino acids (Life 
technologies) and 10% FBS (Life technologies) 
selection antibiotic G418 (500 μg/ml)(Sigma) 
Cell splitting 
Cell culture medium  was removed and trypsin added (GIBCO, Life 
Technologies)  for 2-3 minutes. Trypsin was aspirated and cells resuspended in 
10 ml of culture media. The cell suspension was transferred into 15ml tubes and 
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centrifuged 5 min at 800rpm. The supernatant was aspirated and the cell pellets 
were resuspended in 10 ml stable cell media. Cells were split into 2ml dishes or 
a flask. Best transfection results were obtained with cells at around 90 per cent 
confluence on the day of transfection. 
6.2.2 Transfection of cell lines 
HEK293 Nav1.7 and Nav1.6 stable cell line 
HEK293 cells stably expressing human Nav1.7 plus SCN1B (L11) or Nav1.6 
plus SCN1B (L40) (Scottish Biomedical) were grown according to the 
manufacturer’s instructions and passaged four times before transfections 
begun. Cells were split into 3.5 cm2 dishes and grown to 95% confluency. On 
the day of transfection, cells were transfected with 250 ng of pEGFP-N1 
(Clontech) plus 1000 ng of human NAT in pcDNA3 or empty pcDNA3 using a 
ratio of 1 µg DNA:2.5 µl Lipofectamine 2000 (Life Technologies). After 6 hours, 
the transfected cells were re-seeded at a low density and left for 48 hours prior 
to patch clamp analysis or RNA extraction. 
HEK293 cell line transfection  
HEK293 were grown according to the manufacturer’s instructions and passaged 
four times before transfections begun. Cells were split into 5 cm2 dishes and 
grown to 95% confluency. On the day of transfection, cells were transfected 
with 5000 ng of human Nav1.7TAP in pcDNA3 or empty pcDNA3 using a ratio of 
1 µg DNA:2.5 µl Lipofectamine 2000 (Life Technologies). After 6 hours, the 
transfected cells were re-seeded at a low density and left for 48 hours prior to 
patch clamp analysis or RNA extraction. 
6.2.3 Stable cell lines  
NAT-SH-SY5Y stable cell line 
The human neuroblastoma cell line, SH-SY5Y (Public Health England) was 
cultured at 37oC/5% CO2 in Ham’s F12:EMEM (1:1) supplemented with 2 mM 
glutamine, 1% non essential amino acids and 10% foetal bovine serum (Life 
Technologies). The human NAT in pcDNA3 was linearised with PvuI and 
following gel purification (Qiagen), 10 ug was transfected into a 10 cm 80% 
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confluent dish of SH-SY5Y cells using Lipofectamine 2000 (Life Technologies). 
Six hours later, the medium was replaced with the selection antibiotic G418 
(500 μg/ml). Cells were monitored on a daily basis until twenty-four discrete 
colonies could be selected for expansion and screening by RT-PCR. Real-time 
qPCR was performed using SYBR Green (Applied Biosystems) and the 
following primers: Human SCN9A (efficiency 1.9); Human NAT (efficiency 2); 
Human (efficiency 1.85). Relative expression levels of mRNA were calculated 
using the comparative ΔΔCt (Ct) method and statistical significance was 
determined using an unpaired t-test. 
Nav1.7 TAP-tag stable HEK293A cell line 
The human SCN9A mammalian expression construct, FLB (full-length SCN9A 
without the downstream IRES-DsRED2 sequence) was modified by cloning in a 
sequence encoding a TAP-tag (peptide: SRK DHL IHN VHK EEH AHA HNK 
IEN LYF QGE LPT AAD YKD HDG DYK DHD IDY KDD DDK) prior to the stop 
codon. The TAP tag at the extreme C-terminus of Nav1.7 is comprised of a 
HAT-domain and 3XFLAG tags, enabling immunodetection with either anti-HAT 
or anti-FLAG antibodies. The Nav1.7-TAP stable HEK293A cell line was 
generated using the same methods as described for the NAT-SH-SY5Y stable 
cell line. For the immunoprecipitation experiments, the Nav1.7-TAP stable 
HEK293A cell line was firstly transiently transfected with the human NAT 
expression construct or an empty pcDNA3 control (as described above) and 
cells collected 48 hrs later. Protein was isolated using RIPA buffer (50 mM Tris-
HCl pH 7.4, 150 mM NaCl, 1% Nonidet P40, 0.5% of Sodium deoxycholic acid, 
0.1 % SDS, 1 tablet complete EDTA-free protease inhibitor cocktail) and equal 
amounts loaded onto 100 ul anti-FLAG (Sigma, F1804) coupled Dynabeads 
(Life Technologies), according to the manufacturer’s instructions. Samples were 
then boiled in Laemmli buffer (4% SDS, 20% glycerol, 10% 2-mercaptoethanol, 
0.004% bromphenol blue, 125 mM Tris HCl, pH 6.8) and equal volumes loaded 
onto 4-12% polyacrylamide gels. Immunopurified Nav1.7-TAP was detected on 
immunoblots using an anti-HAT antibody (LSBio, LS-C51508). In addition, equal 
amounts of crude lysate protein were run on a western blot and detected using 
anti-FLAG and anti-alpha tubulin (Abcam, ab7291) antibodies. Densitometry 
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readings were performed using ImageJ software whereby the ROI reading for 
alpha-tubulin was compared to the region of interest (ROI) reading for the HAT 
or FLAG bands and subsequently normalized to the sham control. 
6.3 Electrophysiology recordings  
Patch clamp analysis of Nav1.7-HEK293, Nav1.6-HEK293 and NAT-SH-
SY5Y stable cell lines 
 
Whole cell patch clamp recordings were made from Nav1.7-HEK293, Nav1.6-
HEK293 and NAT-SH-SY5Y stable cell lines at room temperature. In the case 
of the transient Nav1.7 NAT transfections, whole-cell membrane current 
recordings were performed 46 to 78 hrs after transfection. Micropipettes were 
pulled from borosilicate glass capillaries (GC150F-10; Harvard Apparatus, Kent, 
UK) using a Brown-Flaming P-97 horizontal micropipette puller (Sutter 
Instruments, Novato, CA, USA) and then fire polished on a microforge (MF-830 
Narishige Group, Tokyo, Japan). Voltage errors were minimised with correction 
and prediction mode of series resistance compensation both set to 50%. 
Extracellular solution contained (in mmol/L): 140 NaCl, 4 KCl, 2 CaCl2, 1 MgCl2, 
10 HEPES, adjusted to pH 7.4 with NaOH, osmolarity 320-325 mOsm/L with 
glucose. Pipettes were filled with an intracellular solution containing (in mmol/L): 
140 CsCl, 5 NaCl, 5 EGTA, 2 MgCl2, 10 HEPES adjusted to pH 7.3 with CsOH, 
osmolarity 305-310 mOsm/L with glucose. Once filled with the appropriate 
intracellular solution, recording electrodes had a resistance between 2.0 and 3.0 
MΩ. A silver chloride coated silver wire served as a reference electrode with 
one end connected to the ground input of the amplifier and the tip placed 
directly into the bath solution. Cells having a leak current after establishing 
whole-cell configuration of more than 10% of the peak sodium current were 
discarded and those which had developed leak of this magnitude during the 
experiment were not used in the final analysis. The liquid junction potential 
between the bath and the pipette solutions was not corrected. Whole-cell 
membrane currents were filtered at 5 kHz and sampled at 20 kHz using either 
an Axopatch 200B patch clamp amplifier or Axon Multiclamp 700B (Molecular 
Devices, Foster City, CA) and Digidata 1200B A/D converter (Molecular 
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Devices, Foster City, CA). Data were acquired on a Windows-based PC using 
Clampex (Molecular Devices, Foster City, CA) software and analysed by 
pCLAMP (Clampfit) 9.2 software (Molecular Devices, Foster City, CA).To 
characterize the voltage dependency of steady-state channel activation, 
currents were evoked by voltage increments of 5 mV from -80 to +40 mV for 10 
ms from a holding potential of -120 mV with 5 s between pulses. Peak whole 
cell currents (pA) were measured in response to a 10 ms voltage step from a 
holding potential of -120 mV to 0 mV and normalized to cell capacitance (pF). 
6.4 Animal models  
6.4.1 Murine models of inflammatory pain 
Carrageenan  
Lambda Carrageenan (Sigma) was prepared as 2% W/V solution in 0.9% 
sodium chloride and 25μl was injected into the left hind paw of C57BL/6, 6-8 
weeks, males. Control animals Black6, 6-8 weeks, males were injected with 
25μl of 0.9% sodium chloride solution. Behaviour was assessed with Hot 
Hargreaves (AI=12, RL 20sec); withdrawal latency (control around 8-10sec) 
was measured for left and right hind paws independently (Morris 2003, Minett, 
Quick et al. 2011).  
Complete Freund’s adjuvant (CFA) 
6-8 week old male C57BL/6 mice were intraplantar injected into the left hind 
paw with complete Freund’s adjuvant (or 0.9% sodium chloride solution for the 
sham controls), as described in Minett and Quick et al. (2011).  
Formalin test 
Mice received a 20μL intraplantar injection of 5% formalin into the left hindpaw. 
Spontaneous nocifensive behavioural responses were recorded for 60 minutes 
post-injection. Additionally, hindpaw skin temperatures were measured pre-
injection and for 60 minutes post-injection. 
6.4.2 Murine models of neuropathic pain 
Chronic constriction injury (CCI) 
Surgery was performed on 6-8 week old male C57BL/6 mice. Mice were deeply 
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anaesthetized and though an incision in the skin the sciatic nerve was loosely 
ligated various times (Minett and Quick et al. 2011).  
Sciatic nerve transection (SNT) 
Surgery was performed on 6-8 week old male C57BL/6 mice. Mice were deeply 
anaesthetized and though an incision in the skin the sciatic nerve at the height 
of L5 was completely transected (Minett and Quick et al. 2011).  
6.4.3 Behaviour phenotyping  
Motor coordination 
Rotarod test described in (Jones and Roberts 1968) was used to asses motor 
coordination in transgenic Nav1.7 L858F mice and wildtype controls.  
 
Mechanical thresholds 
A modified version of the Randall-Selitto test was used to measure mechanical 
nociceptive thresholds in transgenic and wildtype mice. Pressure was applied to 
the tail via a 3mm2 blunt conical probe with a 500-gram cut-off or to the dorsal 
surface of the hindpaws with a 250-gram cut-off (Randall and Selitto 1957, 
Takesue, Schaefer et al. 1969, Andersson, Gentry et al. 2012). Touch 
perception was assed using von Frey hairs to either the plantar surface of the 
hindpaw or the inferior half of the abdomen on hairy and non-hairy skin, 
respectively (Chaplan, Bach et al. 1994).  
 
Thermal thresholds 
Thermal nociceptive thresholds were measured by hindpaw-withdrawal 
latencies using the Hargreaves apparatus (Hargreaves, Dubner et al. 1988) and 
the hotplate test (50 & 55°C) (Eddy and Leimbach 1953). Additionally a thermal 
place preference (BioSeb) was performed to assess cold and pre-noxious heat 
avoidance as described in Minett, Nassar et al. (2012).  
	   168	  
6.5  Biochemistry and proteomics 
6.5.1 Immunocytochemistry on HEK293 cells  
Cells were seeded on EtOH sterilized, BD matrix gel (BD Biosciences) coated 
glass coverslips and grown to confluence. Cell culture medium was aspirated 
and cells were put on ice. Coverslips were washed three times with cold 1XPBS 
(GIBCO) and blocked for 30 min in 5% goat serum (Sigma) in 1X PBS. 
Incubation with primary antibody in blocking buffer for 1hr on ice was followed 
by secondary antibody goat anti-mouse IgG conjugated Alexa Fluor-488 (1:200) 
in blocking buffer. Coverslips were washed in 1XPBS and fixed in 4%PFA at RT 
for 15min. Cells on coverslips were washed and mounted in 
VECTASHIELD HardSet Mounting Medium with DAPI.  
6.5.2 Immunohistochemistry on tissue sections 
Perfusion of mice and preparation of mouse DRG, spinal cord and olfactory 
tissues for immunohistochemistry used previously described methods Zhao et 
al. (2006). Cryosections (12 - 20 µm) of mouse DRG, spinal cord and olfactory 
tissues were postfixed using 4% PFA in PBS, before blocking and antibody 
administration. Primary antibodies were: mouse anti-FLAG (1:500, Sigma, 
F1804), Rabbit anti-FLAG (1:500, Sigma F7425). Secondary antibodies and 
conjugated compounds were: Alexa-Fluor 594 goat-anti-mouse (1:1000; 
Invitrogen), Alexa-Fluor 488 goat-anti-rabbit (1:1000; Invitrogen).  
6.5.3 Total protein extractions from cell lines   
Cells were grown to confluence in culture medium, washed 1X PBS (Gibco) and 
cells scraped from dishes and pelleted by centrifugation for 5 min at 800 rpm. 
Pellets were re-suspended in an appropriate volume of RIPA buffer or modified 
RIPA buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% Nonidet P40, 0.5% of 
Sodium deoxycholic acid, 1 tablet complete EDTA-free protease inhibitor 
cocktail). Extracts were clarified after incubated on ice by 5000 rpm for 10 mins 
at 4oC. 
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6.5.4 Total protein extracts from tissue 
Tissues were dissected on dry ice and homogenized (Precellys ceromic kit 4.1, 
Peqlab) in RIPA or modified RIPA buffer. Cell lysates were incubated for 1hr 
shaking on ice and clarified by centrifugation at 14 000g for 8 min at 4oC. Lysate 
short-term storage at -80oC. 
6.5.5 Co-Immunoprecipitation  
Proteins were isolated from homogenized tissue (Precellys) in RIPA buffer and 
concentrations measured using BCA Protein assay kit (Pierce). A total starting 
amount of 1mg of protein was incubated with 100ul magnetic M-270 Epoxy 
Dynabeads (14311D, Invitrogen) covalently coupled to mouse Anti-Flag M2 
(Sigma, F-1804). The coupling was carried out for 2hrs at 4°C with constant 
agitation. Captured proteins were boiled off the beads by addition of equal 
amounts of SDS sample buffer (4% SDS, 10% 2-mercaptoethanol, 20% 
glycerol, 0.004% bromophenol blue 125 mM Tris HCl; pH 6.8). Mini-PROTEAN 
TGX Stain-Free precast gels (4-12% Gradient, Bio-Rad) were loaded with equal 
amounts of volume per lane. 1D-SDS-PAGE separations was followed by 
detection of immunopurified Nav1.7-TAP using an anti-HAT antibody or SCN3B 
antibody. 
6.5.6 Single and Tandem Affinity purification  
In each round of sample preparation for single and tandem affinity purification, 
DRG olfactory bulbs and spinal cord samples were separately homogenized 
(Precellys ceramic kit 4.1, Peqlab) in 1% CHAPS (30mM Tris HCL pH 7.5; 
150mM NaCl, 1% CHAPS, 1 complete EDTA free Protease inhibitor cocktail 
(Roche)) and further homogenized using an insulin syringe. The lysates were 
incubated shaking horizontally on ice and clarified by centrifugation at 14 000 g 
for 8 min at 4°C. Protein concentrations were measured using the BCA Protein 
assay kit (Pierce) and a total starting amount of 8 -10 mg of protein containing 
supernatant was incubated with magnetic M-270 Epoxy Dynabeads (14311D, 
Invitrogen) covalently coupled to mouse Anti-Flag M2 (F-1804, Sigma). The 
coupling was carried out for 2hrs at 4°C using an end-over-end shaker. 
Magnetic Dynabeads were collected on a DynaMAG rack (Invitrogen) and 
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washed three times in 1% CHAPS Buffer and 1X AcTEV protease cleavage 
buffer (50 mM Tris-HCl pH 8.0, 0.5 mM EDTA, 1 mM DTT, Invitrogen). 
Dynabead-captured Nav1.7 TAP-tag complex was released from the beads by 
incubation with AcTEV protease (Invitrogen) for 3 hours at 30oC, finalizing the 
single step purification. For the tandem affinity purification, protein elutes were 
collected after AcTEV cleavage and 15 X diluted in protein binding buffer (50 
mM Sodium phosphate, 300mM NaCL, 10 mM imidazole, 0.01% Tween; pH 8). 
Nav1.7 TAP tag was captured using Ni-NTA beads (Qiagen). Ni-NTA beads 
were washed three times in protein binding buffer and overnight incubated at 
4oC on an end-over-end shaker. TAP-tagged protein complexes were released 
from the Ni2+beads by boiling with SDS and DTT. 
6.5.7 Western Blotting 
Cell lysate samples were prepared for Western blotting by addition of 2X SDS 
sample buffer (4% SDS, 10% 2-mercaptoehtanol 20% glycerol, 0.004% 
bromophenol blue 125 mM Tris HCl; pH 6.8) and denatured for 5 min at 95oC. 
Mini-PROTEAN TGX Stain-Free precast gels (4-12% Gradient, Bio-Rad) were 
loaded with 20-30ug per lane and Spectra Multicolor High Range Protein 
Ladder (Thermo scientific). 1D SDS-PAGE separations were performed in 1X 
Western blot Running buffer (10X stock; 25mM Tris, 190mM glycine, 0.1% SDS 
pH 8.3) for 1h 30 min at 120 V. Proteins were then wet transferred to Immobilin-
P membranes (Millipore) activated with Methanol (Sigma) in 1X ice cold transfer 
buffer (10X Stock Transfer Buffer, 25 mM Tris, 192 mM glycine, 20% (v/v) 
methanol) for 1hrs at 100V followed by incubation in blocking solution (1 x PBS 
for 10X stock Gibco pH7.5, 0.1% Tween 20,Sigma; 5% Marvel) and overnight 
incubation at 4°C with primary antibody (dilution 1:500-1:1000) in blocking 
solution. Membranes were washed 4 times in 1X PBST (1X PBS, 0.1% Tween 
20) and incubated with anti-rabbit or anti-mouse secondary antibody 1:5000 
(GE healthcare) in blocking buffer for 1-2 hours at room temperature with 
constant agitation. PVDF Membranes were washed 4 times 1X PBST (1X PBS, 
0.1% Tween 20). Protein was visualized with SuperSignal West Dura Extended 
Duration Substrate (Thermo Scientific) on X-ray films (GE healthcare) using an 
X-ray film developer. 
	   171	  
6.5.8 Silver staining  
Samples were run on Mini-PROTEAN TGX Stain-Free precast (4-12% Gradient, 
Bio-Rad) 8+1 or 12 gels respectively. Silver staining was carried out according 
to the manufacturer’s protocol (LifeTechnology, SilverQuest™ Silver Staining). 
6.5.9 Antibodies  
Table 6.5: Antibodies 
 
Antibody Description Dilution Application 
HAT LSBio, LS-C51508, rabbit 1:500 Western Blot 
(WB) 
FLAG Sigma, F1804, mouse 1:1000 Purification, WB, 
IHC 
Alpha tubulin AB cam ab7291-100 1:1000 WB 
Pan-sodium Sigma, S8809 1:1000 WB 
β-actin AB cam 1:1000 WB 
 
Anti-Nav1.7 NeuroMab 1:250 WB 
 
Secondary 
Antibody 
Description Dilution/ 
Application 
ECL mouse 
NA931 
Amersham ECL Mouse IgG, HRP-linked 
whole Ab (from sheep) 
1:5000/WB 
ECL rabbit 
NA934 
Amersham ECL Rabbit IgG, HRP-linked 
whole Ab (from donkey) 
1:5000/WB 
Alexa-488 
 
 
Life Technology, A-20181 1:200 and 
1:1000 
IHC 
Alexa-594 
 
Life Technology, A-11014 1:200 and 
1:1000 
IHC 
 
6.6  Mass spectrometry 
Filter-aided sample preparation (FASP) for tryptic digestion 
Proteins either TEV-protease cleaved or eluted from NI2+ beads from WT and 
Nav1.7TAP/TAP mice were loaded to 30 KDa filters (Millipore), then filter units were 
centrifuged at 14 000g for 15 min to remove other detergents. Two hundred μl 
of urea buffer (10 mM DTT 8M urea (Sigma) in 0.1 M Tris/HCl pH 8.5) were 
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added to the filters and incubated at room temperature for 1 hour to reduce 
proteins. The filters were centrifuged at 14000 g for 15 min to remove DTT. 200 
μl of 50 mM Iodoacetamide (IAA) in urea buffer was added to filters and 
incubated for 30 min in the dark. The filters were centrifuged as before to 
remove IAA. The samples were then buffer exchanged twice to remove 
detergents using 200μl of urea buffer, and one more time using 200 μl of 50 
mM NH4HCO3 in water. 40μl of 50 ng/ul trypsin in 50 mM NH4HCO3 was added 
to the filters. Filters were then vortexed briefly and proteins digested at 37 °C 
overnight. After tryptic digestion, the filters were transferred to new collection 
tubes, and all the peptides were collected by placing the filter upside down and 
centrifuging. The filters were washed with 200 μl of 500 mM NaCl, and collected 
all of the washing solution by placing the filter upside down and centrifuging. 
The filters were washed with 100 μl of water and spun at 14 000 g for 15 min in 
the same collection tube. The samples were then acidified with CF3COOH and 
desalted with C18 cartridges (Waters). The pure peptides were dried by 
Spedvac (Millipore) and resuspended with 20 ul of 2% ACN, 0.1% FA. 5ul of 
samples were injected into a Orbitrap velos mass spectrometer (Thermo) 
coupled to a UPLC (Waters). 
Mass spectrometry analysis  
 
LC-MS/MS analysis of the digested material was carried out by nano-ultra 
performance liquid chromatography tandem MS (nano-UPLC-MS/MS) using a 
75 µm-inner diameter x 25 cm C18 nanoAcquityTM UPLCTM column (1.7-µm 
particle size, Waters) with a 180 min gradient of 3–40% solvent B (solvent A: 
99.9% H2O, 0.1% formic acid; solvent B: 99.9% ACN, 0.1% Formic acid). The 
Waters nanoAcquity UPLC system (final flow rate, 250 nl/min) was coupled to a 
LTQ Orbitrao Velos (Thermo Scientific, USA) and run in positive ion mode. The 
MS survey scan was performed in the FT cell recoding a window between 300 
and 2000 m/z. The resolution was set to 30,000, the automatic gain control 
target was set to 1,000,000 ions with a maximal acquisition time of 100 ms. 
Minimum MS signal for triggering MS/MS was set to 500 m/z values triggering 
MS/MS were put on a dynamic exclusion list (500 entries), exclusion duration as 
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30. Maximum of 20 MS/MS scans were triggered per MS scan. The lock mass 
option was enabled and Polysiloxane (m/z 371.10124) was used for internal 
recalibration of the mass spectra. CID was done with a target value of 30,000 in 
the linear ion trap, maximal acquisition time 500ms, collision energy of 35% and 
an activation time of 10 ms. All samples were measured in triplicate with the MS 
setting charge state rejection enabled and only more than 1 charges procures 
ions selected for fragmentation. 
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Abstract
The Nav1.7 voltage-gated sodium channel, encoded by SCN9A, is critical for human pain
perception yet the transcriptional and post-transcriptional mechanisms that regulate this
gene are still incompletely understood. Here, we describe a novel natural antisense tran-
script (NAT) for SCN9A that is conserved in humans and mice. The NAT has a similar tissue
expression pattern to the sense gene and is alternatively spliced within dorsal root ganglia.
The human and mouse NATs exist in cis with the sense gene in a tail-to-tail orientation and
both share sequences that are complementary to the terminal exon of SCN9A/Scn9a. Over-
expression analyses of the human NAT in human embryonic kidney (HEK293A) and
human neuroblastoma (SH-SY5Y) cell lines show that it can function to downregulate
Nav1.7 mRNA, protein levels and currents. The NAT may play an important role in regulat-
ing human pain thresholds and is a potential candidate gene for individuals with chronic
pain disorders that map to the SCN9A locus, such as Inherited Primary Erythromelalgia,
Paroxysmal Extreme Pain Disorder and Painful Small Fibre Neuropathy, but who do not
contain mutations in the sense gene. Our results strongly suggest the SCN9A NAT as a
prime candidate for new therapies based upon augmentation of existing antisense RNAs in
the treatment of chronic pain conditions in man.
Introduction
Following the cataloguing of the human genome and transcriptome it has become apparent
that there are probably more genes in the human genome that encode regulatory RNAs than
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those that encode proteins [1]. One major class of regulatory RNA genes contains the long
non-coding RNAs (lncRNAs), of which natural antisense transcripts (NATs) are an important
subset. NATs can be defined as processed transcripts that are complementary to the corre-
sponding processed sense transcript in exonic regions [2]. NATs can exist in cis or trans to the
target gene and are relatively common, with approximately 70% of all genomic loci showing ev-
idence of transcription from both sense and antisense strands [3]. Prominent examples of
NATs include Tsix (the NAT for Xist),Wrap53 (the NAT for p53) and BACE1-AS (the NAT
for beta-secretase-1) [4–6]. In the pain field, a NAT was recently reported for the voltage-de-
pendent potassium channel Kcna2 [7]. This NAT is expressed in rat dorsal root ganglion
(DRG) neurons and is upregulated in response to peripheral nerve injury. The increase in NAT
levels downregulates Kcna2, attenuating total voltage-gated potassium currents, increasing ex-
citability in DRG neurons and producing neuropathic pain symptoms.
We were interested to discover whether a NAT exists for SCN9A, another pain-related
gene, which encodes the Nav1.7 voltage-gated sodium channel. Previously we reported that re-
cessive loss of function mutations in this channel result in a complete inability to perceive pain
(CIP) [8]. In addition to being pain-free from birth, SCN9A-CIP patients also lack a sense of
smell, but are otherwise normal [9]. Consequently, this channel has been identified as a prom-
ising target in the pharmaceutical industry for the development of new analgesic drugs [10]. In
contrast to the pain-free phenotype, there are also debilitating painful Mendelian disorders re-
sulting from gain of function of Nav1.7, such as Inherited Primary Erythromelalgia (IEM), Par-
oxysmal Extreme Pain Disorder (PEPD) and painful small fibre neuropathy [11–13]. We
considered that if a NAT did exist for SCN9A, then perhaps it played a role in regulating
Nav1.7 protein levels and hence altering responses to painful stimuli.
In this study, using an in silico approach to inform the design of RT-PCR reactions, we have
cloned a NAT for SCN9A that is conserved in humans and mice. The tissue expression profile
of the NAT is similar to the sense gene, indicating that it may play an important functional
role. Overexpression analyses of the NAT have shown that it reduces Nav1.7 mRNA, protein
and currents. This NAT is therefore a potentially interesting candidate gene for IEM, PEPD
and small fibre neuropathy patients that lack pathogenic mutations in SCN9A [14,15].
Results
Cloning the SCN9A/Scn9a natural antisense transcripts
In silico analyses of the human and mouse SCN9A/Scn9a gene footprints using the UCSC ge-
nome browser identified several expressed sequence tags (ESTs) that were partially complemen-
tary to exonic regions of the sense gene. Alignment of the longest human EST, BC051759, to the
genomic sequence indicated a cDNA comprised of 12 exons; four of which were complementary
to and partly or wholly overlapped exons from SCN9A (S1 Fig); and with five exons containing
SINE and/or LINE repeat sequences. Exons were flanked with the canonical AG-GT splice accep-
tor and donor sites and the final exon contained an AAUAAA polyadenylation signal. In Gen-
bank the assembly of ESTs has subsequently been annotated as LOC101929680 (NR_110260),
which spans 220 kb on chromosome 2 and encodes an uncharacterized long non-coding RNA of
2305 bp (Fig 1A). Using human dorsal root ganglion cDNA as template we amplified two alter-
native splice variants, which were submitted to Genbank. Compared to NR_110260, the first
splice variant (KM096550) excludes exon 2 and uses an alternative splice acceptor site within
exon 7. The second splice variant (KM096551) excludes both exon 2 and exon 8 (Fig 1A). Inter-
estingly, some SCN9A point mutations previously shown to cause the human monogenic pain
disorders CIP, IEM and PEPD also change the sequence of the NAT (S1 Fig).
SCN9ANatural Antisense Transcript
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Analysis of the mouse genome also led to the identification of several ESTs that were
antisense to Scn9a. For example, EST AK138532 indicated a cDNA comprised of four exons,
one of which splices into a LINE repeat and two of which overlap Scn9a sense gene exons
(NR_033495; Fig 1B). Similar to the human SCN9A NAT, exons were flanked with canonical
AG-GT splice acceptor and donor sites and the final exon contained an AAUAAA polyadeny-
lation signal. Both the human and mouse NATs contain sequences that overlap the final sense
SCN9A/Scn9a exon, potentially indicating a conserved regulatory function of these NATs in
man and mouse. Using mouse dorsal root ganglion cDNA as template we amplified the identi-
cal sequence to NR_033495 (KM096552, Fig 1B) as well as a splice variant (KM096553, Fig
1B), which uses an alternative splice donor site in exon 3.
In silico translation of the human and mouse NAT sequences shows that the longest poten-
tial open reading frames are 67 and 114 amino acids respectively (S2 Fig). The lack of a long
Fig 1. Genomic organization of the human (A) andmouse (B) SCN9A/Scn9a natural antisense transcripts (NATs). The sense genes are shown at the
top of each panel with the NAT splice variants shown below. The sense genes and NATs are arranged in a tail-to-tail orientation (i.e. 3’ ends overlapping).
Transcriptional start sites (TSS) and direction of transcription are denoted by green exons and arrows respectively; overlapping regions between sense and
NAT sequences are shown by purple exons; LINE and SINE repeat sequences are shown as orange exons; and the primer pairs used to amplify the
respective NAT sequences are also highlighted.
doi:10.1371/journal.pone.0128830.g001
SCN9ANatural Antisense Transcript
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open reading frame and the poor codon conservation is consistent with the definition of a long
non-coding RNA [1].
Scn9a sense and NAT genes have a similar tissue expression profile
To investigate the tissue expression profile of the Scn9a NAT compared with the sense gene,
we ran qPCR assays across a range of mouse tissue cDNA samples (Fig 2). The Scn9a sense and
NAT genes have a relatively restricted expression pattern and are co-expressed in adult brain,
DRG and spinal cord tissues. In addition, the NAT also shows expression within adult eye. The
co-expression of the sense and NATs in similar tissues suggests that the NAT could have a di-
rect regulatory effect on Scn9a gene functions. To further understand the relative expression of
the NAT and Scn9a within DRG neurons, we analysed data from a recent paper in which DRG
neurons have been categorized into 11 subtypes based on single-cell RNA-seq expression data
(S3 Fig) [16]. This shows that the NAT is expressed in six of the eleven DRG neuronal sub-
types. Interestingly, in the remaining five DRG subtypes with no NAT expression detected,
there is robust Scn9a expression. Conversely, in the only neuronal subtype without Scn9a ex-
pression (‘NF5’), there is relatively high expression of the NAT, indicating that within particu-
lar neuronal cell populations there are contrasting expression profiles of the NAT and Scn9a.
Fig 2. Real-time qPCR assaysmeasuring the expression level of the NAT (A; upper panel) and Scn9a (B; lower panel) in specific mouse tissues
(expression levels relative to DRG). Both the sense and NAT genes are expressed in similar tissues.
doi:10.1371/journal.pone.0128830.g002
SCN9ANatural Antisense Transcript
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Overexpression of the human NAT specifically reduces Nav1.7 peak
sodium currents
To functionally test the effects of overexpressing the human NAT on sodium currents,
HEK293 cells stably expressing either Nav1.7 or Nav1.6 were transfected with (1) NAT in
pcDNA3 plus a GFP-expressing vector (pEGFP-N1) or (2) empty pcDNA3 plus pEGFP-N1.
Two days after transfection the green fluorescing cells were patch clamped. Overexpression of
the human SCN9ANAT in the Nav1.7 stable cell line resulted in a statistically significant reduc-
tion in the peak sodium current (Fig 3). In Nav1.6 stably expressing cells, overexpression of the
NAT had no effect on the sodium current, indicating that the NAT specifically affects the activ-
ity of Nav1.7.
Stable expression of the human NAT in SH-SY5Y neuroblastoma cells
The SH-SY5Y neuroblastoma cell line endogenously expresses the SCN9A gene [17] but does
not co-express the NAT (Fig 4A). We generated a SH-SY5Y cell line that stably expresses the
human NAT cDNA under the control of a CMV promoter to assess the effect of overexpres-
sion of the NAT on endogenously-expressed Nav1.7. The SCN9AmRNA level in the NAT-sta-
ble cell line was significantly downregulated compared to wild-type SH-SY5Y cells (Fig 4B).
Furthermore, patch clamping of this cell line showed a statistically significant reduction in the
peak sodium current compared to a SH-SY5Y cell line that did not express the human NAT
(Fig 4C and 4D). Voltage-current relationships were unaltered between the two cell lines.
Fig 3. Overexpression of the human NAT inhibits Nav1.7 but not Nav1.6 currents.Whole cell voltage
clamp recording from HEK cells stably expressing human Nav1.7 or human Nav1.6. Cells were transiently
transfected with either pcDNA3 vector (black bars) or Nav1.7 NAT (white bars) along with a GFP-expressing
vector and recorded from 48 hrs later. Peak whole cell current (pA) was measured in response to a 10 ms
voltage step from the holding potential of -120 mV to 0 mV and normalized to cell size (pF). n = 17–20;
* indicates p<0.05 when compared to control (unpaired t-test).
doi:10.1371/journal.pone.0128830.g003
SCN9ANatural Antisense Transcript
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In addition to sharing overlapping sequences with SCN9A, the NAT also contains sequences
overlapping with two exons from each of SCN1A, SCN2A and SCN3A (S4 Fig). As the NAT
shows high expression in the brain it is possible that the NAT may also regulate the
Fig 4. Overexpression of the NAT reduces Nav1.7-mRNA, protein and currents. (A) Real-time qPCR
showing that the NAT is not expressed in naïve SH-SY5Y cells (sham) but is expressed in the stable-NAT
SH-SY5Y cell line (n = 3). (B) Real-time qPCR showing that the endogenous SCN9AmRNA level is
significantly reduced in the stable-NAT SH-SY5Y cell line compared to in naïve SH-SY5Y cells (sham)
(n = 3). (C-D) Whole cell voltage clamp recordings of naïve (sham) and stable-NAT SH-SYSY (Nav1.7 NAT)
cells showed a significant reduction of the peak sodium current (D), with voltage-current relationships
unaltered (C) (n = 16–21). (E) Reduction in Nav1.7-TAP tag protein levels due to overexpression of the NAT
for 48 hrs in a Nav1.7-TAP stable HEK293 cell line. Densitometry readings comparing alpha-tubulin to either
HAT or FLAG bands were normalized to the sham controls and shown below each band. Transfection of the
NAT results in a reduction in Nav1.7 protein. (Ei) Nav1.7-TAP protein detected by immunoblotting using an
anti-HAT antibody following pull-down of Nav1.7-TAP with an anti-FLAG antibody (sham corresponds to
mock-transfected cells). (Eii) Immunoblot of crude lysate using an anti-FLAG antibody confirms a reduction in
Nav1.7 protein levels following NAT transfection. (Eiii) Immunoblot of crude lysate using an antibody to a
house-keeping protein, confirming equal loading. * indicates p<0.05 when compared to control (unpaired t-
test).
doi:10.1371/journal.pone.0128830.g004
SCN9ANatural Antisense Transcript
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Nav1.1-Nav1.3 brain-expressed sodium channels encoded by SCN1A-SCN3A. We were there-
fore interested to determine whether overexpression of the NAT downregulated endogenously
expressed Nav1.1, Nav1.2 or Nav1.3 in the NAT-stable SH-SY5Y cell line. Real-time qPCR
showed the expression level of SCN2A and SCN3A were not significantly different between the
naïve SH-SY5Y cells (sham) and the stable-NAT SH-SY5Y cells (SCN1A expression could not
be detected in the SH-SY5Y cell lines) (S5 Fig), further indicating that the functional effects of
the NAT are SCN9A-specific.
Next, the effect of NAT overexpression on Nav1.7 protein levels was investigated. A
HEK293 cell line was generated which stably expressed an epitope-tagged (TAP) Nav1.7 under
the control of a CMV promoter. This cell line was transiently transfected with the human
NAT, and anti-FLAG coupled Dynabeads were used to pull down TAP-tagged Nav1.7, which
was subsequently detected on a western blot using an anti-HAT antibody. Comparison of NAT
transfected and sham transfected cells showed that the transient NAT transfection resulted in a
reduction in TAP-tagged Nav1.7 protein levels (Fig 4E). This reduction in protein level was fur-
ther confirmed by immunoblotting using a pan sodium channel antibody (S6 Fig).
NAT and Scn9amRNA levels are unchanged in inflammatory and
neuropathic pain states
Given that the NAT specifically downregulates human Nav1.7 protein levels and attenuates its
currents, we investigated whether the NAT has a role in vivo to regulate mouse Scn9amRNA
levels in different pain states. Two different inflammatory pain mouse models (carrageenan
and complete Freund’s adjuvant (CFA)) and one neuropathic pain model (chronic constriction
injury) were used. Injection of carrageenan into the hind paw induces an acute and highly re-
producible inflammatory response resulting in oedema, hyperalgesia and erythema that can
persist for 6 days [18]. Likewise, injection of CFA results in acute thermal and mechanical
hyperalgesia that can persist for more than 2 weeks. In the chronic constriction injury model,
sutures are tied around the sciatic nerve which leads to thermal and mechanical hyperalgesia
presenting within the first week and persisting for several weeks. Real-time qPCR assays using
RNA isolated from ipsilateral L4-L6 dorsal root ganglia dissected 3 days (CFA), 2 hrs and 24
hrs (carrageenan) and 2 weeks (CCI) following the start of each pain model showed that nei-
ther Scn9a sense nor NAT mRNA levels change significantly (Fig 5A–5C).
Discussion
We have identified, cloned and characterized a human and mouse natural antisense transcript
for the SCN9A gene. Both human and mouse NATs are organised in a tail-to-tail configuration
with the sense gene and both show evidence of alternative splicing, which is consistent with
other reported NATs [1]. Although the mouse Scn9aNAT has fewer exons than the human
NAT, both contain conserved sequences that overlap the final sense SCN9A/Scn9a exon. Given
this conserved gene structure and the similar tissue expression profile of the sense and NAT
genes, we hypothesized that the NAT regulates the function of SCN9A. We overexpressed the
NAT in human cell lines that endogenously expressed Nav1.7 and in cells that stably expressed
from a CMV promoter either Nav1.7 or epitope-tagged Nav1.7. Real-time qPCR, immunoblot-
ting and electrophysiological assays showed a significant reduction in Nav1.7 mRNA, protein
levels and currents.
How do NATs regulate the function of their sense gene counterparts? Characterization of
other NATs has ascribed to them diverse cellular functions including transcriptional collision,
RNA interference, regulation of alternative splicing, RNA editing, epigenetic regulation, RNA
masking, translation inhibition and mRNA destabilisation [19]. In our experimental set-up we
SCN9ANatural Antisense Transcript
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overexpressed the processed NAT from a CMV promoter in cell lines. This led to a reduction
in sense mRNA and consequently a reduction in functional Nav1.7 protein. The NAT might
function by downregulating SCN9A transcription, for example by guiding chromatin-modify-
ing enzymes to the SCN9A promoter region. Alternatively, overexpression of the NAT could
Fig 5. Scn9a and NAT expression levels in DRG do not change significantly in inflammatory and
neuropathic pain models.Real-time qPCR assays for (A) CFA-induced pain (saline n = 3, CFA n = 4); (B)
carrageenan-induced pain (saline n = 4, carrageenan n = 4); (C) chronic constriction injury (mock n = 6, CCI
n = 6). Sham refers to saline injection (A, B) or mice undergoing a mock surgery (C).
doi:10.1371/journal.pone.0128830.g005
SCN9ANatural Antisense Transcript
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be leading to the generation of endogenous short RNAs (endo-siRNAs) thus leading to promo-
tion of the RNA interference pathway [20]. A third mechanism could be that the NAT:sense
mRNA duplexes are promoting destabilisation and degradation of the sense mRNA and/or in-
hibiting translation. A greater insight into the function of the NAT in vivo would be gleaned
from the creation of a NAT knockout mouse. In a comparable experiment, Komine et al. gener-
ated a Zfhx2-AS knockout mouse through deletion of the transcriptional start site region for its
corresponding NAT [21]. Normally, the Zfhx2 expression pattern in the developing brain is
complementary to the expression of its NAT. However in the Zfhx2-AS knockout mouse, the
expression of the Zfhx2 homeobox-containing transcription factor becomes dysregulated. It
would be interesting to determine whether the expression pattern of Scn9a is altered in a Scn9a
NAT knockout mouse. Furthermore, the effects on transcription of other genes, which may
also be potentially regulated by the NAT, could also be investigated in a NAT knockout, for ex-
ample Scn1a and Scn7a, which reside in the same chromosomal region as Scn9a.
Detailed analyses of Scn9a knockout mice have shown that acute, inflammatory and some
forms of neuropathic pain require the expression of Nav1.7 [22–24]. We hypothesized that the
NAT may be downregulated in pain states, hence leading to upregulation of SCN9A. To test
this, we assessed mRNA levels of the sense and NAT genes in CFA and carrageenan-induced
models of inflammatory pain and in the chronic constriction injury neuropathic pain model.
This showed that the mRNA level of neither the sense nor the NAT gene was significantly al-
tered. The lack of change in the sense gene mRNA was a surprising finding given that, for ex-
ample, Nav1.7 protein levels have previously been shown to increase following carrageenan
injections [25]. Further work on epitope-tagged Nav1.7 knockin mice using anti-FLAG/HAT
antibodies should help to confirm whether protein levels change in different pain models. Fur-
thermore, intrathecal NAT overexpression by viral delivery could help to determine whether
the NAT is able to confer analgesia and reduce the pain experienced in different inflammatory
and neuropathic pain states.
In summary, this DRG-expressed natural antisense transcript attenuates native sodium cur-
rents, is co-expressed with its corresponding gene, and consequently has the potential to regu-
late pain thresholds via transcriptional and post-transcriptional regulation of SCN9A. Given
that the presence of the NAT reduces Nav1.7 currents, then intuitively the lack of the NAT
may increase sodium currents. This could lead to increased excitability of damage-sensing neu-
rons, enabling a fine-control of responses to painful stimuli. Other regulatory mechanisms me-
diated by the NAT are also plausible, as discussed above. It will be interesting to determine
whether loss of function mutations in the NAT are responsible for inherited painful disorders
that map to human chromosome 2, and whether SNPs within the NAT alter pain thresholds in
the general population.
Material and Methods
Cloning the human and mouse NATs
Human dorsal root ganglia total RNA was purchased from Clontech; mouse total RNA was
isolated from DRGs dissected from wild-type C57BL/6 mice using the RNeasy MinElute Kit
(Qiagen). Total RNA was reverse transcribed into cDNA using Superscript III (Life Technolo-
gies) and oligo d(T), according to the manufacturer’s instructions. The human SCN9ANAT
was PCR-amplified from DRG cDNA using KAPA HiFi DNA polymerase (Kapa Biosystems)
or LA Taq (TaKaRa) in three overlapping fragments using the following primers: Fragment 1,
5’ GAA TGA AAT TTA GTG TTT CCC ATC C, 5’ AGC AAT GTT TCA CCT CCA GAG
ATC; Fragment 2, 5’ GGA ATT CAG GCA AAG TTG GA, 5’ CAC CAA CAT TCA GCC ATT
TG; Fragment 3, 5’ CTG ATT ATT GGG AGA CTT TTG GAG, 5’ GCT CCT ATT TCT GAG
SCN9ANatural Antisense Transcript
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TTT ATA CTG TG. The mouse Scn9aNAT was PCR-amplified using the primers 5’ agc aag
agt aag aag tat tgg c, 5’ cat tat att tca ttt taa tg. PCR products were cloned using the Zero Blunt
TOPO PCR Cloning Kit (Life Technologies). Individual colonies were Sanger sequenced and
submitted to GenBank under the accession numbers KM096550 (clone LA5), KM096551
(clone LA8), KM096552 (clone 3.2) and KM096553 (clone 3.1).
Real-time qPCR assay for mouse tissue panel
One μg of total RNA derived from a range of tissues (Clontech) or prepared in-house from
DRG was reverse-transcribed into cDNA using Superscript III (Life Technologies) and oligo d
(T). Real-time qPCR using technical triplicates was performed using SYBR Green (Applied
Biosystems) and the following primers: Mouse Scn9a 5’ GAG GGG CAA ACT GAC TAC A
and 5’ AGA AAC ATT CCT ACA ATG GAG (efficiency 1.91); Mouse NAT 5’ TGC TGT CAA
CTC CTG AAC CA and 5’ TCC AAC TTT GCC ACA ATG AG (efficiency 1.96); Mouse Actb
5’ TTC TTT GCA GCT CCT TCG TT and 5’ ATG GAG GGG AAT ACA GCC C (efficiency
1.83). Relative expression of the target gene was calculated using the comparative ∆∆CT meth-
od [26,27]. Briefly, expression of the test gene was compared with that of Actbmeasured on the
same sample, giving a CT difference (∆CT) for Actbminus the test gene. The relative expres-
sion of Scn9a and the NAT in specific tissues was calculated in relation to the expression levels
in DRG using the comparative ∆∆CT method [26]. ∆CT values of individual tissues were com-
pared to ∆CT of DRG, giving ∆∆CT values of a specific tissue and relative expression was cal-
culated as 2-∆∆CT. Mean, standard error and statistics were calculated from the ∆∆CT data.
Data were analysed using Microsoft Excel, and statistics were calculated using GraphPad Prism
5.01 software (GraphPad Software, San Diego, CA).
Cloning the human NAT into an expression vector
The human SCN9ANAT was PCR-amplified from IMAGE clone 5582960 (BC051759) using
Phusion High-Fidelity DNA polymerase (NEB) and primers 5’ CCC AAG CTT gtc tta gtc ctc
tga ata ttt t and 5’ CGG GGT ACC CCA ATT GAT GGA GAA TTT TAT. The PCR product
was then cloned into theHindIII and KpnI restriction sites of pcDNA3 (Life Technologies) and
fully sequenced. The cloning was designed so that the NAT was inserted at the most 5’ end of
the multiple cloning site and near to the transcription start site of the vector, to minimise the
additional nucleotides that were added to the 5’ end of the transcribed long ncRNA.
Transfection of cell lines
HEK293 cells stably expressing human Nav1.7 plus SCN1B (L11) or Nav1.6 plus SCN1B (L40)
(Scottish Biomedical) were grown according to the manufacturer’s instructions and passaged
four times before transfections began. Cells were split into 3.5 cm dishes and grown to 95%
confluency. On the day of transfection, cells were transfected with 250 ng of pEGFP-N1 (Clon-
tech) plus 1000 ng of human NAT in pcDNA3 or empty pcDNA3 using a ratio of 1 μg
DNA:2.5 μl Lipofectamine 2000 (Life Technologies). After 6 hours, the transfected cells were
re-seeded at a low density and incubated for 48 hours prior to patch clamp analysis. Two inde-
pendent transfections were tested.
NAT-SH-SY5Y stable cell line
The human neuroblastoma cell line, SH-SY5Y (Public Health England) was cultured at 37°C/
5% CO2 in Ham’s F12:EMEM (1:1) supplemented with 2 mM glutamine, 1% non essential
amino acids and 10% foetal bovine serum (Life Technologies). The human NAT in pcDNA3
SCN9ANatural Antisense Transcript
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was linearised with PvuI and following gel purification (Qiagen), 10 ug was transfected into a
10 cm 80% confluent dish of SH-SY5Y cells using Lipofectamine 2000 (Life Technologies). Six
hours later, the medium was replaced with the selection antibiotic G418 (500 μg/ml). Cells
were monitored on a daily basis until twenty-four discrete colonies could be selected for expan-
sion and screening by RT-PCR. Real-time qPCR was performed using SYBR Green (Applied
Biosystems) and the following primers: Human SCN9A 5’ AGA GGG GTA CAC CTG TGT
GAA and 5’ CCC AGG AAA ATC ACT ACG ACA AA (efficiency 1.9); Human NAT 5’ GGA
GTC ACT GGG ATT AAA GGC AT and 5’ TTC TTT GTC GCT GGT GGC TAG AG (effi-
ciency 2); Human ACTB 5’ CGC CGC CAG CTC ACC ATG and 5’ CAC GAT GGA GGG
GAA GAC GG (efficiency 1.85). The expression levels of SCN1A, SCN2A and SCN3A in the
SH-SY5Y cells was determined using Taqman assays (Life Technologies) according to the man-
ufacturer’s instructions. The following probes were used SCN1A (Hs00374696_m1), SCN2A
(Hs01109877_m1), SCN3A (Hs00366902_m1) and GAPDH (Hs02758991_g1). Relative ex-
pression levels of mRNA were calculated using the comparative ΔΔCt (Ct) method and statisti-
cal significance was determined using an unpaired t-test.
Patch clamp analysis of Nav1.7-HEK293, Nav1.6-HEK293 and
NAT-SH-SY5Y stable cell lines
Whole cell patch clamp recordings were made from Nav1.7-HEK293, Nav1.6-HEK293 and
NAT-SH-SY5Y stable cell lines at room temperature. In the case of the transient Nav1.7 NAT
transfections, whole-cell membrane current recordings were performed 46 to 78 hrs after
transfection. Micropipettes were pulled from borosilicate glass capillaries (GC150F-10; Har-
vard Apparatus, Kent, UK) using a Brown-Flaming P-97 horizontal micropipette puller (Sutter
Instruments, Novato, CA, USA) and then fire polished on a microforge (MF-830 Narishige
Group, Tokyo, Japan). Voltage errors were minimised with correction and prediction mode of
series resistance compensation both set to 50%. Extracellular solution contained (in mmol/L):
140 NaCl, 4 KCl, 2 CaCl2, 1 MgCl2, 10 HEPES, adjusted to pH 7.4 with NaOH, osmolarity
320–325 mOsm/L with glucose. Pipettes were filled with an intracellular solution containing
(in mmol/L): 140 CsCl, 5 NaCl, 5 EGTA, 2 MgCl2, 10 HEPES adjusted to pH 7.3 with CsOH,
osmolarity 305–310 mOsm/L with glucose. Once filled with the appropriate intracellular solu-
tion, recording electrodes had a resistance between 2.0 and 3.0 MO. A silver chloride coated sil-
ver wire served as a reference electrode with one end connected to the ground input of the
amplifier and the tip placed directly into the bath solution. Cells having a leak current after es-
tablishing whole-cell configuration of more than 10% of the peak sodium current were dis-
carded and those which had developed leak of this magnitude during the experiment were not
used in the final analysis. The liquid junction potential between the bath and the pipette solu-
tions was not corrected. Whole-cell membrane currents were filtered at 5 kHz and sampled at
20 kHz using either an Axopatch 200B patch clamp amplifier or Axon Multiclamp 700B (Mo-
lecular Devices, Foster City, CA) and Digidata 1200B A/D converter (Molecular Devices, Fos-
ter City, CA). Data were acquired on a Windows-based PC using Clampex (Molecular Devices,
Foster City, CA) software and analysed by pCLAMP (Clampfit) 9.2 software (Molecular De-
vices, Foster City, CA).
To characterize the voltage dependency of steady-state channel activation, currents were
evoked by voltage increments of 5 mV from -80 to +40 mV for 10 ms from a holding potential
of -120 mV with 5 s between pulses. Peak whole cell currents (pA) were measured in response
to a 10 ms voltage step from a holding potential of -120 mV to 0 mV and normalized to cell ca-
pacitance (pF).
SCN9ANatural Antisense Transcript
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Nav1.7-TAP tag stable HEK293A cell line
The human SCN9Amammalian expression construct, FLB [8] was modified by cloning in a se-
quence encoding a TAP tag (peptide: SRK DHL IHN VHK EEH AHAHNK IEN LYF QGE
LPT AAD YKD HDG DYK DHD IDY KDD DDK) immediately prior to the stop codon. The
TAP tag at the extreme C-terminus of Nav1.7 is comprised of a HAT domain and 3 FLAG tags,
enabling immunodetection with either anti-HAT or anti-FLAG antibodies. The Nav1.7-TAP
stable HEK293A cell line was generated using the same methods as described for the NAT-
SH-SY5Y stable cell line. For the immunoprecipitation experiments, the Nav1.7-TAP stable
HEK293A cell line was firstly transiently transfected with the human NAT expression con-
struct or an empty pcDNA3 control (as described above) and cells collected 48 hrs later. Pro-
tein was isolated using RIPA buffer and equal amounts loaded onto 100 ul anti-FLAG (Sigma,
F1804) coupled Dynabeads (Life Technologies), according to the manufacturer’s instructions.
Samples were then boiled in Laemmli buffer and equal volumes loaded onto 4–12% polyacryl-
amide gels. Immunopurified Nav1.7-TAP was detected on immunoblots using an anti-HAT
antibody (LSBio, LS-C51508). In addition, equal amounts of crude lysate protein were sub-
jected to immunoblotting and detected using anti-FLAG, anti-alpha tubulin (Abcam, ab7291),
anti-pan sodium channel (SIGMA, S8809) and anti-beta actin (Santa Cruz) antibodies. Densi-
tometry readings were performed using ImageJ software whereby the region of interest (ROI)
reading for alpha-tubulin was compared to the ROI reading for the HAT or FLAG bands and
subsequently normalized to the sham control.
Murine pain behaviour models
All experiments were performed in accordance with the UK Animals (Scientific Procedures)
Act 1986 with prior approval under a Home Office project license (PPL 70/7382). Two differ-
ent inflammatory pain models were used: intraplantar injection into the left hind paw of carra-
geenan or complete Freund’s adjuvant (or 0.9% sodium chloride solution for the sham
controls), as described in [18]. The chronic constriction injury (CCI) model of neuropathic
pain was also used, in which sutures were tied around the sciatic nerve [18]. All experiments
were performed using 6–8 week old male C57BL/6 mice. Total RNA was isolated from dissect-
ed L4-L6 ipsilateral DRGs using the RNeasy MinElute Kit (Qiagen). Real-time qPCR was per-
formed using SYBR Green (Applied Biosystems) and the following primers: Mouse Scn9a 5’
GAG GGG CAA ACT GAC TAC A and 5’ AGA AAC ATT CCT ACA ATG GAG (efficiency
1.91); Mouse NAT 5’ TGC TGT CAA CTC CTG AAC CA and 5’ TCC AAC TTT GCC ACA
ATG AG (efficiency 1.96); Mouse Gapdh 5’ TGC GAC TTC AAC AGC AAC TC and 5’ CTT
GCT CAG TGT CCT TGC TG (efficiency 1.76); Mouse Actb 5’ TTC TTT GCA GCT CCT
TCG TT and 5’ ATG GAG GGG AAT ACA GCC C (efficiency 1.83). Relative expression levels
of mRNA were calculated using the comparative ΔΔCt (Ct) method and statistical significance
was determined using an unpaired t-test.
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